REPORT MEDICAL RADIATION EXPOSURE STUDY IN MALAYSIA
Transcript of REPORT MEDICAL RADIATION EXPOSURE STUDY IN MALAYSIA
MINISTRY OF HEALTH MALAYSIA
REPORT
MEDICAL RADIATION EXPOSURE STUDY IN MALAYSIA
REPORT MEDICAL RADIATION EXPOSURE STUDY IN MALAYSIA
TABLE OF CONTENTS
1. Executive Summary i
2. Organization of the Report iii
3. Acknowledgements iv
4. List of Tables vi
5. List of Figures xi
6. List of Abbreviations xv
7. Chapter 1: Introduction
1.1 Background of the Study 1
1.2 Importance of the Study 3
1.3 Objectives 4
1.4 Analysis 5
8. Chapter 2: Diagnostic, Interventional and Dental Radiology
2.1 Literature Review 12
2.2 Methodology 18
2.3 Data Analysis 32
2.4 Result and Discussion 36
9. Chapter 3: Nuclear Medicine
3.1 Literature Review 69
3.2 Methodology 76
3.3 Data Analysis 96
3.4 Result and Discussion 103
10. Chapter 4: Summary, Conclusions and Recommendations 133
11. References 135
12. Appendixes
Appendix A A1
Appendix B A5
Appendix C A11
Appendix D A23
Appendix E A25
Appendix F A30
Appendix G A32
Appendix H A35
Appendix I A38
i
EXECUTIVE SUMMARY
The United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR)
was mandated with the task to assess and report levels of exposure to ionizing radiation and their
effects. This committee reports annually to the general assembly of the United Nations.
UNSCEAR collects and analyses data on the global and regional levels and trends of human
exposure to ionizing radiation. The Global Survey of Medical Radiation Usage and Exposures
was carried out since 1970 and the results published in various UNSCEAR Reports. UNSCEAR
2000 report states that radiation is carcinogenic. About 4% of all deaths from cancer can be
ascribed to ionizing radiation and the majority of these results from the natural radiation sources
outside human control [UNSCEAR, 2000]. In this regard, UNSCEAR collects and analyses data
on the global and regional use of radiation in medical diagnosis and treatment. The ICRP had
just presented the latest data from “UNSCEAR 2008 Report: Sources of ionizing radiation (2000
– 2005)” on Dec 2009.
The first national dose survey in Malaysia was initiated by the University of Malaya in
collaboration with the Ministry of Health (MOH). The survey was conducted from 1993 to 1995
to establish baseline patient dose data for seven routine types of x-ray examinations. For the first
time in history Malaysian data made it to the UNSCEAR 2000 report.
The second national medical radiation exposure study was commissioned by the MOH as a
follow up to the first study. The survey was conducted from 2005 to 2009. The scope covers
diagnostic and interventional radiology, nuclear medicine, radiotherapy and dental radiology. In
preparation for the study, four training courses for the MOH officers and research officers had
been conducted.
This report describes the objective, methodology developed for the dose survey, internal
dosimetry quantities and calculation, data analysis, results and discussion for the diagnostic,
interventional and dental radiology, nuclear medicine and also radiotherapy in Malaysia.
In the UNSCEAR 2000 report on the annual global practice and doses from medical uses
of radiation (1991-1996), it was estimated that 2,500 million procedures (medical, dental and
ii
nuclear medicine) were performed annually resulting in a collective dose of 2.5 million manSv.
The average effective dose per caput was 0.4 mSv.
Four levels of health-care in the world have been defined based on the population per
physician in the UNSCEAR 1988 report. At the highest level of health-care (Level I), there are
one or more physicians for each 1,000 population. In less developed countries with lower levels
of health-care, there is one physician each for 1,000 to 3,000 population (Level II), 3000 to
10,000 population (Level III) or greater than 10,000 population (Level IV). Malaysia with 1,429
persons per physician in 2009 belongs to health-care level II.
This survey, basically following the guidelines established by the UNSCEAR, was
conducted in 437 public and private hospitals, medical centres or general practitioners’ clinics;
and 329 public and private dental clinics in Malaysia. These hospitals / medical centres / clinics
(hereafter referred as “sites”) were selected nationwide by population and site-weighted to
represent 30% of the total number of sites in the country. The sites were grouped into five (5)
categories in this survey: public hospital, private hospital, general practitioners’ (GP) clinic,
public dental clinic and private dental clinic. Six (6) different diagnostic modalities were
included: general x-ray, mammography, fluoroscopy/angiography, computed tomography (CT),
bone mineral densitometry (BMD) and dental radiology.
The survey was conducted on the basis of statistics from all the common examinations
performed in diagnostic radiology and dental radiology from 2007 until 2009. The survey was
completed with demographic data covering different information including the equipment,
personnel and patient’s information, as well as the dosimetry data which some were measured
using TLD (i.e. general x-ray, BMD and dental) and Gafchromic films (i.e. fluoroscopy and
interventional radiology) while others were calculated using mathematical formula (i.e.
mammography) or computer software (i.e. computed tomography).
iii
ORGANIZATION OF THE REPORT
This report is a summary of overall design of the survey and analysis outcomes for
diagnostic, interventional and dental radiology, nuclear medicine and radiotherapy. It is divided
into four chapters:
• Chapter 1 for Introduction
• Chapter 2 for Diagnostic, Interventional and Dental Radiology
• Chapter 3 for Nuclear Medicine
• Chapter 4 for Summary, Conclusions and Recommendations
Chapter 2 and Chapter 3 are divided into four sub-chapters. First sub-chapter is Literature
Review which summarizes the literature review of this study. Second sub-chapter is
Methodology which describes the methodology of conducting the survey and the specific survey
protocol for different modality. Third sub-chapter is Data Analysis which explains the methods
of data analysis. Finally, sub-chapter Result and Discussion describe the summary of the analysis
result and discussion.
iv
ACKNOWLEDGEMENTS
This study was funded by Ministry of Health through its research grant, No. MRG-2006-
34. The Committee’s appreciation goes to all who had patiently responded to the questionnaire,
both staff and also clients of the healthcare system.
The Committee also wishes to express our heartfelt thanks to all those who had contributed
at any stage of the research process, from the formulation of the research proposal to the
production of this report.
Members of the committee list:
1. Dr. Gerard Lim Chin Chye Ketua Penyelaras Radioterapi dan Onkologi Kebangsaan
2. Y. Bhg. Datin Dr. Zaharah binti Musa Ketua Penyelaras Radiologi Kebangsaan
3. Y. Bhg. Dato’ Dr. Mohamed Ali bin Abd Kader
Ketua Penyelaras Perubatan Nuklear Kebangsaan
4. Y. Bhg. Dato’ Dr. Omar bin Ismail Ketua Penyelaras Kardiologi Kebangsaan
5. Y. Bhg. Dato’ Dr. Ibrahim bin A. Wahid
Malaysian Oncological Society
6. Prof. Madya Dato’ Dr. Fuad bin Ismail Pakar Perunding Radioterapi Pusat Perubatan Universiti Kebangsaan Malaysia
7. Prof. Dr. Ng Kwan Hoong Ahli Fizik Perubatan Pusat Perubatan Universiti Malaya
8. Prof. Dr. Phrabhakaran a/l N Nambiar Fakulti Pergigian Universiti Malaya
9. Y. Bhg. Datuk Dr. Subramani a/l Venugopal
Pakar Perunding Kanan dan Ketua Jabatan Pengimejan Diagnostik Hospital Tuanku Jaafar
10. Dr. Noraini binti Ab. Rahim Pakar Perunding Kanan dan Ketua Jabatan Pengimejan Diagnostik Hospital Serdang
v
11. Dr. Lee Boon Nang Pakar Perunding Kanan dan Ketua Jabatan Perubatan Nuklear Hospital Kuala Lumpur
12. Dr. Mohd Rashid bin Baharon Timbalan Pengarah Bahagian Kesihatan Pergigian KKM
13. En. Nik Mohd Hazmi bin Nik Husain Timbalan Pengarah Kanan Bahagian Sains Kesihatan Bersekutu KKM
14. En. Mohd Azhar bin Musa Ahli Fizik Perubatan Hospital Kuala Lumpur
15. En. Mohd Hizwan bin Yahya Ahli Fizik Perubatan Hospital Pulau Pinang
URUSETIA
16. En. Zunaide bin Kayun @ Farni Timbalan Pengarah (Keselamatan Sinaran)
17. Dr. Pirunthavany a/p Muthuvelu Ketua Penolong Pengarah Kanan
18. En. Bazli bin Sapiin Ketua Penolong Pengarah Kanan
19. Dr. Bidi bin Ab. Hamid Ketua Penolong Pengarah Kanan
20. En. Mohd Khairudin bin Mohamed Samsi
Ketua Penolong Pengarah Kanan
21. Pn. Nurmazaina binti Md Ariffin Ketua Penolong Pengarah
22. Pn. Siti Nor binti Mohd Amin Ketua Penolong Pengarah
23. En. Yusri bin Yusuf Penolong Pengarah Kanan
24. Pn. Maznah binti Mohamad Penolong Pengarah Kanan
25. En. Syarul Iman bin Saufi Penolong Pengarah
26. Pn. Fazilatul Liza binti Idris Penolong Pengarah
27. En. Ng Aik Hao Penolong Pengarah
28. Pn. Soh Hwee Shin Penolong Pengarah
29. Cik Tan Hun Yee Penolong Pengarah
30. Pn. Nur Hafizah binti Zakaria Penolong Pengarah
31. En. Abdullah bin Mat Hussin Juru X-Ray Kanan
32. Pn. Rosnita binti Ibrahim Juru X-Ray Terapi Kanan RESEARCH ASSISTANTS TEAM MEMBERS
33. Zuridah binti Bodong
34. Nordiana binti Md Din
vi
35. Nur Syafura binti Ariffin
36. Saidatul Julia binti Jaafar
37. Farizan binti Abdul Mokti
38. Syarul Iman bin Saufi
39. Norzalina binti Zulkifli
40. Puteri Afini binti Abdul Razak
41. Muhammad Zaimie bin Zahari
42. Roslan bin Husin
43. Norshuhada ninti Mohamad Amir
44. Hirnani binti Ghazali
45. Nurhazwani binti Abdul Samad
46. Mohamad Shahir bin Abdul Kharim
47. Siti Fatimah binti Mat Husin
48. Norsuhaida binti Mohd Noor
49. Azalina binti Yahya
OTHERS
50. En. Taiman bin Kadni Agensi Nuklear Malaysia
51. En. Hasan bin Sham Agensi Nuklear Malaysia
52. Cik Yeong Chai Hong Universiti Malaya
vii
LIST OF TABLES
Table 1.1 Overall summary from UNSCEAR year 2000-2005 survey.
Table 2.1 Dosimetric quantities and units for different modalities in diagnostic, interventional and dental radiology.
Table 2.2 Types of examinations and radiographic projections for general x-ray.
Table 2.3 Types of procedures for fluoroscopy and interventional radiology.
Table 2.4 Types of CT examinations.
Table 2.5 Types of BMD examinations.
Table 2.6 Types of dental radiology examinations.
Table 2.7 Total number of personnel in diagnostic, interventional and dental radiology from all the sample sites in this survey (2007-2009).
Table 2.8 Total number of equipment in diagnostic, interventional and dental radiology from all the sample sites in this survey (2007-2009).
Table 2.9 Total number of cases collected by modality.
Table 2.10 Number of cases collected for general x-ray from all the sample sites in this survey.
Table 2.11 Entrance Surface Dose (mGy) by examination.
Table 2.12 Comparison of Entrance Surface Dose (mGy) for general x-ray collected from this survey with DRLs recommended by different international organizations.
Table 2.13 Number of cases collected for fluoroscopy and interventional radiology.
Table 2.14 Air Kerma-Area Product (mGy.m2) for different fluoroscopy examination types in conventional and interventional studies.
Table 2.15 Peak Skin Dose (mGy) for different fluoroscopy examination types in conventional and interventional studies.
Table 2.16 Mean Skin Dose (mGy) for different fluoroscopy/angiography examination types in conventional and interventional studies.
viii
Table 2.17 Comparison of Air Kerma-Area Product (AKAP) from this survey with other published literature.
Table 2.18 Number of cases collected for computed tomography.
Table 2.19 CTDIw (mGy) for different examination types in CT.
Table 2.20 DLP (mGy.cm) for different examination types in CT.
Table 2.21 Effective dose (mSv) for different examination types in CT.
Table 2.22 Comparison of CTDIw (mGy) from this survey with other published surveys.
Table 2.23 Comparison of DLP (mGy.cm) from this survey with other published surveys.
Table 2.24 Comparison of effective dose (mSv) from this survey with other published surveys.
Table 2.25 Number of cases for mammography.
Table 2.26 Mean Glandular Dose (mGy) for different breast thickness in mammography.
Table 2.27 Number of cases collected for bone mineral densitometry.
Table 2.28 Entrance Surface Dose (mGy) for different examination types in bone mineral densitometry.
Table 2.29 Number of cases collected for dental radiology.
Table 2.30 Entrance Surface Dose (mGy) for intraoral examinations in dental radiology.
Table 2.31 Air Kerma-Area Product (mGy.m2) for panoramic examinations in dental radiology.
Table 2.32 Comparison of Entrance Surface Dose (mGy) for intraoral dental examinations collected from this survey with DRLs recommended by different international organizations.
Table 2.33 Comparison of Air Kerma-Area Product (mGy.m2) for panoramic dental examinations collected from this survey with other published literature.
ix
Table 3.1 Reference levels for diagnostic nuclear medicine procedures.
Table 3.2 Total number of personnel in nuclear medicine sites in Malaysia from 2005-2007.
Table 3.3 Total number of nuclear medicine equipment in Malaysia from 2005-2007.
Table 3.4 (a) Annual number of nuclear medicine diagnostic examinations in Malaysia from 2005-2007 according to examination types.
Table 3.4 (b) Annual number of nuclear medicine therapeutic procedures in Malaysia from 2005-2007 according to treatment types.
Table 3.4 (c) Annual number of PET/CT examinations in Malaysia from 2005-2007.
Table 3.5 (a)
Percentage contributions by types of examinations to total number of diagnostic examinations (2005-2007).
Table 3.5 (b) Percentage contributions by types of treatments to total number of therapeutic procedures (2005-2007).
Table 3.5 (c) Percentage contributions to total number of PET/CT examination (2005-2007).
Table 3.6 (a) Gender and age distribution of patients undergoing diagnostic examinations in nuclear medicine (2005-2007).
Table 3.6 (b) Gender and age distribution of patients undergoing therapeutic procedures in nuclear medicine (2005-2007).
Table 3.6 (c) Gender and age distribution of patients undergoing PET/CT examination in nuclear medicine (2005-2007).
Table 3.7(a) Administered activities (MBq) in different types of diagnostic examinations for paediatrics <16 years (2005-2007).
Table 3.7 (b) Administered activities (MBq) in different types of diagnostic examinations for adults ≥16 years (2005-2007).
Table 3.7 (c) Administered activities (MBq) in different types of therapeutic procedures for paediatrics <16 years (2005-2007).
Table 3.7 (d) Administered activities (MBq) in different types of therapeutic procedures for adults ≥16 years (2005-2007).
Table 3.7 (e) Administered activities (MBq) in PET/CT (2005-2007).
Table 3.8 (a) Mean effective dose (mSv) calculated for different types of diagnostic examinations for paediatrics <16 years (2005-2007).
x
Table 3.8 (b) Mean effective dose (mSv) calculated for different types of diagnostic examinations for adults ≥16 years (2005-2007).
Table 3.9 Comparison of mean administered activity and mean effective dose for paediatrics (age <16) and adults (age ≥16) for different diagnostic examinations.
Table 3.10 Comparison of number of nuclear medicine diagnostic imaging equipment per million population with UNSCEAR 2000 report.
Table 3.11 Comparison of number of procedures per 1000 population with UNSCEAR 2000 report (Table 46).
Table 3.12 Comparison of effective dose per procedure with UNSCEAR 2000 report (Table 46).
Table 3.13 Comparison of annual collective dose per procedure with UNSCEAR 2000 report (Table 46).
Table 3.14 Comparison of percentage contribution to total annual frequency with UNSCEAR 2000 report (Table 47).
Table 3.15 Comparison of percentage contribution to total annual collective dose with UNSCEAR 2000 report (Table 47).
Table 3.16 Summary of the data comparison between this survey and UNSCEAR 2000 report (Table 50).
Table 3.17 (a) Comparison of average administered activity (MBq) of different types of diagnostic examinations with difference recommended DRLs (Adults ≥ 16 years old).
Table 3.17 (b) Comparison of average administered activity (MBq) of different types of diagnostic examinations with difference recommended DRLs (Paediatrics < 16 years old).
Table 3.18 Comparison of average administered activity (MBq) of different types of diagnostic examinations with other national surveys (Adults ≥ 16 years old).
Table 3.19 Comparison of average administered activity (MBq) of different types of radionuclide therapy with other national surveys (Adults ≥ 16 years old).
xi
LIST OF FIGURES
Figure 1.1 Explanation of mean, median and mode.
Figure 1.2 An example of pie chart used in this survey.
Figure 1.3 An example of bar chart used in this survey.
Figure 1.4 An example of histogram used in this survey.
Figure 1.5 Interpretation of a typical box-plot.
Figure 2.1 Radiation dosimetric quantities.
Figure 2.2 The breakdown of data collection methodology.
Figure 2.3 Patient measurement set up.
Figure 2.4 Orientation markings on the reversed side of the Gafchromic® film.
Figure 2.5 AKAP reading displayed on fluoroscopy console.
Figure 2.6 Example of the calibration strips during the calibration of Gafchromic® film.
Figure 2.7 Scanned Gafchromic® film and the skin dose distribution map.
Figure 2.8 Medical Radiation Exposure Survey database management system.
Figure 2.9 Histogram showing the number of personnel in diagnostic, interventional and dental radiology from all the sample sites in this survey from 2007 to 2009.
Figure 2.10 Histogram showing the number of personnel in diagnostic, interventional and dental radiology from all the sample sites in this survey from 2007 to 2009.
Figure 2.11 Number of cases collected for general x-ray.
Figure 2.12 Entrance surface dose (mGy) by examination.
xii
Figure 2.13 Number of cases collected for angiography, conventional and interventional studies using fluoroscopy/angiography.
Figure 2.14 Number of cases collected for angiography (cardiac and non-cardiac).
Figure 2.15 Number of cases collected for fluoroscopy (conventional studies).
Figure 2.16 Number of cases collected for fluoroscopy (interventional studies).
Figure 2.17 Air Kerma-Area Product (mGy.m2) for different examination types in angiography and conventional fluoroscopy studies.
Figure 2.18 Air Kerma-Area Product (mGy.m2) for different procedures in interventional studies.
Figure 2.19 Peak Skin Dose (mGy) for different examination types in angiography and conventional fluoroscopy.
Figure 2.20 Peak Skin Dose (mGy) for different procedures in interventional studies.
Figure 2.21 Mean Skin Dose (mGy) for different examination types in angiography and conventional fluoroscopy.
Figure 2.22 Mean Skin Dose (mGy) for different procedures in interventional studies.
Figure 2.23 Number of cases collected for computed tomography.
Figure 2.24 CTDIw (mGy) for different examination types in CT.
Figure 2.25 DLP (mGy.cm) for different examination types in CT.
Figure 2.26 Effective dose (mSv) for different examination types in CT.
Figure 2.27 Mean Glandular Dose (mGy) for different breast thickness in mammography.
Figure 2.28 Number of cases collected for bone mineral densitometry.
Figure 2.29 Entrance Surface Dose (mGy) for different examination types in bone mineral densitometry.
Figure 2.30 Number of cases collected for dental radiology.
xiii
Figure 2.31 Entrance Surface Dose (mGy) for intraoral examinations in dental radiology.
Figure 2.32 Air Kerma-Area Product (mGy.m2) for panoramic examinations in dental radiology.
Figure 3.1 The flow chart of operation of study.
Figure 3.2 Types of diagnostic examinations and therapeutic procedures in nuclear medicine.
Figure 3.3 The structure of data collection methodology.
Figure 3.4 Screen shot of the login page of the database.
Figure 3.5 Screen shot of the database main page showing the organization of the database main and sub-menu.
Figure 3.6 Screen shot of the database “System Parameter” menu.
Figure 3.7 Screen shot of the database “Hospital Maintenance” menu.
Figure 3.8 Screen shot of the database “Case” menu for diagnostic examination entry.
Figure 3.9 Screen shot of the database “Case” menu for PET/CT data entry.
Figure 3.10 Screen shot of the database “Inquiry” menu.
Figure 3.11 Parameter tables relationship of the database.
Figure 3.12 Hospital tables relationship of the database.
Figure 3.13 Overall relationship of the database.
Figure 3.14 Radiation dose survey protocol for Nuclear Medicine procedures.
Figure 3.15 Medical Radiation Exposure Survey Database Management System.
Figure 3.16 Statistics of Malaysian population from 2005 to 2009.
xiv
Figure 3.17 (a) Bar chart showing the frequency of nuclear medicine diagnostic examinations in Malaysia from 2005 to 2007 according to different examination types.
Figure 3. 17 (b) Bar chart showing the frequency of nuclear medicine therapeutic procedures in Malaysia from 2005 to 2007 according to different treatment types.
Figure 3. 17 (c) Bar chart showing the frequency of PET/CT in Malaysia from 2005 to 2007.
Figure 3.18 (a) Pie chart showing the frequency distribution of different examination types in diagnostic nuclear medicine (2005-2007).
Figure 3.18 (b) Pie chart showing the frequency distribution of different treatment types in therapeutic nuclear medicine (2005-2007).
Figure 3.19 (a) Bar chart showing the frequency of nuclear medicine diagnostic examinations in Malaysia according to age groups (2005-2007).
Figure 3.19 (b) Bar chart showing the frequency of nuclear medicine therapeutic procedures in Malaysia according to age groups (2005-2007).
Figure 3.20 (a) Box plot showing the administered activities for different examination types in diagnostic nuclear medicine (2005-2007).
Figure 3.20 (b) Box plot showing the administered activities for different treatment types in therapeutic nuclear medicine (2005-2007).
Figure 3.21 Box plot showing the effective dose for different examination types in diagnostic nuclear medicine (2005-2007).
Figure 3.22 Comparison of number of procedure per 1,000 population with different healthcare levels.
Figure 3.23 Comparison of effective dose per procedure with different healthcare levels.
Figure 3.24 Comparison of annual collective effective dose with different healthcare levels.
Figure 3.25 Comparison of annual per caput effective dose with different healthcare levels.
xv
LIST OF ABBREVIATIONS
AAPM American Association of Physicists in Medicine
ACR American College of Radiology
AEC Automatic Exposure Control
AK Air Kerma
AKAP Air Kerma-Area Product
AP Anterior Posterior
ARSAC Administration of Radioactive Substances Advisory Committee
BMD Bone Mineral Densitometry
BSS Basic Safety Standards
CC Cranial-Caudal View
CRCPD Conference of Radiation Control Program Directors
CT Computed Tomography
CTDI Computed Tomography Dose Index
DLP Dose Length Product
DMSA Dimercaptosuccinic Acid
DRL Diagnostic Reference Level
xvi
DSA Digital Subtraction Angiography
DTPA Diethyl Triamine Penta-Acetic, Dithiophosphoric Acid, Diethylene Triamine Pentacetate, Diethylenetriamine Pentaacetic Acid
DXA Dual X-Ray Absorptiometry
EANM European Association of Nuclear Medicine
EC European Commission
ED Effective Dose
ERCP Endoscopic Retrograde Cholangiopancreatography
ESAK Entrance Surface Air Kerma
ESD Entrance Surface Dose
ESWL Extracorporeal Shock Wave Lithotripsy
FDG Fluoro-Deoxy-Glucose
FFD Focus-to-Film Distance
FOV Field of View
GP General Practitioners’
HDP Hydroxymethylene Diphosphonate
HIDA Hepatobiliary Iminodiacetic Acid
HMPAO Hexamethylpropyleneamine Oxime
HPA Health Protection Agency
xvii
HVL Half Value Layer
HQ Headquarters
IAEA International Atomic Energy Agency
ICRP International Commission on Radiological Protection
ICRU International Commission on Radiation Units
IPSM Institute of Physical Sciences in Medicine
KAP Kerma Area Product
KUB Kidney, Ureter and Bladder
LAT Lateral
MAA Methyl Acetoacetate
MAG 3 Mercaptoacetyltriglycine
MCU Micturating Cystourography
MCU Micturating Cysto-Urethrogram
MDP Methylene Diphosphonate
MGD Mean Glandular Dose
MIBG Meta-iodobenzylguanidine
MIBI Methoxy-Isobutyl-Isonitrile
MIRD Medical Internal Radiation Dosimetry
xviii
MLO Mediolateral Oblique
MNA Malaysian Nuclear Agency
MOH Ministry of Health
MRI Magnetic Resonance Imaging
MSAD Multiple Scan Average Dose
MSD Mean Skin Dose
MSCT Multi-Slice Computed Tomography
NRPB National Radiological Protection Board
OPG Orthopantomogram
PA Posterior Anterior
PACS Picture Archive and Communications Systems
PET Positron Emission Tomography
PSD Peak Skin Dose
PTBD Percutaneous Transhepatic Biliary Drainage
PTCA Percutaneous Transluminal Coronary Angioplasty
QA Quality Assurance
RADAR Radiation Dose Assessment Resource
RSNA Radiological Society of North America
xix
SPECT Single Positron Emission Computed Tomography
SPSS Statistical Package for the Social Sciences
SSDL Secondary Standard Dosimetry Laboratory
TAT Targeted Alpha Therapy
TLD Thermoluminescent Dosimeters
UNSCEAR United Nations Scientific Committee on the Effects of Atomic Radiation
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 1: Introduction
1
CHAPTER 1: INTRODUCTION
1.1 BACKGROUND OF THE STUDY
Medical radiation is by far the largest man-made source of public exposure to
ionizing radiation. Such examinations are performed in all kinds of health care
establishments, including hospitals and clinics. Although the doses from diagnostic
radiology examinations are generally low, the magnitude of the practice makes for a
significant radiation impact but this is outweighed by the direct benefits in health
improvement. Nevertheless, there is a continuing need to analyze the frequencies,
doses and trends of radiological procedures [Ng et al., 1999].
Worldwide interest in patient dose measurement was stimulated by the
publication of Patient Dose Reduction in Diagnostic Radiology by the UK National
Radiological Protection Board (NRPB) [NRPB, 1990]. Several major dose surveys
have been reported, especially from advanced countries. However, in developing
countries, such basic information is still lacking [Ng et al., 1998].
The Global Survey of Medical Radiation Usage and Exposures has been
carried out since 1970’s over a period of five year interval, i.e., 1970-1979, 1980-
1984, and 1985-1989. The results were published in the UNSCEAR 1993 Report. In
the UNSCEAR 2000 Report, data were added covering the years 1990 to 1994 and
compared with the three preceding 5-years interval among countries from all regions
of the world. UNSCEAR has released the publication of the UNSCEAR 2008
Report. This report constitutes two volumes publishing the ionizing radiation survey
data from year 2000 to 2005. Table 1.1 summarizes the overall results from this
latest survey (2000 – 2005) which is published in the UNSCEAR 2008 report
[UNSCEAR, 2008]. This survey aims to establish national data and supplement to
UNSCEAR database.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 1: Introduction
2
Table 1.1: Overall summary from UNSCEAR year 2000-2005 survey (UNSCEAR, 2008).
UNSCEAR 2008 – Overall Summary
Source Collective Dose (man Sievert)
Worldwide average dose (mSv)
Typical range of individual doses (mSv)
Comments
Total natural 15,000,000 2.4 1-10 Sizeable population at 10-20 mSv
Medical diagnosis
4,200,000 0.6 0-several tens Average is 1.9mSv in countries with high level healthcare
Atmospheric nuclear testing
32,000 0.005 Mainly from residual activity in soils
Peak 0.11mSv in 1963
Occupational exposure
29,000 0.005 0-20 Highest collective doses to exposures from natural radiation (e.g. radon in mines)
Nuclear power public exposure
1,300 0.0002 Up to 0.3 near nuclear installations
Total man-made
4,260,000 0.6 From essentially zero up to several tens
Individual doses depend primarily on medical treatment and occupational exposure
Malaysia is a healthcare level II country according to the United Nations
Scientific Committee on the Effects of Atomic Radiation (UNSCEAR) definition
based on physician densities, i.e., 1000-3000 population per physician. In 2004,
Malaysia was classified as a level II country where the population to physician ratio
was 1402:1. In level I countries there are fewer than 1000 population per physician.
Level I countries, with 25% of the world population, account for some 70% of the
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 1: Introduction
3
diagnostic x-ray examinations [UNSCEAR, 1993]. The distribution of medical
radiation services in the world is far from equitable [Ng et al., 1998]. The statistics in
Malaysia showed that there were 1429 population per physician in 2009 [Department
of Statistics, Malaysia], which indicated that Malaysia was still classified as a
healthcare level II country.
1.2 IMPORTANCE OF THE STUDY
The measurement of patient dose will provide information for optimization of
radiation dose by obtaining radiological images with lowest amount of radiation.
This report would be able to assess radiation exposure as a factor of patient-outcome
efficacy, develop national reference levels as well as being an indicator of radiology
quality assurance (QA). The result of the first local dose survey provide valuable
baseline data for Malaysian patient doses. Ng et al. [Ng et al., 1998] reported a wide
variation in patient dose for the same type of x-ray examination carried out on
similar-sized patients in different hospitals. This suggested that significant reductions
in the dose from these exposures would be possible without adversely affecting
image quality. The spread is mainly due to the choice of exposure factors, technique,
focus-to-film distance, collimation, film-screen speed and the output of the x-ray
machine used.
This survey presents the results of an updated, broad review of medical
radiation exposures in Malaysia. Its purpose is to provide new qualitative and
quantitative information on the frequencies and doses for diagnostic and therapeutic
procedures to assess medical radiation exposures in Malaysia. Comparisons were
made with data from a previous survey and international published studies. This
survey also aims to explore temporal and regional trends in the usage of radiation in
medicine in Malaysia. Although the survey is not intended as a means to optimize
procedures or as a national guideline for radiation protection, it will nevertheless
provide the background for such work.
The Ministry of Health (MOH) Malaysia has designed and developed a
national medical radiation exposure database as a result of this project. The database
consists of the hospital data including equipment and personnel information, as well
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 1: Introduction
4
as the patients’ data associated with the medical radiation exposure. It is
recommended that the database be maintained and reviewed periodically and reports
to be published. The ultimate aim is to set up a long term, sustainable, national
medical radiation exposure database that can be reviewed periodically by the MOH
and relevant authorities and organizations. This database will be useful in providing
advice to the professional and regulatory bodies on national reference dose levels for
various examinations and procedures involving ionising radiation.
1.3 OBJECTIVES
The primary objectives were:
(i) to review the status of the medical radiation exposure in Malaysia as compared
to other countries.
(ii) to establish the national Diagnostic Reference Levels (DRLs) in promoting the
basis of optimization procedures in diagnostic radiology and nuclear medicine.
Secondary objectives were:
(i) to evaluate the trends in number of cases medical radiation exposure in
Malaysia in the period of 2005 to 2009.
(ii) to determine corresponding the number of personnel in selected site involved in
diagnostic radiology, nuclear medicine and radiotherapy department.
(iii) to determine the annual collective effective dose to the Malaysian population
from different disciplines and the relative contributions from various diagnostic
procedures.
(iv) to compare the local diagnostic dosimetry status with the DRLs recommended
by the international organizations such as International Atomic Energy Agency
(IAEA) and Health Protection Agency (HPA) (formerly known as NRPB).
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 1: Introduction
5
1.4 ANALYSIS
1.4.1 Statistic Methods
Descriptive statistics were used in this survey to describe the main features of a
collection of data in quantitative terms. The statistics were divided into univariate
(one variable) and bivariate (two variables). The descriptive terms used in this survey
are as follows:
(a) Univariate statistics:
• Frequency or counts (expressed in numbers or percentages)
(b) Bivariate statistics:
• Mean and standard deviation
• Median
• Mode
• Minimum (min) and maximum (max)
• 25th percentile (1st quartile) and 75th percentile (3rd quartile)
Mean or arithmetic mean of a list of numbers is the sum of all list divided by
the number of items in the list. If the list is a statistical population (i.e. number of
cases performed per year), the mean of that population is called a population mean; if
the list is a statistical sample (i.e. average administered activity per patient), the
resulting statistics is called a sample mean. To simplify, we used “mean” in both
conditions in this report. Mean is sometimes called the average which carries the
same meaning. The mean is often quoted along with the standard deviation: the mean
described the central location of the data, and the standard deviation describes the
spread. The value is written as mean ± standard deviation.
Median is the numeric value separating the higher half of the sample from the
lower half. The median of a finite list of numbers can be found by arranging all the
observations from lowest value to highest value and picking the middle one. If there
is an even number of observations, then there is no single middle value; the median is
then defined to be the mean of the two middle values. Median is generally a good
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 1: Introduction
6
descriptive measure of the location which works well for skewed data, or data with
outliers.
Mode is the most frequently occurring value in a set of discrete data. There can
be more than one mode if two or more values are equally common. The mode values
were not listed in the analysis tables in this report, however they were shown in the
histogram of some of the statistics. Figure 1.1 demonstrates the difference between
mean, median and mode. For an ideal symmetrical distribution, the mean, median and
mode are the same, however asymmetrical distribution is more likely in practice.
Minimum and maximum are the smallest (or lowest) and largest (or highest)
numerical value in the data set.
A percentile is the value of a variable below which a certain percent of
observations fall. So the 25th percentile is the value below which 25% of the
observations may be found; and 75th percentile is the value below which 75% of the
observations may be found. The 25th percentile is also known as the first quartile
(Q1); the 50% percentile as the median or second quartile (Q2); the 75th percentile as
the third quartile (Q3).
Figure 1.1: Explanation of mean, median and mode. (www.syque.com/quality_tools/toolbook/Variation/measuring_centering.htm)
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 1: Introduction
7
1.4.2 Graphical Display of Statistics Data (a) Pie Chart
A pie chart is a way of summarizing a set of categorical data. It is a circle
which is divided into different segments. Each segment represents a particular
category. The area of each segment is proportional to the number or percentage of
cases in that category. It was used to show the distribution and frequency of different
cases for a particular discipline, modality or parameter in this survey. Figure 1.2
demonstrates an example of pie chart plotted in this survey.
Figure 1.2: An example of pie chart used in this survey.
The Use of AEC mode in General X‐Ray Examinations
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 1: Introduction
8
(b) Bar Chart
Bar chart is one of the most commonly used graphical statistics in this survey.
It shows the numerical values of different variables represented by the height or
length of the rectangle bars with equal width. The bars can be drawn vertically or
horizontally depending on individual preference. In this study, we often use vertical
bar charts for those variables with long characters or names. The bar charts are
usually used for the comparison of numerical data for different variables, i.e. the
mean administered activity for different examinations types in diagnostic nuclear
medicine. The clustered bar charts were used in some circumstances when there was
a comparison of different groups of variables, as shown in Figure 1.3.
Figure 1.3: An example of bar chart used in this survey.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 1: Introduction
9
(c) Histogram
Histogram was used to present the tabular frequencies of the specific
parameters or variables, shown as adjacent rectangles. Each rectangle is erected over
an interval, with an area equal to the frequency of the interval. The height of a
rectangle is also equal to the frequency density of the interval, i.e. the frequency
divided by the width of the interval. The total area of the histogram is equal to the
total number of data. A histogram may also be based on the relative frequencies
instead. It then shows what proportion of cases fall into each of several categories (a
form of data binning), and the total area then equals 1.
We used histogram to demonstrate the tabulation of the frequency for some
important parameters in this survey. For example, the histogram for the administered
activity for the specific cases is shown in Figure 1.4. The histogram shows the
number of cases fall in different intervals of administered activity. There was a total
number of 15,472 cases of bone scan performed in 2005 to 2007; the most frequent
used administered activity was between 700 – 800 MBq; and the mean administered
activity was 832.24 ± 141.01 MBq.
Figure 1.4: An example of histogram used in this survey.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 1: Introduction
10
(d) Box Plot
In general, most of the dosimetric analysis outputs were demonstrated in box-
plot, which is an useful graphical display to depict groups of numerical data through
their five (5) number summaries: lowest value (sample minimum), 25 percentile (1st
quartile), 50 percentile (median), 75 percentile (3rd quartile) and highest value
(sample maximum). A box-plot may also indicate which observations, if any, might
be considered as outliers. Box-plot is also useful to display differences between
populations without making any assumptions of the underlying statistical distribution
because they are non-parametric. The spacing between the different parts of the box
helps indicate the degree of dispersion (spread) and skewness in the data, and identify
outliers. Figure 1.5 illustrates the interpretation of a typical box-plot using SPSS.
Figure 1.5: Interpretation of a typical box-plot (Source: SPSS version 16 user’s manual).
Outliers
75th percentile (3rd quartile)
50th percentile (median)
25th percentile (1st quartile)
Highest value (Sample maximum excluded outliers)
Lowest value (Sample minimum excluded outliers)
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 1: Introduction
11
Interpretation of Box-Plot:
1. Box and Whiskers:
The box plot shows a box encased by two outer lines known as whiskers. The box
represents the middle 50% of the data sample - half of all cases are contained within
it. The remaining 50% of the sample is contained within the areas between the box
and the whiskers, with some exceptions (outliers).
2. Median Line:
Inside the box, there is a single line. This line represents the median, which is the
middle value of the entire sample. Trace this line back to the axis to derive its value.
The location of the median line can also suggest skewness in the distribution if it is
noticeably shifted away from the center.
3. Box Position:
The location of the box within the whiskers can provide insight on the normality of
the sample's distribution. When the box is not centered between the whiskers, the
sample may be positively or negatively skewed. If the box is shifted significantly to
the low end, it is positively skewed; if the box is shifted significantly to the high end,
it is negatively skewed.
4. Box Size:
The size of the box can provide an estimate of the kurtosis - the peakedness of the
distribution. A very thin box relative to the whiskers indicates that a very high
number of cases are contained within a very small segment of the sample. This
signifies a distribution with a thinner peak. A wider box relative to the whiskers
indicates a wider peak. The wider the box, the more U-shaped the distribution
becomes.
5. Outliers:
Outliers are not present in every box plot. When they are present, they are found in
the form of points, circles, or asterisks outside of the boundaries of the whiskers.
These are extreme values that deviate significantly from the rest of the sample and
they can exist above or below the whiskers of the box plot.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Literature Review
12
2.1 LITERATURE REVIEW
2.1.1 History of Medical X-Ray Development
Diagnostic examinations with x-rays have been used in medicine for over a
century. It represents the largest portion of medical radiation source according to the
UNSCEAR 2000 report. During the last two decades in particular, medical imaging
has experienced a technological revolution, and it now allows the improved imaging
of anatomy, physiology and metabolism. Steady advances in the quality of x-ray
images and in patient protection have ensured a continuing role for diagnostic x-rays
in healthcare, although alternative modalities for diagnosis are becoming
increasingly available, such as ultrasound, endoscopy and MRI. Nevertheless, since
x-ray examinations remain the most frequent use of ionizing radiation in medicine,
they are the most significant source of medical exposure for the world population.
An increasingly wide range of equipment and techniques is employed to meet a wide
range of diagnostic clinical purposes.
Digital methods for the processing and display of x-ray images were first
introduced into clinical practice with the advent of computed tomography (CT) in
1972. This revolutionary technology was able to provide high-quality images of
isolated slices of the patient using a thin rotating beam of x-rays, albeit with
relatively high patient doses. The subsequent development of helical CT has lead to
further scanning techniques such as CT endoscopy and CT fluoroscopy. Continuing
advances in computer technology have also promoted the general development of
digital radiography, where images are acquired in digital form. The technique of
digital subtraction angiography (DSA) is based on digital image processing with
logarithmic subtraction and edge enhancement. It is used increasingly for the
visualization of blood vessels throughout the body. Such improvements in imaging
and innovations in other equipment, such as needles, catheters, stents and contrast
media, have facilitated the development of interventional radiological techniques, in
CHAPTER 2: DIAGNOSTIC, INTERVENTIONAL AND DENTAL RADIOLOGY
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Literature Review
13
which imaging helps to guide therapeutic procedures and to deliver therapeutic
agents. Digital technology also provides for the storage and transfer of images within
and between hospitals and their transmission for remote consultation (teleradiology)
using digital networks known as picture archive and communications systems
(PACS).
2.1.2 Definition of Diagnostic and Interventional Radiology
Diagnostic radiology is the use of various imaging modalities to aid in the
diagnosis of disease. Diagnostic radiology can be further divided into multiple sub-
specialty areas. Interventional radiology uses the imaging modalities of diagnostic
radiology to perform minimally invasive procedures.
Imaging modalities include general radiography, mammography, fluoroscopy,
angiography, bone mineral densitometry (BMD), dental radiology, CT, magnetic
resonance imaging (MRI) and ultrasound.
2.1.3 Dosimetry in Diagnostic, Interventional and Dental Radiology
Although there are many articles and surveys in the literature concerning
dosimetry for a specific examination or procedure, there are few places in which the
recent literature has been reviewed and summarized in a concise form. There are a
number of ways in which radiation exposure and dose in medicine are quantified.
Measured quantities include Air Kerma (AK), Entrance Surface Dose (ESD), Air
Kerma-Area Product (AKAP), Peak Skin Dose (PSD), Dose-Length Product (DLP)
and Computed Tomography Dose Index (CTDI). Organ absorbed doses can be
estimated by using the radiation weighting factor and tissue weighting factor
recommended by International Commission on Radiological Protection (ICRP).
The levels of dose to patients undergoing diagnostic examinations with x-rays
are in principle determined by the quality of images required and the extent of
investigation necessary to meet the specific clinical objectives. In practice, numerous
factors relating to both the radiological equipment and the procedures in use have an
influence on the imaging process. UNSCEAR 2000 report Annex D summarised the
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Literature Review
14
important aspects of practice that have a broad impact on patient dose. X-ray
procedures characteristically involved exposures to the patients. They produce
complex patterns of energy deposition within the patient and various dose
measurement strategies are necessarily employed. Organ doses are in general
difficult to assess. In practice routine patient monitoring is usually based on directly
measurable dose quantities, such as ESD (with backscatter) per radiograph and,
particularly for complex procedures involving fluoroscopy, AKAP per examination.
AKAP meters are increasingly being fitted to x-ray equipment. Their development
allow the display in real-time of dose rate and cumulative dose.
Organ dose and effective dose are generally estimated from routine dose
measurements using conversion factors appropriate to the conditions of exposure;
coefficients that have been used in various dose studies are reviewed elsewhere.
These coefficients may be derived experimentally on the basis of physical
anthropomorphic phantoms. Theoretical normalised organ dose data are available in
relation to routine examinations of adults, paediatric patients, cardiac and
angiographic examinations, although care is needed when applying such coefficients
to clinical practice. The comparison of organ and effective doses derived from
measurements and calculations under similar conditions of exposure indicates
reasonable agreement between the methods and highlights the limitations and
uncertainties in both approaches. Computational methods of dosimetry in particular
are advancing steadily, with the development of more realistic (voxel) phantoms
based on digital images of humans.
Special dosimetric techniques are often employed in the case of mammography
and CT in view of the peculiar conditions of irradiation for these examinations.
Practice in mammography is generally assessed in terms of the mean dose to
glandular tissue, derived in relation to a standard breast thickness using coefficients
normalised to measurements of AK made free-in-air, although direct measurements
of ESD on patients have also been employed.
CT generally involves the irradiation of thin slices of the patient in rotational
geometry by a fan beam of x-rays. The principal dosimetric quantity in CT is the
CTDI, in which the dose profile along the axis of rotation for a single slice is
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Literature Review
15
averaged over the nominal slice thickness. The CTDI can be measured free-in-air or
in homogeneous CT dosimetry phantoms for the head and body, although such
reported values can reflect subtle differences in the definition of CTDI. A related
quantity, the multiple scan average dose (MSAD), provides an indication of the dose
in a phantom for a series of multiple scans with a constant separation. Organ dose
and effective dose to patients for particular scanning protocols can be estimated
using dose coefficients provided by mathematical modeling, which are normalized to
a free-in air axial dose, or by dose measurements with thermoluminescence
dosimeter (TLD) in phantoms. Other dosimetric quantities for CT practice include
DLP in relation to CTDI measurements in standard phantoms; these quantities in turn
allow the broad estimation of effective dose to patients.
2.1.4 Diagnostic Reference Levels (DRLs)
Diagnostic Reference Levels (DRLs) is defined by IAEA Basic Safety
Standards (BSS) as a value of dose, dose rate or activity selected by professional
bodies in consultation with the regulatory authority to indicate a level above which
there should be a review by medical practitioners in order to determine whether or
not the value is excessive. ICRP Publication 73 [ICRP, 1996] introduced the term
“diagnostic reference levels” (DRLs) and explained its place in the broader ICRP
concept of reference levels. The main points are summarised below:
(a) The term used is diagnostic reference levels (DRLs).
(b) The purpose is advisory. It is a form of investigation level to identify
unusually high levels, which calls for local review if consistently exceeded.
In principle, there could be a lower level also (i.e. below which there is
insufficient radiation dose to achieve a suitable medical image). DRLs are not
for regulatory or commercial purposes, not a dose constraint, and not linked
to limits or constraints.
(c) The examination types include diagnostic radiology and nuclear medicine.
(d) Their selection is by professional medical bodies, using a percentile point on
the observed distribution for patients, and specific to a country or region.
(e) The quantities should be easily measured, such as absorbed dose in air or
tissue-equivalent material at the surface of a simple standard phantom or
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Literature Review
16
representative patient for diagnostic radiology and administered activity for
diagnostic nuclear medicine.
The objective of DRLs is to optimize the use of radiation in medicine and help
avoid excessive radiation exposure. This is accomplished by comparison between
the numerical value of the DRL (derived from relevant regional, national or local
data) and the mean or other appropriate value observed in practice from a suitable
reference group of patients. A suitable reference group of patients is defined within a
certain range of physical parameters (e.g. height, weight). Corrective action should
be taken as necessary if exposures do not provide useful diagnostic information and
do not yield the expected medical benefit to patients.
There have been a number of different quantities used for DRLs. The quantity
selected is dependent on the type of clinical procedure, for example, whether it is an
individual radiographic projection, a procedure or examination consisting of multiple
projections or field locations, or a diagnostic nuclear medicine procedure. The
quantity used is also dependent on the authority setting the reference level, and is
related to the desired aim, local preference and the unique irradiation conditions. The
concept of a DRL permits flexibility in the choice of quantities, numerical values and
technical or clinical specifications, in order to allow authorized bodies to meet the
objective relevant to their circumstances.
DRLs for diagnostic radiology should be based on doses measured in various
types of hospitals, clinics and practices and not only in well-equipped hospitals.
These levels should be higher than the median or mean value of the measured patient
doses or doses in a phantom. Given that the curve representing the number of
examinations and their doses is usually skewed with a long tail, the level of the 75th
percentile seems appropriate. The use of this percentile is a pragmatic first approach
to identifying those situations in most urgent need of investigation [European
Commission, 1999].
DRLs can be assessed using ESD, measured with a TLD fixed on the patient’s
body, or the AKAP. For CT, the weighted CTDI (CTDIw) and the DLP are suitable
quantities to be used as DRLs. For mammography, there is a specific DRL called
Mean Glandular Dose (MGD) which indicate the absorbed dose to the breast tissues.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Literature Review
17
For guided interventional procedures (especially fluoroscopy-guided
procedures), DRLs would provide useful guidance in the endeavour to avoid
deterministic effect (non-stochastic). However, the observed distribution of patient
doses is very wide, even for a specified protocol, because the duration and
complexity of the fluoroscopic exposure for each conduct of a procedure is strongly
dependent on the individual clinical circumstances. A potential approach is to take
into consideration not only the usual clinical and technical factors, but also the
relative “complexity” of the procedure.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Methodology
18
2.2 METHODOLOGY
2.2.1 Introduction
This survey, basically following the guidelines established by UNSCEAR, was
conducted in 437 public and private hospitals, medical centres or general
practitioner’s clinics; and 329 public and private dental clinics in Malaysia. These
hospitals/medical centres/clinics (hereafter referred as “sites”) were selected
randomly nationwide to represent 30 percent of the total number of sites in the
country. The sites are generally categorized into five (5) categories: public hospitals,
private hospitals, general practitioners’ (GP) clinics, public dental clinics and private
dental clinics. The 30 percent sampling size will serve as the minimum number of
sites for this survey. The selection of the sites should also represent the reasonable
good geographical spread of the population.
This survey was conducted on the basis of statistics from all the common
examinations performed in diagnostic radiology and dental radiology in 2007, 2008
and 2009. The survey was completed with demographic data covering different
information including the equipment, personnel and patients information, as well as
the dosimetric data which some were measured using TLD (i.e. general x-ray, BMD
and dental) and Gafchromic® films (i.e. fluoroscopy and interventional radiology)
while others were calculated using mathematical formula (i.e. mammography) or
computer software (i.e. CT). On the basis of above mentioned data, estimations were
carried out based on the frequency of examinations and the relative contribution (%)
of each procedure.
Six (6) different diagnostic modalities were included in this survey: general
x-ray, mammography, fluoroscopy/angiography, CT, BMD and dental radiology.
To estimate the typical dose delivered to an average Malaysian adult patient,
measurements were made on a sample of patients within a range of 40 – 80 kg. Both
genders were included in this survey.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Methodology
19
2.2.2 Dosimetric Quantities
Radiation quantities that are involved in patient dosimetry are basically divided
into three categories, namely, source quantities, field quantities and patient dose
quantities, as shown in Figure 2.1. In this survey, we only measured or calculated the
patient dose quantities based on the exposure parameters.
Figure 2.1: Radiation dosimetric quantities [Wall et al., 1998].
In patient dosimetry, several specialized dosimetric quantities can be used for
different radiation assessment purposes. Therefore, the recommended dosimetric
quantities to be used in this survey were explained clearly before the data collection
and analysis to meet the following objectives which are to:
(a) enable unambiguous definition so that everyone can clearly understand
what is to be measured;
(b) enable simple, direct measurement with readily available dosimeters of
sufficient precision and accuracy;
Energy imparted
SOURCE QUANTITIES Tube current Exposure time Applied potential Filtration FIELD QUANTITIES Photon fluence Energy fluence Exposure Absorbed dose in air Air Kerma Air Kerma-Area Product PATIENT DOSE QUANTITIESEntrance Surface Dose (with backscatter)
Depth Dose
Exit Surface Dose Organ Dose
Image Receptor
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Methodology
20
(c) provide a measurement of the typical dose received by patients examined
in a particular centre.
Table 2.1 summarizes different quantities and units used in different modality
of diagnostic, interventional and dental radiology in this survey.
Table 2.1: Dosimetric quantities and units for different modalities in diagnostic, interventional and dental radiology.
Modality Measured Quantity
(Unit)
Derived Quantity
(Unit)
General X-ray Entrance Surface Dose (mGy) Effective Dose (mSv)
Mammography Incident Air Kerma (mGy) Mean Glandular Dose
(mGy)
Fluoroscopy / Angiography Kerma-Area Product
(mGy.m2) or
Peak Skin Dose (mGy)
Effective Dose (mSv)
Computed Tomography CT Dose Index (mGy) or
Dose Length Product
(mGy.cm)
Effective Dose (mSv)
Bone Mineral Densitometry Entrance Surface Dose (mGy) Effective Dose (mSv)
Dental - Intraoral
Dental - Panoramic
Entrance Surface Dose (mGy)
Air Kerma-Area Product
(mGy.m2)
Effective Dose (mSv)
Effective Dose (mSv)
2.2.3 Selection of Cases and Sample Size
A sample of diagnostic radiological examinations or procedures were taken for
dose measurement. Minimum 30 cases per examination were taken for measurement
in order to be statistically representative of the actual scenario of the exposure of
medical radiation in the country.
2.2.4 Data Collection Protocols
The data collection was basically divided into three (3) surveys: Background
information survey (Appendix A), radiation dose survey (Appendix B) and
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Methodology
21
questionnaire survey (Appendix C). Figure 2.2 shows the breakdown of the overall
data collection methodology. The following section elaborate the specific objectives
and protocols for different survey.
Figure 2.2: The breakdown of data collection methodology.
2.2.5 Background Information Survey
The background information provides general information of the hospitals or
centres: The number of physicians in the hospital may be interpreted as the number
of medically qualified doctors. This survey aimed to obtain the total number of
personnel serving at diagnostic radiology and dental radiology departments from
2007 to 2009 according to different categories, i.e. radiologists, medical physicists
and radiographers.
Other than personnel information, the background information also includes
the modality or equipment information. For each centre, general information and
equipment specific data such as room or location of the equipment, model,
manufacturer, serial number and year of purchase were recorded. There are different
equipment used for different diagnostic modalities, for example, the general x-ray
Diagnostic & Dental Radiology Dose Survey
Part A Background Information
Survey
Part B Radiation Dose Survey
• General X-ray • CT • Mammography • BMD • Dental • Fluoroscopy/Angiography
Equipment Information
Part C Questionnaire Survey
Personnel Information
• Demographic
• Frequency
• Dosimetric
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Methodology
22
unit used at diagnostic radiology is very much different from the x-ray unit used in
dental radiology.
A background information survey form was prepared and distributed to all the
research assistants for data collection as explained in the following sections.
(a) Diagnostic and Interventional Radiology Background Information
Information was recorded in the form as in Appendix A. Background
information was needed for the number of personnel; these include radiologists,
interventional radiologists, interventional cardiologists, medical physicists and
radiographers. Any operator who performs x-ray examinations should be included in
the number of radiographers. Information was required concerning the numbers of
individual machine used in diagnostic radiology. For x-ray equipment, this is broadly
taken to be the number of mobile or static generators (rather than x-ray tubes) that
were used for radiography or fluoroscopy, CT, mammography, BMD and dental
radiology. This information was recorded in form as in Appendix D. Detail
information such as the room location of the machine, model, manufacturer, serial
number and year of purchase also recorded. Additional information such as the
number of slices for each CT unit, half value layer (HVL) and incident air kerma
value for mammography unit would be useful for the dose measurement exercise.
(b) Dental Radiology Background Information
Information was recorded in the form as in Appendix A. Background information
was needed for the number of personnel; these included dentist, medical physicists
and radiographers. Information regarding dental x-ray and dental CT were recorded
in the same form as in Appendix D.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Methodology
23
2.2.6 Questionnaire Survey
The questionnaire survey forms recorded the number of cases performed
annually as well as the estimated patient dose. The dosimetric data should represent
typical or average values per examination or treatment. Data were also requested for
each type of procedure concerning the distributions of patients by age (0-15 years,
16-40 years, and >40 years) and by gender. It is important to know how many
examinations were undertaken on male and female patients separately. Consequently,
the data in the six boxes (3 age bands by 2 genderes) should add up to 100%. The
survey forms were designed based on the original UNSCEAR form with some minor
modifications to suit local conditions. The questionnaire survey forms are attached in
the Appendix C.
2.2.7 Dose Measurement Protocols
(a) General X-ray
General x-ray is by far the most common form of radiography technique all
over the world. The different types of radiographic techniques require knowledge of
the frequency of each type of examination and the associated levels of patient dose.
The general x-ray examinations and projections that were studied in this survey are
as listed in Table 2.2. The positioning of the TLDs for each examination type was
explained in detail in the document “Research Methodology”.
Table 2.2: Types of examinations and radiographic projections for general x-ray.
Examination Projections Chest Chest PA
Chest LAT Limbs & Joints
Upper Extremities: Hand, Wrist, Radius, Ulna, Elbow, Humerus, Shoulder Lower Extremities: Foot, Ankle, Tibia, Fibula, Femur, Knee
Spine
Lumbo-sacral AP Lumbo-sacral LAT Thoracic AP Thoracic LAT Cervical AP Cervical LAT
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Methodology
24
Pelvis/Hip Skull
AP Lateral Others (Towne, Caldwell, etc)
Abdomen/KUB
TLDs were used for measurement of ESD. The TLD that was used in this
survey was LiF(Tl) thermoluminescent dosimetry chips (TLD-100, Harshaw®). The
TLDs were calibrated at the Secondary Standard Dosimetry Laboratory of the
Malaysian Nuclear Agency (MNA). MNA did the annealing of the TLD chips to
erase the residual signal then packaged them into small sachets with two TLDs in
each sachet. Each TLD sachet was labeled with a unique code as agreed by both
MOH and MNA. Each TLD code consisted of two parts: a letter state code followed
by three numbers, e.g., A_001. The exposed TLDs were then sent back to MNA’s
Secondary Standard Dosimetry Laboratory (SSDL) for reading. Each TLD gave an
individual reading of ESD. Therefore, for each sachet, two ESD readings were
obtained. The average of the two TLD chips’ readings was calculated as the ESD for
that particular case.
2ESDESD ESD Dose, Surface Entrance 21
avg+
=
(b) Fluoroscopy and Interventional Radiology
For fluoroscopy and interventional radiology procedures, the Gafchromic® XR
type R film and KAP meter were used to measure the PSD and AKAP. The types of
fluoroscopy and interventional radiology procedures that were studied are as follows:
Table 2.3: Types of procedures for fluoroscopy and interventional radiology.
Procedures Types of procedures
Angiography
(Diagnostic)
Cardiac
Non-cardiac
Conventional Studies Endoscopic retrograde cholangiopancreatography (ERCP)
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Methodology
25
Gastrointestinal Lower
Gastrointestinal Upper
Micturating Cystourography (MCU)
Interventional
Radiology
Cerebral
Extracorporeal Shock Wave Lithotripsy (ESWL)
Percutaneous Transluminal Coronary Angioplasty (PTCA)
Vascular
Others
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Methodology
26
Figure 2.4: Orientation markings on the reversed side of the Gafchromic® film.
X-ray tube
Couch
Typical patient-examination distance KAP meter
Patient
Image Intensifier/Flat Panel Detector
Collimator
Head
RDenoting the right side of the patient
Marker showing the orientation of the Gafchromic® film
Figure 2.3: Patient measurement set up.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Methodology
27
The AKAP value was obtained from the console of the fluoroscopy unit, as
shown in Figure 2.5. During the data collection, the unit of the AKAP reading was
converted into mGy.m2.
Figure 2.5: AKAP reading displayed on fluoroscopy console.
Prior to using the Gafchromic® film, the film was calibrated and the
characteristic calibration curve was established. This was done by cutting the sheets
of films into a 5 cm × 5 cm square. These pieces of films were then exposed to a
series of known amount radiation doses using the fluoroscopy unit. This created a
step-like calibration strip, as shown in Figure 2.6. The darkening of the film can be
cross-calibrated with an ion-chamber to determine the radiation dose.
Figure 2.6: Example of the calibration strips during the calibration of Gafchromic® film.
AKAP reading
0 mGy (Control)
3258 mGy
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Methodology
28
The calibration strips were scanned by the computer using a reflective flat-bed
scanner (ScanMakerTM 9800XL, Microtek®) to obtain its pixel values related to the
known radiation dose. Therefore a calibration curve was obtained and the formula
was worked out from the relationship of pixel-radiation dose. This formula was used
later to analyze the exposed Gafchromic® film from the patient cases. The exposed
Gafchromic® films were scanned by the computer and the map of the skin dose
distribution was plotted. PSD as well as the mean and minimum dose were obtained
from the analysis of the intensity of the dose distribution map. Matlab® program
version R2007b was used for this analysis. An example of the skin dose distribution
map is shown in Figure 2.7.
Figure 2.7: Scanned Gafchromic® film and the skin dose distribution map.
(c) Computed Tomography (CT)
The introduction of CT into clinical practice was followed by a dramatic
increase in the number of CT examinations performed, hence the increase in
radiation dose delivered to the patients. Multi-slice CT (MSCT) increases the
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Methodology
29
efficacy of CT procedures and offers new promising applications. The expanding use
of MSCT, however, has resulted in an increase in both frequency of procedures and
levels of patient exposure. The CT examinations that were studied in this survey
were as follow:
Table 2.4: Types of CT examinations.
Types of examinations
Brain
Spine/Musculo-skeletal (including Cervical, Thorax, Lumbo-Sacral Spine)
Chest
Abdomen
Pelvis
Cardiac CT
The effective dose from CT examinations was calculated using the CT Expo
software version 1.6E developed by Georg Stamm and Hans Dieter Nagel. There
were three principal application modules in CT Expo: “Calculate”, “Standard” and
“Benchmarking”. The parameters required to calculate the effective dose include
patient age, patient gender, scan range, scanner model, select mode (helical or spiral),
scan parameters such as kV, mA, time, mAs, beam width, table feed per rotation,
reconstructed slice thickness, and number of scan series. The results of the dose
calculation were displayed as CTDIw, CTDIvol, DLP, ED and dose to the uterus (for
women). In addition, this version of CT Expo also provides the equivalent dose for
each different organ or tissue.
(d) Mammography
The risk and benefits of mammography screening programs are still being
widely debated. Although mammography may now be regarded as a ‘low-dose’
procedure, there remains a continuing need for periodic dose measurement. This
study recorded the mammography cases with cranial-caudal (CC), mediolateral
oblique (MLO) and lateral views. Finally the MGD were obtained by calculation
using the following formula:
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Methodology
30
Kgcs= D m
where K is the incident air kerma calculated (in the absence of scattered
radiation) at the upper surface of the breast. The factor g corresponds to a
glandularity of 50% adipose and 50% glandular breast tissue. c is factors for typical
breast compositions in the age ranges 40-49 and 50-64. The factor s corrects for any
difference due to the choice of x-ray spectrum.
(e) Bone Mineral Densitometry (BMD)
Dual x-ray absorptiometry (DXA) provides the gold standard for performing
bone mineral densitometry measurement. They provide a convenient, non-invasive
method of assessing skeletal bone mineral density which is widely used for clinical
studies. Just as any technique involving exposure of patient to ionizing radiation
requires an assessment of the risk of radiation injury. The quantity that is commonly
used to assess the radiation dose is the ESD, which is similar to the method used for
general x-ray dose measurements.
There were two types of bone mineral densitometry examination included in
this survey:
Table 2.5: Type of BMD examinations.
Types of examinations
AP Spine
Left Hip / Right Hip
(f) Dental Radiology
New therapeutic techniques in dental medicine require diagnostic procedures
that allow accurate planning of the dental implants and familiarization of the dental
anatomy. Conventional dental radiography is associated with low doses and risks for
the individual patient. However, while dental radiography is generally ‘low dose’, it
is a high volume procedure. Therefore, an assessment of the radiation dose incurred
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Methodology
31
to patients from dental radiological procedures is needed. There were two types of
dental radiology examination studied in this survey:
Table 2.6: Type of dental radiology examinations.
Types of examinations
Intraoral
Panoramic
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Data Analysis
32
2.3 DATA ANALYSIS
2.3.1 Introduction
This survey provides qualitative and quantitative information on the doses for
diagnostic, interventional and dental radiology, to assess medical radiation exposure
in Malaysia and to allow data comparison with other countries. The results of the
survey provide the basis for optimization procedures and guidelines for radiation
protection as well as the establishment of national DRLs for the country.
A centralized computer database was designed and developed for the data
management (Figure 2.8). The data from the background information survey and
dose survey were stored in the database. This database was also built in with the
radiation dose calculation formula for mammography; hence the MGD of patients
were calculated automatically and stored in the database as long as the
mammography x-ray unit and the exposure parameters were given.
Data analysis was done using the Statistical Package for the Social Sciences
(SPSS) version 16. SPSS is an established statistical analysis software used for
descriptive statistics, bivariate statistics, prediction for numerical outcomes and
prediction for identifying groups. Generally, the data analysis in this survey could be
divided into two (2) main categories, which are descriptive statistics and dosimetric
analysis. Descriptive statistics include the analysis of number of personnel, number
of equipment and frequency of cases performed; whereas the dosimetric analysis
include the numerical calculation for the radiation exposure such as mean, minimum,
maximum, standard deviation, median, 1st quartile and 3rd quartile. The analysis
outputs are displayed in pie charts and tables for descriptive statistics and box plots
for the dosimetric analysis. Histograms were also included in the analysis to
demonstrate the distribution or proportion of cases that fall into each of several
categories.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Data Analysis
33
Figure 2.8: Medical Radiation Exposure Survey database management system.
2.3.2 Data Screening
Prior to data analysis, the data was screened several times to identify errors and
outliers. The errors could be from human mistakes such as typographical errors, error
in calculation, unit conversion errors, misplaced variables, etc. These data were
either corrected or rejected from analysis depending on the validity of the data.
Incomplete or invalid data were rejected from the analysis.
During screening of the dosimetric data, values less than 2% and more than
98% from the mean were excluded (the first step of data screening to avoid being
affected by extreme values), and a new mean was calculated. The values which were
smaller, or larger than 2 standard deviations from the new mean were considered as
outliers and were excluded from the analysis.
Medical
Radiation Exposure Survey Central
Database
Dose Calculation
Program
Background Information
Survey
Radiation Dose Survey
Statistical Analysis
Output / Result
Input Dose
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Data Analysis
34
2.3.3 Descriptive Statistics
The United Nations defines four levels of health care in the world based on
population per physician [UNSCEAR, 1988]. At the highest level of health care
(Level I), there are one or more physicians for each 1,000 population; Level II has
one physician for each 1,000 to 3,000 population; Level III has one physician for
3,000 to 10,000 population, and for Level IV has one physician for more than 10,000
population. The Background Information Survey allows the analysis of the number
of personnel, including physicians, medical physicists and
technologists/radiographers per 1,000 population. In this survey, the trend of
personnel growth in diagnostic, interventional and dental radiology was monitored
from 2007-2009. Malaysia with 27.17 million population in 2007, and an average of
1,429 population per physician is classified as health care Level II country.
The number of equipment or facilities provides useful information on the unit
to population ratio of the country. The results would be compared to the survey in
other countries worldwide to estimate the trend of growth of human assets in
Malaysia. The equipment in diagnostic and dental radiology include general x-ray,
mammography, fluoroscopy/angiography, CT scanner, BMD and dental x-ray.
For each procedure, basic patient demographics such as age, gender, ethnic
group, height and weight data were acquired from the respective hospital’s database.
Descriptive statistics such as mean, median, range, 1st quartile and 3rd quartile
histogram were tabulated.
2.3.4 Dosimetric Analysis
Patient dose for common types of diagnostic examinations were summarized as
follows:
(a) Entrance Surface Dose (mGy) for general x-ray, bone mineral
densitometry and dental radiology (intraoral);
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Data Analysis
35
(b) Air Kerma-Area Product (mGy.m2) and Peak Skin Dose (mGy) for
fluoroscopy/angiography;
(c) Computed Tomography Dose Index (mGy), Dose Length Product
(mGy.m2) and Effective Dose (mSv) for computed tomography;
(d) Mean Glandular Dose (mGy) for mammography;
(e) Air Kerma-Area Product (mGy.m2) for dental radiology (panoramic)
Finally, the dosimetric data collected for all modalities were compared with the
data published from other surveys.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
36
2.4 RESULT AND DISCUSSION
2.4.1 Descriptive and Numerical Analysis
This section includes the analysis for number of personnel (radiation workers),
number of equipment or facilities, total number of cases and patient dosimetry in
30% of healthcare facilities of diagnostic and interventional radiology services in
Malaysia from 2007 to 2009.
(a) Number of Personnel
The radiation workers at above mentioned centres are radiographers, dental
practitioners, general medical practitioners, dental surgery assistants, trained
operators, radiologists, medical physicists, interventional cardiologists and
interventional radiologists. Table 2.7 summarizes the number of radiation workers in
all the sample sites from 2007 to 2009.
Among all the personnel, radiographers remained the highest number for all
three years. This was followed by dental practitioners, general medical practitioners,
dental surgery assistants and trained operators. A radiologist is defined as a physician
specialized in diagnostic radiology, the branch of medicine that uses ionizing and
non-ionizing radiation for the diagnosis and treatment of disease. An interventional
radiologist is a radiologist subspecialized in advanced interventional radiology
procedures. Both use imaging modalities such as fluoroscopy/angiography,
angiography, CT, MRI and ultrasound. An interventional cardiologist is a
cardiologist subspecialized in invasive cardiology who uses fluoroscopy/
angiography guidance to treat coronary and cardiovascular diseases.
In general, the number of personnel in diagnostic and interventional radiology
services in Malaysia are increasing over the years as shown in Table 2.7 and Figure
2.9.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
37
Table 2.7: Total number of personnel in diagnostic, interventional and dental radiology from all the sample sites (2007-2009).
Personnel 2007 2008 2009
Radiographers 656 690 1110
Dental Practitioners 300 322 528
General Medical Practitioners 170 195 312
Dental Surgery Assistants 76 103 237
Trained Operators 205 217 231
Radiologists 129 126 170
Medical Physicists 8 10 24
Interventional Cardiologists 14 15 20
Interventional Radiologists 3 4 4 Figure 2.9: Histogram showing the number of personnel in diagnostic, interventional and dental radiology from all the sample sites from 2007 to 2009.
2009
2008
2007
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
38
(b) Number of Equipment
The equipments were grouped according to the modality, which are general x-
ray, mammography, fluoroscopy/angiography, CT, BMD and dental x-ray units
(intraoral and orthopantomogram (OPG)).
Table 2.8 and Figure 2.10 shows the total number of equipment in diagnostic,
interventional and dental radiology from all the sample sites. General x-ray made up
the highest number among all the equipment/modalities. This was followed by dental
x-ray, fluoroscopy/angiography, CT scanners, mammography and BMD.
Table 2.8: Total number of equipment in diagnostic, interventional and dental radiology from all the sample sites (2007-2009).
Equipment/Modality Total Number of Equipment
2007 2008 2009
General x-ray 424 467 530
Dental x-ray 348 384 419
Fluoroscopy / angiography 76 80 92
CT scanner 50 60 68
Mammography 36 43 50
Bone mineral densitometer 11 12 13
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
39
Figure 2.10: Histogram showing the number of equipment in diagnostic, interventional and dental radiology from all the sample sites from 2007 to 2009.
(c) Total Number of Cases
The total number of cases collected is presented in Table 2.9. There was a total
of 19,885 cases collected from all the modalities. General x-ray examinations
constituted the highest number of cases, followed by CT, mammography, dental
radiology, fluoroscopy/angiography (includes interventional studies) and BMD.
Table 2.9: Total number of cases collected by modality.
Modality Number of Cases Collected
General X-ray 6533
Fluoroscopy/Angiography 410
Computed Tomography 6236
Mammography 5226
Bone Mineral Densitometry 154
Dental Radiology 1326
TOTAL 19885
2009
2008
2007
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
40
2.4.2 General X-ray
(a) Number of Cases
The total number of cases collected is shown in Table 2.10 and Figure 2.11.
Table 2.10: Number of cases collected for general x-ray from all the sample sites.
Exam. Type Frequency Percentage (%)
Abdomen/KUB 402 6.2
Cervical AP, LAT 254 3.9
Chest LAT 32 0.5
Chest PA 2743 42.0
Lower and Upper Extremities 1963 30.0
Lumbo-Sacral AP, LAT 542 8.3
Pelvis/Hip 263 4.0
Skull 196 3.0
Thoracic AP, LAT 138 2.1
Total 6533 100.0
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
41
Figure 2.11: Number of cases collected for general x-ray.
(b) Dosimetric Data
The dosimetric data for general x-ray was expressed in ESD using TLD. The
unit for ESD is mGy. The mean, median, minimum, maximum, standard deviation,
1st quartile (1st Q) and 3rd quartile (3rd Q) for ESD collected were summarized in
Table 2.11 by type of examination. Figure 2.12 shows the box-plot from the analysis.
Table 2.11: Entrance Surface Dose (mGy) by examination.
Exam. Type Entrance Surface Dose (mGy)
Mean Median Min Max Std. Dev. 1st Q 3rd Q
Abdomen / KUB 5.05 4.58 0.96 11.78 2.64 3.22 7.36
Cervical AP 1.58 1.10 0.27 6.40 1.25 0.69 2.10
Cervical LAT 1.57 1.44 0.28 5.66 1.03 0.76 2.05
Chest LAT 1.34 1.22 0.21 3.08 0.80 0.73 1.83
Chest PA 0.61 0.50 0.05 2.00 0.43 0.29 0.87
Extremities (Lower) 0.71 0.54 0.08 4.82 0.61 0.29 0.93
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
42
Extremities (Upper) 0.67 0.52 0.08 3.08 0.53 0.29 0.85
Lumbo-Sacral AP 5.44 5.10 1.08 10.97 2.47 3.69 7.50
Lumbo-Sacral LAT 10.96 11.26 1.17 18.73 4.14 6.63 13.4
Pelvis 4.32 3.67 0.29 12.85 2.83 1.83 5.80
Skull AP 3.76 3.54 0.68 8.56 1.94 2.37 4.80
Skull LAT 1.77 1.60 0.50 3.46 0.79 0.98 2.40
Skull Others 3.85 3.16 1.10 7.53 2.37 1.85 5.51
Thoracic AP 4.78 4.36 1.29 9.61 2.28 3.24 6.80
Thoracic LAT 6.38 6.30 1.38 12.90 2.90 3.94 7.50
Figure 2.12: Entrance surface dose (mGy) by examination.
(c) Data Comparison with Recommended DRLs
The dosimetric data for general x-ray collected from this survey were
compared to the DRLs recommended by different international organizations, such
as NRPB, AAPM, EC, IAEA, IPSM and CRCPD. One of the main objectives of this
ESD (mGy) for Different Examination Types in General X-ray
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
43
survey was to develop a local DRL in the relevant diagnostic imaging disciplines to
fit the local population and conditions. Table 2.12 presents the comparison between
the data collected from this survey with the DRLs recommended by the international
organizations for common general x-ray examinations.
Table 2.12: Comparison of Entrance Surface Dose (mGy) for general x-ray collected from this survey with DRLs recommended by different international organizations.
Exam.
Type
Projection Entrance Surface Dose (mGy)
*This
Survey
(2009)
UK1NRPB
(1999)
US2AAPM
(1999)
EC3EUR96
(1996)
IAEA 4BSS
(1996)
UK 5IPSM
(1992)
USA 6CRCPD
(1988)
Abdomen AP 7.4 10 4.50 N/A 10.00 10.00 4.30
Cervical
Spine
AP 2.1 N/A 1.25 N/A N/A N/A 1.20
LAT 2.1 N/A N/A N/A N/A N/A N/A
Chest PA 0.9 0.30 0.25 0.30 0.40 0.30 0.10
LAT 1.8 1.50 N/A 1.50 1.50 1.50 N/A
Lumbar
Spine
AP 7.5 10.00 5.00 10.00 10.00 10.00 3.90
LAT 13.4 30.00 N/A 30.00 30.00 30.00 N/A
Pelvis/Hi
p
AP 5.8 10.00 N/A 10.00 10.00 10.00 N/A
Skull AP/PA 4.8 5.00 N/A 5.00 5.00 5.00 N/A
Lateral 2.4 3.00 N/A 3.00 3.00 3.00 1.30
Others 5.5 N/A N/A N/A N/A N/A N/A
Thoracic
Spine
AP 6.8 N/A N/A N/A 7.00 N/A 2.30
LAT 7.5 N/A N/A N/A 20.00 N/A N/A* The entrance surface doses presented in this table are the 3rd quartile values calculated from the
total cases collected in this survey in the period of 2007-2009. 1. National Radiological Protection Board. Guidance on patient dose to promote optimization of
protection for diagnostic medical exposures. Documents of the NRPB, Vol 10, No. 1. 1999.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
44
2. American Association of Physicists in Medicine Task Group. Reference values – Application and impact in radiology. AAPM. 1999.
3. European Commission. European guidelines of quality criteria for diagnostic radiographic images. Eur 16260 EN. EC. 1996.
4. International Atomic Energy Agency. International Basic Safety Standards protection against ionizing radiation and for the safety of radiation sources. Safety Series No. 115. IAEA. 1996.
5. Institute of Physical Sciences in Medicine. National protocol for patient dose measurements in diagnostic radiology. Dosimetry Working Party, IPEM. 1992.
6. Conference of Radiation Control Program Directors. Average patient exposure guides. CRCPD Publication 88-5. 1988.
2.4.3 Fluoroscopy and Interventional Radiology
(a) Number of Cases Collected
The total number of cases collected for fluoroscopy and interventional
radiology is shown in Table 2.13.
Table 2.13: Number of cases collected for fluoroscopy and interventional radiology.
Exam. Categories Exam. Type Frequency Percentage
(%)
Angiography Cardiac 88 21.5
Non-cardiac 36 8.8
Conventional Studies ERCP 25 6.0
Lower Gastrointestinal 82 20.0
MCU 4 1.0
Upper Gastrointestinal 29 7.0
Interventional Cardiac (PTCA) 31 7.6
Cerebral 32 7.8
ESWL 8 2.0
Vascular 57 13.9
Others 18 4.4
Total 410 100.0
Note: Others include Nephrostomy, Percutaneous Transhepatic Biliary Drainage (PTBD), Sinogram, Anal Fistulogram, Ascending Urethrogram, Lower Limb Angiography, Cystography and Renal Embolization
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
45
Figure 2.13: Number of cases for angiography, conventional and interventional studies using fluoroscopy/angiography
Figure 2.14: Number of cases for angiography (cardiac and non-cardiac).
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
46
Figure 2.15: Number of cases for fluoroscopy (conventional studies).
Figure 2.16: Number of cases collected for fluoroscopy (interventional studies).
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
47
(b) Dosimetric Data
The dosimetric data for fluoroscopy and interventional radiology were
expressed in both AKAP using KAP meter and PSD using gafchromic film. The unit
used for AKAP is mGy.m2 whereby for PSD is mGy. PSD represents the maximum
point dose in a defined area or volume. In this survey, the Mean Skin Dose (MSD)
which represents the average skin dose in a defined exposure area was also presented.
The mean, median, minimum, maximum, standard deviation, 1st quartile (1st Q) and
3rd quartile (3rd Q) for AKAP, PSD and MSD collected were summarized in Table
2.14 to 2.16 according to different examination types. Figure 2.17 to 2.22 shows the
box-plot from the analysis.
Table 2.14: Air Kerma-Area Product (mGy.m2) for various fluoroscopy examination types in conventional and interventional studies.
Exam. Type Air Kerma-Area Product (mGy·m2)
Mean Median Min Max Std. Dev. 1st Q 3rd Q
Angiography
Cardiac 4.19 3.08 0.23 15.21 3.13 2.22 5.44
Non-Cardiac 3.06 1.35 0.01 13.26 3.77 0.05 5.22
Conventional Studies
ERCP 0.64 0.49 0.20 1.57 0.38 0.35 0.83
GI Lower 0.70 0.48 0.03 3.90 0.75 0.25 0.68
GI Upper 0.65 0.58 0.07 2.52 0.52 0.26 0.85
MCU 1.16 1.28 0.49 1.92 0.50 0.80 1.41
Interventional Studies
Cerebral 8.22 6.61 3.10 31.32 5.96 4.81 8.70
ESWL 0.62 0.58 0.15 1.18 0.43 0.39 0.81
PTCA 13.01 12.52 2.10 34.02 8.50 5.38 15.70
Vascular 4.76 1.94 0.01 36.58 7.07 0.62 5.87
Others 1.55 0.80 0.06 4.68 1.52 0.63 2.01
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
48
Figure 2.17: Air Kerma-Area Product (mGy.m2) for various examination types in angiography and conventional fluoroscopy.
Figure 2.18: Air Kerma-Area Product (mGy.m2) for various procedures in interventional studies.
AKAP (mGy.m2) for Various Examination Types in Angiography & Conventional Fluoroscopy Studies
AKAP (mGy.m2) for Various Procedures in Interventional Studies
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
49
Table 2.15: Peak Skin Dose (mGy) for various fluoroscopy examination types in conventional and interventional studies.
Exam. Type Peak Skin Dose (mGy)
Mean Median Min Max Std. Dev. 1st Q 3rd Q
Angiography
Cardiac 693.16 560.70 221.50 2186.40 466.50 346.9 825.63
Non-Cardiac 696.53 648.00 196.30 1403.10 310.27 515.3 753.80
Conventional Studies
ERCP 747.54 620.45 245.60 1894.10 477.87 351.98 961.50
GI Lower 621.95 503.50 210.63 1710.90 338.53 355.80 844.40
GI Upper 458.41 387.75 199.70 977.30 216.75 279.30 602.93
MCU 770.67 803.40 268.00 1383.20 428.70 434.95 991.25
Interventional Studies
Cerebral 891.77 609.10 330.10 2322.40 590.06 444.90 1108.80
ESWL 273.80 278.75 165.90 371.80 106.18 141.18 361.38
PTCA 1116.01 951.70 199.20 2675.90 650.78 30.00 1508.28
Vascular 576.31 422.90 207.70 1577.60 367.31 8.00 703.40
Others 657.35 511.80 270.00 1535.70 406.12 392.00 790.85
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
50
Figure 2.19: Peak Skin Dose (mGy) for various examination types in angiography and conventional fluoroscopy.
Figure 2.20: Peak Skin Dose (mGy) for various procedures in interventional studies.
PSD (mGy) for Various Examination Types in Angiography & Conventional
Fluoroscopy Studies
PSD (mGy) for Various Procedures in Interventional Studies
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
51
Table 2.16: Mean Skin Dose (mGy) for various fluoroscopy/angiography examination types in conventional and interventional studies.
Exam. Type Mean Skin Dose (mGy)
Mean Median Min Max Std. Dev. 1st Q 3rd Q
Angiography
Cardiac 111.76 113.20 79.60 163.50 18.00 97.05 122.13
Non-Cardiac 117.71 118.00 88.50 172.20 21.54 105.00 122.40
Conventional Studies
ERCP 103.53 97.05 79.10 181.20 27.39 82.95 115.18
GI Lower 100.68 97.20 73.90 152.40 19.87 82.20 115.40
GI Upper 106.93 113.75 76.30 141.90 20.51 81.85 118.03
MCU 95.22 93.55 79.70 114.60 15.72 81.25 107.95
Interventional Studies
Cerebral 128.12 132.70 98.90 183.90 18.24 117.00 135.80
ESWL 113.62 113.20 111.00 117.10 2.93 111.30 115.53
PTCA 145.58 141.05 84.80 251.40 37.09 119.25 168.10
Vascular 125.31 120.20 86.80 261.70 34.56 108.85 134.80
Others 103.54 109.40 80.90 129.10 16.74 86.33 115.83
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
52
Figure 2.21: Mean Skin Dose (mGy) for various examination types in angiography and conventional fluoroscopy.
Figure 2.22: Mean Skin Dose (mGy) for various procedures in interventional studies.
MSD (mGy) for Various Examination Types in Angiography & Conventional
Fluoroscopy Studies
MSD (mGy) for Various Procedures in Interventional Studies
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
53
(c) Data Comparison with Published Literature
The dosimetric data collected for fluoroscopy and interventional radiology
were compared with the data published from other national surveys. Table 2.17
presents the comparison between the data collected from this survey with the
published data from other studies.
Table 2.17: Comparison of Air Kerma-Area Product (AKAP) with other published literature.
Exam.
Type
Air Kerma-Area Product or Dose-Area Product (mGy.m2)1This
Survey
(2009)
2Efstathopoulous
et al.(2005)
3Sapiin et al.
(2004)
4Van de Putte et al.
(2000)
5Tsalafoutas
et al. (2003)
6Vano et al.
(1998)
7Warren-Forward
et al. (1998)
Angiography
Cardiac 5.4 N/A 3.70 5.68 N/A 4.58 N/A
Non-
Cardiac
5.2 N/A 8.66 N/A N/A 6.66 N/A
Conventional Studies
ERCP 0.8 N/A N/A N/A 0.85 N/A N/A
GI Lower 0.7 N/A N/A N/A N/A N/A 0.22-0.77
GI Upper 0.9 N/A N/A N/A N/A N/A 0.11-0.44
MCU 1.4 N/A N/A N/A N/A N/A N/A
Interventional Studies
Cerebral 8.7 10.98 N/A N/A N/A N/A N/A
ESWL 0.8 N/A N/A N/A N/A N/A N/A
PTCA 15.7 7.89 11.06 10.88 N/A 6.68 N/A
Vascular 5.9 32.50 12.81 N/A N/A N/A N/A
Others 2.0 N/A N/A N/A N/A N/A N/A1. The AKAP presented in this table are the 3rd quartile values calculated from the total cases
collected (2007-2009). 2. Efstathopoulous EP, Brountzos EN, Alexopoulou E. Patient radiation exposure measurements
during interventional procedures: a prospective study. Health Physics; 91(1): 41-45.2006. 3. Sapiin B, Ng KH, Abdullah BJJ. Radiation dose to patients undergoing interventional
radiological procedures in selected hospitals in Malaysia: retrospective study. J HK Coll. Radiol. 7: 129-136. 2004.
4. Van de Putte S, Verhaegen F, Taeymans Y, Thierens H. Correlation of patient skin doses in cardiac interventional radiology with dose area product. Br. J Radiol. 73: 504-513. 2000.
5. Tsalafoutas IA, Paraskeva KD, Yakoumakis EN, Vassilaki AE et al. Radiation doses to patients from endoscopic retrograde cholangiopancreatography examinations and image quality considerations. RPD; 106(3): 241-246. 2003.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
54
6. Vano E, Arranz L, Sastre JM et al. Dosimetric and radiation protection considerations based on some cases of patient skin injuries in interventional cardiology. Br. J Radiol. 71: 510-516. 1998.
7. Warren-Forward HM, Haddaway MJ, Temperton DH, McCall IW. Dose-are product readings for fluoroscopic and plain film examinations, including an analysis of the source of variation for barium enema examinations. Br. J Radiol. 71:961-967. 1998.
2.4.4 Computed Tomography
(a) Number of Cases
The total number of cases collected for computed tomography is shown in
Table 2.18 and Figure 2.23.
Table 2.18: Number of cases for computed tomography.
Exam Type Frequency Percentage (%)
Abdomen 1137 18.2
Brain 2648 42.5
Cardiac 134 2.2
Chest 351 5.6
Pelvis 234 3.8
Spine/Musculo-skeletal 145 2.3
Thorax 371 5.9
Others 1216 19.5
Total 6236 100.0
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
55
Figure 2.23: Number of cases for computed tomography.
(b) Dosimetric Data
The dosimetric data for computed tomography was expressed in CTDI, DLP
and ED. The mean, median, minimum, maximum, standard deviation, 1st quartile and
3rd quartile for CTDIw and DLP collected were summarized in Table 2.19 and Table
2.20 according to different examination types, respectively. Figure 2.24 and Figure
2.25 shows the box-plot from the analysis.
In addition, the mean, median, minimum, maximum, standard deviation, 1st
quartile and 3rd quartile for ED calculated were summarized in Table 2.21 according
to different examination types. Figure 2.26 shows the box-plot from the analysis. The
examination types are listed by region only and did not take into consideration the
type of scanner or type of study (contrast, non-contrast, single or multi-phase).
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
56
Table 2.19: CTDIw (mGy) for various examination types in CT.
Exam. Types CTDIw (mGy)
Mean Median Min Max Std. Dev. 1st Q 3rd Q
Abdomen 11.1 10.2 6.2 18.5 2.6 9.8 12.8
Brain 42.3 43.8 12.8 61.2 7.9 36.1 46.8
Cardiac 9.2 8.2 1.2 28.5 6.7 2.9 11.8
Chest 15.1 13.4 4.8 31.4 6.8 10.4 19.9
Pelvis 23.3 11.6 5.1 72.2 18.5 10.2 39.1
Spine/Musculo-Skeletal 13.5 12.8 6.5 26.9 5.4 10.0 16.3
Thorax 18.8 18.3 3.1 46.9 11.4 10.2 21.3
Others 9.5 10.0 5.1 29.9 4.4 6.1 12.3
Table 2.20: DLP (mGy.cm) for various examination types in CT.
Exam. Types DLP (mGy.cm)
Mean Median Min Max Std. Dev. 1st Q 3rd Q
Abdomen 371.5 291.5 40.0 1030.0 269.1 148.2 454.7
Brain 665.2 588.0 39.0 1773.0 462.5 295.5 1050.0
Cardiac 646.2 447.5 44.0 3263.0 643.8 163.7 869.2
Chest 478.6 267.0 67.0 3994.0 551.4 143.0 606.5
Pelvis 521.7 324.0 63.0 2271.0 503.8 224.5 726.5
Spine/Musculo-Skeletal 399.4 279.0 64.0 1383.0 348.0 175.0 389.0
Thorax 337.2 303.0 45.0 1195.0 198.8 212.0 415.0
Others 326.0 244.5 55.0 1308.0 281.2 136.2 378.0
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
57
Table 2.21: Effective dose (mSv) for various examination types in CT.
Exam. Types Effective Dose (mSv)
Mean Median Min Max Std. Dev. 1st Q 3rd Q
Abdomen 8.3 7.3 1.8 26.7 4.8 4.5 10.1
Brain 1.9 1.6 0.5 8.1 1.1 0.9 2.1
Cardiac 9.1 9.2 1.0 19.7 5.9 2.7 12.3
Chest 7.9 7.3 1.4 17.7 4.0 4.5 8.97
Pelvis 7.5 6.7 2.0 19.0 4.0 3.75 8.4
Spine/Musculo-Skeletal 4.9 3.8 1.0 15.8 3.3 2.3 6.15
Thorax 6.2 5.2 1.2 22.5 3.7 3.4 8.0
Others 7.0 5.0 0.6 23.6 5.6 2.73 10.3
Figure 2.24: CTDIw (mGy) for various examination types in CT.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
58
Figure 2.25: DLP (mGy.cm) for various examination types in CT.
Figure 2.26: Effective dose (mSv) for various examination types in CT.
Effective Dose (mSv) for Various Examination Types in Computed
Tomography
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
59
(c) Data Comparison with Published Literature
The dosimetric data collected for CT in this survey were compared with the
data published from other studies. The DRLs recommended for CT are expressed in
MSAD (mGy), CTDIw (mGy) or DLP (mGy.cm2) by international organizations such
as IAEA, NRPB, EC and AAPM. The dosimetric data for CT in this survey were
compared with the recommended DRLs in other published surveys. Table 2.22 and
Table 2.23 presents the comparison of CTDIw and DLP between the data collected
from this survey with the published data from other studies. Table 2.24 presents the
comparison of effective dose between the data collected from this survey with the
published data from other studies.
Table 2.22: Comparison of CTDIw (mGy) from this survey with other published surveys.
Exam Types CTDIw (mGy) *This Survey
(2009)
1NRPB
(1999)
2EC
(1999)
3UK
(2003)
Abdomen 12.8 35 35 20 Brain 46.8 60 60 N/A Cardiac 11.8 N/A N/A N/A
Chest 19.9 30 30 N/A
Pelvis 39.1 35 35 N/A
Spine/Musculo-
Skeletal
16.3 N/A 70 N/A
Thorax 21.3 N/A N/A N/A
Others 12.3 N/A N/A N/A
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
60
Table 2.23: Comparison of DLP (mGy.cm) with other published surveys.
Exam Types DLP (mGy.cm) *This Survey
(2009)
1NRPB
(1999)
2EC
(1999)
3UK
(2003)
Abdomen 454.7 800 780 470
Brain 1050.0 1050 1050 930
Cardiac 869.2 N/A N/A N/A
Chest 606.5 650 650 N/A
Pelvis 726.5 600 570 N/A
Spine/Musculo-
Skeletal
389.0 N/A 460 N/A
Thorax 415.0 N/A N/A N/A
Others 378.0 N/A N/A N/A
* Table 2.22 and Table 2.23 presenting CTDIw and DLP values of 3rd quartile values calculated from the total cases collected of 2007-2009.
1. National Radiological Protection Board. Guidance on patient dose to promote optimization of protection for diagnostic medical exposures. NRPB, Vol 10, No. 1. 1999.
2. European Commission. European Guidance on Quality Criteria for Computed Tomography. EUR16262. EC. 1999.
3. Shrimpton P.. Assessment of Patient Dose in CT in Bongart G.Z., Golding S.J, Jurik A.G., et. al., European Guidelines for Multislice Computed Tomography. 2004.
Table 2.24: Comparison of effective dose (mSv) from this survey with other published surveys.
Exam Types Effective Dose (mSv) *This
Survey
(2009)
1Yales
et al.
Survey
(2004)
2Brix
et al.
Survey
(2003)
3UK CT
Dose
Review
(2003)
4Mettler
et al.
Survey
(1999)
5NRPB
(1999)
Abdomen 10.1 7.0-9.2 14.4 4.3-5.5 3.1 10
Brain 2.1 1.7 2.8 0.3-1.7 1.5 2
Cardiac 12.3 N/A 6.7 2.2-7.1 N/A N/A
Chest 8.97 2.2-10.9 5.7 2.6-8.8 5.4 8
Pelvis 8.4 N/A 7.2 6.1-8.0 3.1 N/A
Spine/Musculo-
Skeletal
6.15 6.4 8.1 8.2-12 N/A N/A
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
61
Thorax 8.0 N/A 6.7 2.4-7.1 N/A N/A
Others 10.3 N/A N/A N/A 3.0 N/A* The effective doses presented in this table are the 3rd quartile values calculated from the total cases
collected in this survey in the period of 2007-2009. 1. Yales SJ, Pike LC, Goldstone KE. Effect of multi-slice scanners on patient dose from routine CT
examinations in East Anglia. Br. J. Radiol. 77:472-478. 2004. 2. Brix G, Nagel HD, Stamm G, Veit R, Lechel U, Griebel J, Galanski M. Radiation exposure in
multi-slice versus single-slice spiral CT: results of a nationwide survey. Eur. Radiol. 13: 1973-1991. 2003.
3. Shrimpton PC, Hillier MC, Lewis MA, Dunn M. Doses from Computed Tomography (CT) examinations in the UK – 2003 Review. NRPB-W67. 2005.
4. Mettler FA, Wiest PW, Locken JA, Kelsey CA. CT scanning: patterns of use and dose. J Radiol. Prot. 20: 353-359. 2000.
5. National Radiological Protection Board. Guidelines on patient dose to promote the optimization of protection for diagnostic medical exposures. NRPB Vol 10, No. 1. 1999.
2.4.5 Mammography
(a) Number of Cases
The total number of cases for mammography is shown in Table 2.25.
Table 2.25: Number of cases for mammography.
Exam. Type Frequency Percentage (%)
Mammography 5226 100.0
(b) Dosimetric Data
The dosimetric data for mammography was expressed in MGD. The unit used
for MGD is mGy. The mean, median, minimum, maximum, standard deviation, 1st
quartile (1st Q) and 3rd quartile (3rd Q) for MGD collected in this survey were
summarized in Table 2.26 according to different breast thickness. Figure 2.27 shows
the box-plot from the analysis.
Table 2.26: Mean Glandular Dose (mGy) for various breast thickness in mammography.
Breast thickness Mean Glandular Dose (mGy)
Mean Median Min Max Std. Dev. 1st Q 3rd Q
2 – 3.9 cm 1.43 1.21 0.10 4.85 0.86 0.77 1.89
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
62
Breast thickness Mean Glandular Dose (mGy)
Mean Median Min Max Std. Dev. 1st Q 3rd Q
2 – 3.9 cm 1.43 1.21 0.10 4.85 0.86 0.77 1.89
4 – 7.9 cm 1.56 1.36 0.09 4.97 0.87 0.93 1.99
8 - 10 cm 2.32 2.21 0.34 4.87 1.22 1.32 3.23
Figure 2.27: Mean Glandular Dose (mGy) for various breast thickness in mammography.
2.4.6 Bone Mineral Densitometry
(a) Number of Cases
The total number of cases for bone mineral densitometry is shown in Table
2.27 and Figure 2.28.
Table 2.27: Number of cases collected for bone mineral densitometry.
Exam. Type Frequency Percent (%)
AP Spine 83 53.9
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
63
Left Hip / Right Hip 71 46.1
Total 154 100.0
Figure 2.28: Number of cases collected for bone mineral densitometry.
(b) Dosimetric Data
The dosimetric data for bone mineral densitometry was expressed in Entrance
Surface Dose (ESD). The unit used for ESD is mGy. The mean, median, minimum,
maximum, standard deviation, 1st quartile (1st Q) and 3rd quartile (3rd Q) for ESD
collected in this survey were summarized in Table 2.28 according to different
examination types. Figure 2.29 shows the box-plot from the analysis.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
64
Table 2.28: Entrance Surface Dose (mGy) for different examination types in bone mineral densitometry.
Exam. Type Entrance Surface Dose (mGy)
Mean Median Min Max Std. Dev. 1st Q 3rd Q
AP Spine 0.33 0.23 0.01 0.96 0.28 0.08 0.51
L/R Hip 0.37 0.26 0.00 1.16 0.33 0.07 0.61
Figure 2.29: Entrance Surface Dose (mGy) for different examination types in bone mineral densitometry.
2.4.7 Dental Radiology
(a) Number of Cases
The total number of cases for dental radiology is shown in Table 2.29 and
Figure 2.30.
ESD (mGy) for Different Examination Types in
Bone Mineral Densitometry
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
65
Table 2.29: Number of cases collected for dental radiology.
Exam. Type Frequency Percent (%)
Intraoral 1205 90.9
Panoramic 121 9.1
Total 1326 100.0
Figure 2.30: Number of cases collected for dental radiology.
(b) Dosimetric Data
The dosimetric data for dental radiology was expressed in ESD for intraoral
examinations and AKAP for panoramic examinations. The unit used for ESD is mGy
whereby for AKAP is mGy.m2. The mean, median, minimum, maximum, standard
deviation, 1st quartile (1st Q) and 3rd quartile (3rd Q) for ESD and AKAP collected in
this survey were summarized in Table 2.30 and Table 2.31 according to different
examination types. Figure 2.31 and Figure 2.32 shows the box-plot from the analysis.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
66
Table 2.30: Entrance Surface Dose (mGy) for intraoral examinations in dental radiology.
Exam. Type Entrance Surface Dose (mGy)
Mean Median Min Max Std. Dev. 1st Q 3rd Q
Intraoral 2.39 2.45 0.10 4.12 0.99 1.42 3.18
Figure 2.31: Entrance Surface Dose (mGy) for intraoral examinations in dental radiology.
ESD (mGy) for Intraoral Examinations in Dental Radiology
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
67
Table 2.31: Air Kerma-Area Product (mGy.m2) for panoramic examinations in dental radiology.
Exam. Type AKAP (mGy·m2)
Mean Median Min Max Std. Dev. 1st Q 3rd Q
Panoramic 0.011 0.011 0.005 0.018 0.003 0.007 0.016
Figure 2.32: Air Kerma-Area Product (mGy.m2) for panoramic examinations in dental radiology.
(c) Data Comparison with Recommended DRLs
The dosimetric data for dental radiology collected from this survey were
compared to the DRLs recommended by different international organizations such as
NRPB, AAPM and CRCPD. Table 2.32 presents the comparison between the data
collected from this survey with the DRLs recommended by the international
organizations for intraoral examinations. As for panoramic dental examination, there
is no DRL available recommended by the above mentioned organizations. However
the data for panoramic dental collected from this survey were compared with the
published data from other surveys/countries, as shown in Table 2.33.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 2: Diagnostic, Interventional and Dental Radiology, Result and Discussion
68
Table 2.32: Comparison of Entrance Surface Dose (mGy) for intraoral dental examinations collected from this survey with DRLs recommended by different international organizations.
Exam.
Type
Entrance Surface Dose (mGy)
* This
Survey
(2009)
UK1NRPB
(1999)
US2AAPM
(1999)
EC3EUR96
(1996)
IAEA 4BSS
(1996)
UK 5IPSM
(1992)
USA 6CRCPD
(1988)
Intraoral 3.18 1.80 3.50 NA NA NA 2.10-3.10* The entrance surface doses presented in this table are the median values calculated from the total
cases collected in the period of 2007-2009. 1. National Radiological Protection Board. Guidance on patient dose to promote optimization of
protection for diagnostic medical exposures. Documents of the NRPB, Vol 10, No. 1. 1999. 2. American Association of Physicists in Medicine Task Group. Reference values – Application
and impact in radiology. AAPM. 1999. 3. European Commission. European guidelines of quality criteria for diagnostic radiographic
images. Eur 16260 EN. EC. 1996. 4. International Atomic Energy Agency. International Basic Safety Standards protection against
ionizing radiation and for the safety of radiation sources. Safety Series No. 115. IAEA. 1996. 5. Institute of Physical Sciences in Medicine. National protocol for patient dose measurements in
diagnostic radiology. Dosimetry Working Party, IPEM. 1992. 6. Conference of Radiation Control Program Directors. Average patient exposure guides. CRCPD
Publication 88-5. 1988.
Table 2.33: Comparison of Air Kerma-Area Product (mGy.m2) for panoramic dental examinations collected from this survey with other published literature.
Exam.
Type
Air Kerma-Area Product (mGy.m2)
*This
Survey
(2009)
1Chu
et al.
(2007)
2Doyle
et al.
(2006)
3Helmrot
et al.
(2005)
4Perisinakis
et al.
(2004)
5Tierris
et al.
(2004)
6Williams
et al.
(2000)
Panoramic 0.0160 0.0071 0.0089 0.0073 0.0113 0.0101 0.0113* The entrance surface doses presented in this table are the median values calculated from the total
cases collected of 2007-2009. 1. Chu RYL, Lam T, Liang Y. GafChromic XR-QA film in testing panoramic dental radiography. J
Appl. Clin. Med. Phys. 8(2): 727-730. 2007. 2. Doyle P, Martin CJ, Robertson J. Techniques for measurement of dose width product in
panoramic dental radiography. Br. J Radiol. 79: 142-147. 2006. 3. Helmrot E, Carlsson GA. Measurement of radiation dose in dental radiology. RPD; 114(1-3):
168-171. 2005. 4. Perisinakis K, Damilakis J, Neratzoulakis J, Bourtsoiannis N. Determination of dose-area
product from panoramic radiography using a pencil ionization chamber: normalized data for the estimation of patient effective and organ doses. Med. Phys. 31-4. 2004.
5. Tierris CE, Yakoumakis EN, Bramis GN, Georgiou E. Dose area product reference levels in dental panoramic radiology. RPD; 111 (3): 283-287. 2004.
6. Williams JR, Montgomery A. Measurement of dose in panoramic dental radiology. Br. J. Radiol. 73: 1002-1006. 2000.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Literature Review
69
CHAPTER 3: NUCLEAR MEDICINE
3.1 LITERATURE REVIEW
3.1.1 History of Nuclear Medicine Development
Nuclear Medicine is a branch of medicine that uses radionuclides to provide
information about the function of a person's specific organs (diagnosis) or to treat
disease (therapy). In most cases, the information is used by physicians to make a
quick, accurate diagnosis of the patient's illness. The thyroid, bones, heart, liver and
many other organs can be easily imaged, and disorders in their function revealed. In
some cases radiation can be used to treat diseased organs, or tumours. Five Nobel
Laureates have been intimately involved with the use of radioactive tracers in
medicine [World Nuclear Association, 2009].
Over 10,000 hospitals worldwide use radioisotopes in medicine, and about
90% of the procedures are for diagnosis. The most common radioisotope used in
diagnosis is Technetium-99m (Tc-99m), with some 30 million procedures per year,
accounting for 80% of all nuclear medicine procedures worldwide. In developed
countries (26% of world population) the frequency of diagnostic nuclear medicine is
1.9% per year, and the frequency of therapy with radioisotopes is about one tenth of
this. In the USA there are some 18 million nuclear medicine procedures per year
among 305 million people, and in Europe about 10 million among 500 million
people. In Australia there are about 560,000 per year among 21 million people,
470,000 of these using reactor isotopes. The use of radiopharmaceuticals in diagnosis
is growing at over 10% per year [World Nuclear Association, 2009].
Nuclear medicine was developed in the 1950s by physicians with an endocrine
emphasis, initially using Iodine-131 (I-131) to diagnose and then treat thyroid
disease. In recent years specialists have also come from radiology, as dual PET/CT
procedures have become established. According to the US National Council on
Radiation Protection & Measurements report in 2009, Computed Tomography (CT)
and nuclear medicine contribute 36% of the total radiation exposure and 75% of the
medical exposure to the US population. The report also showed that American’s
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Literature Review
70
average total yearly radiation exposure had increased from 3.6 mSv to 6.2 mSv per
year since the early 1980s, due to medical-related procedures.
3.1.2 Diagnostic Examination in Nuclear Medicine
Diagnostic techniques in nuclear medicine use radioactive tracers which emit
gamma rays from within the body. These tracers are generally short-lived isotopes
linked to chemical compounds which permit specific physiological processes to be
scrutinized. They can be given by injection, inhalation or orally. The first SPECT
prototype of diagnostic imaging in nuclear medicine is where single photons are
detected by a gamma camera which can view organs from many different angles.
The camera builds up an image from the points from which radiation is emitted; this
image is enhanced by a computer and viewed by a physician on a monitor for
indications of abnormal conditions.
A more recent development is Positron Emission Tomography (PET) which is
a more precise and sophisticated technique using isotopes produced in a cyclotron. A
positron-emitting radionuclide is introduced, usually by injection, and accumulates in
the target tissue. As it decays it emits a positron, which promptly combines with a
nearby electron with innihilates resulting in the simultaneous emission of identifiable
gamma rays in diametrically opposite directions. These are detected by a PET
camera and give very precise indication of their origin. The most important clinical
role in PET scanning is in oncology, with Fluorine-18-Fluorodeoxyglucose (F-18
FDG) as the tracer, since it has proven to be the most accurate non-invasive method
of detecting and evaluating most cancers. It is also well used in cardiac and brain
imaging.
New procedures combine PET with computed tomography (CT) scans to give
co-registration of the two images (PET/CT), enabling better diagnosis than with
traditional PET alone. It is a very powerful and significant tool which provides
unique information on a wide variety of diseases from dementia to cardiovascular
disease and cancer.
Positioning of the radiation source within the body makes the fundamental
difference between nuclear medicine imaging and other imaging techniques such as
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Literature Review
71
x-rays. Gamma imaging by either method described provides a view of the position
and concentration of the radioisotope within the body. Organ malfunction can be
indicated if the isotope is either partially taken up in the organ (cold spot), or taken
up in excess (hot spot). If a series of images is taken over a period of time, an
unusual pattern or rate of isotope movement could indicate malfunction in the organ.
A distinct advantage of nuclear imaging over x-ray techniques is that it provides
functional rather than structural information successfully. This has led to an
increasing number of nuclear medicine procedures in the country over the years.
3.1.3 Therapeutic Procedure in Nuclear Medicine
Rapidly dividing cells are particularly sensitive to damage by radiation. For
this reason, some cancerous growths can be controlled or eliminated by irradiating
the area containing the growth. The radioisotope that generates the radiation can be
localized in the required organ in the same way it is used for diagnosis, through a
radionuclide following its usual biological path, or through the radionuclide being
attached to a suitable biological compound. In most cases, it is beta radiation which
causes the destruction of the abnormal cells. Iodine-131 (I-131) which is commonly
used to treat thyroid cancer is probably the most successful example of therapeutic
radionuclide. It is also used to treat non-malignant thyroid disorders. Phosphorus-32
(P-32) is another commonly used radioisotope in treating the disease called
polycythemia vera, where an excess of red blood cells is produced in the bone
marrow.
Many therapeutic procedures are palliative, usually to relieve pain. For
instance, Strontium-89 (Sr-89) and Samarium-153 (Sm-153) are used for the relief of
cancer-induced bone pain. Rhenium-186 (Re-186) is a newer product for this.
Although therapeutic application is less common than diagnostic use of radioisotopes
in nuclear medicine, it is nevertheless widespread, important and growing. An ideal
therapeutic radioisotope is a strong beta emitter with just enough gamma to enable
imaging, eg. Yttrium-90 (Y-90) is used for treatment of cancer, particularly non-
Hodgkin's lymphoma and liver carcinoma, and its more widespread use is envisaged,
including for arthritis treatment. Considerable medical research is being conducted
worldwide into the use of radionuclides attached to highly specific biological
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Literature Review
72
chemicals such as immunoglobulin molecules (monoclonal antibodies). The eventual
tagging of these cells with a therapeutic dose of radiation may lead to the regression,
or even cure of some diseases.
3.1.4 Diagnostic Radiopharmaceuticals
Every organ in our bodies acts differently from a chemical point of view.
Doctors and chemists have identified a number of chemicals which are absorbed by
specific organs. The thyroid, for example, takes up iodine, the brain consumes
quantities of glucose, and so on. With this knowledge, radiopharmacists are able to
attach various radioisotopes to biologically active substances. Once a radioactive
form of one of these substances enters the body, it is incorporated into the normal
biological processes and excreted in the usual ways.
Diagnostic radiopharmaceuticals can be used to examine blood flow to the
brain, function of the liver, lungs, heart or kidneys, to assess bone growth, and to
confirm other diagnostic procedures. Another important use is to predict the effects
of surgery and assess changes after treatment. The amount of the
radiopharmaceutical given to a patient is just sufficient to obtain the required
information before its decay. The radiation dose received is medically insignificant.
The patient experiences no discomfort during the test and after a short time there is
no trace that the test was ever done. The non-invasive nature of this technology,
together with the ability to observe an organ functioning from outside the body,
makes this technique a powerful diagnostic tool.
A radioisotope used for diagnosis must emit gamma rays of sufficient energy
to escape from the body and it must have a half-life short enough for it to decay away
soon after imaging is completed. The radioisotope most widely used in medicine is
Tc-99m, employed in some 80% of all nuclear medicine procedures. It is an isotope
of the artificially-produced element Technetium and it has almost ideal
characteristics for a nuclear medicine scan. These are:
(a) It has a physical half-life of six hours which is long enough to examine
metabolic processes yet short enough to minimize the radiation dose to the
patient.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Literature Review
73
(b) Tc-99m decays by a process called "isomeric"; which emits gamma rays
and low energy electrons. Since there is no high energy beta emission the
radiation dose to the patient is low.
(c) The low energy gamma rays easily escape the human body and are
accurately detected by a gamma camera. Hence the radiation dose to the
patient is minimized.
(d) The chemistry of Tc-99m is versatile. It can form tracers by being
incorporated into a range of biologically-active substances to ensure that it
concentrates in the tissue or organ of interest.
Its logistics also favour its use. Tc-99m generators, a lead pot enclosing a glass
tube containing the radioisotope, are supplied to hospitals from the nuclear reactor
where the isotopes are made. They contain Molybdenum-99 (Mo-99), with a half-life
of 66 hours, which progressively decays to Tc-99m. The Tc-99m is washed out of
the lead pot by saline solution when it is required. A similar generator system is used
to produce Rubidium-82 (Rb-82) for PET imaging from Strontium-82 (Sr-82) which
has a half-life of 25 days.
For PET imaging, the main radiopharmaceutical is Fluoro-Deoxy-Glucose
(FDG) incorporating F-18 with a half-life of less than two hours, as a tracer. The
FDG is readily incorporated into the cell without being broken down, and is a good
indicator of cell metabolism. In diagnostic medicine, there is a strong trend to using
more cyclotron-produced isotopes such as F-18 as PET and PET/CT become more
widely available. However, the procedure generally needs to be undertaken within
two hours reach of a cyclotron.
3.1.5 Therapeutic Radiopharmaceuticals
For some medical conditions, it is useful to destroy or weaken malfunctioning
cells using radiation. The radioisotope that generates the radiation can be localized in
the required organ in the same way it is used for diagnosis through a radioactive
element following its usual biological path, or through the element being attached to
a suitable biological compound. In most cases, it is beta radiation which causes the
destruction of the abnormal cells. This is a form of radionuclide therapy.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Literature Review
74
I-131 and Phosphorus-32 (P-32) are also used for therapy. I-131 is used to treat
the thyroid for cancers and other abnormal conditions such as hyperthyroidism (over-
active thyroid). In a disease called polycythemia vera, an excess of red blood cells is
produced in the bone marrow. P-32 is used to control the disease.
Considerable medical research is being conducted worldwide into the use of
radionuclides attached to highly specific biological chemicals such as
immunoglobulin molecules (monoclonal antibodies). The eventual tagging of these
cells with a therapeutic dose of radiation may lead to the regression or cure of some
diseases.
3.1.6 Diagnostic Reference Levels (DRLs)
The objective of DRL is to optimize the use of radiation in medicine and help
avoid excessive radiation exposure. This is accomplished by comparison between the
numerical value of the DRL (derived from relevant regional, national or local data)
and the mean or other appropriate value observed in practice from a suitable
reference group of patients. A suitable reference group of patients defined within a
certain range of physical parameters (e.g. height and weight). Corrective actions
should be taken as necessary if exposures do not provide useful diagnostic
information and do not yield the expected medical benefit to patients.
In diagnostic nuclear medicine, DRLs are expressed in administered activity
(MBq) rather than as absorbed dose. This reference administered activity is based on
the administered activity necessary for a good image during a standard procedure. In
standard diagnostic nuclear medicine procedure, a poorly-functioning gamma camera
or other equipment are factors that can necessitate a higher activity. Another
important factor influencing the administered activity is the quality of the dose
calibration.
Apart from the quantity used, DRLs in nuclear medicine differ in two ways
from those in diagnostic radiology:
(a) The DRL in nuclear medicine is a guidance level for administered
activities. It is recommended that this level of activity be administered for a
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Literature Review
75
certain type of examination in standard situations. (In diagnostic radiology,
if the DRL is consistently exceeded there should be a review or
investigation).
(b) In nuclear medicine, for a recommended amount of administered activity
the outcome may be poor. This indicates that the efficacy of gamma
cameras, the dose calibration or the procedures used by the staff need to be
checked. (In diagnostic radiology, the criterion is normally a satisfactory
image. However, the dose needed for this image quality can be too high,
and in this case, the radiological equipment should be checked).
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Methodology
76
3.2 METHODOLOGY
3.2.1 Introduction
Nuclear medicine is a branch or specialty of medicine that uses radioactive
isotopes (radioisotopes) and relies on the process of radioactive decay in the
diagnosis and treatment of disease. The procedures are primarily intended for
diagnostic purposes. Many of the diagnostic applications of radioisotopes are
conducted in vitro rather than in vivo. For example, about 100 million procedures
with such material were performed in the United States in 1989, although only 10%
of these involved the administration of radiopharmaceuticals directly to patients. The
remaining 90% of practice comprised radioimmunoassay procedures, which use
small amounts of radioactive material in the analysis of biological specimens such as
blood and urine and do not give rise to the exposure of patients [UNSCEAR, 2000].
It is important to clarify that the in vitro applications are not included in this survey.
The radioactivity is generally administered to the patient in the form of a
radiopharmaceutical - the term “radiotracer” is also commonly used. This follows
some physiological pathway to accumulate for a short period of time in some part of
the body. A good example is Tc-99m sulphur colloid which following intravenous
injection accumulates mainly in the patient's liver. The substance emits gamma rays
while it is in the patient's liver and we can produce an image of its distribution using
a nuclear medicine imaging system. This image can tell us whether the function of
the liver is normal or abnormal or if sections of it are damaged from some forms of
diseases. The “Tc-99m” is the radioisotope which emits gamma ray for imaging
purposes; whereas “sulphur colloid” is a chemical form which to deliver the
radioisotope to the targeting tissue or organ for uptake. Different
radiopharmaceuticals are used to produce images from almost every regions of the
body. Table 3.1 shows the examples of reference level for diagnostic nuclear
medicine procedures recommended by the International Atomic Energy Agency
(IAEA) associated with the commonly used radiopharmaceutical. Appendix E
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Methodology
77
summarizes the procedures and types of radiopharmaceuticals with the relevant
diagnostic and therapeutic purposes in nuclear medicine.
Table 3.1: Reference levels for diagnostic nuclear medicine procedures (IAEA BSS, 2006).
Examination Radio-nuclide Chemical Form
Max Usual
Activity (MBq)
Bone imaging Tc-99m Phosphonate & phosphate compound
600
Bone imaging (SPECT) Tc-99m Phosphonate & phosphate compound
800
Brain imaging Tc-99m TcO4 -, DTPA 500
Brain imaging(SPECT) Tc-99m TcO4 -, DTPA 800
Liver & spleen imaging Tc-99m Labelled colloid 80 Liver & spleen imaging (SPECT)
Tc-99m Labelled colloid 200
Lung perfusion studies Tc-99m Isotonic solution 200 Lung imaging (SPECT) Tc-99m MAA 200 Myocardial imaging Tc-99m Phosphonate &
phosphate compound 600
Myocardial imaging (SPECT) Tc-99m Phosphonate & phosphate compound
800
Renal imaging Tc-99m DMSA 160 Renal imaging/Renography Tc-99m DTPA gluconate &
glucoheptonate 350
Thyroid imaging Tc-99m TcO4 - 200
Thyroid imaging I-123 20 Thyroid metastases (after ablation)
I-123
400
This survey was conducted on the basis of statistics from nuclear medicine
diagnostic examinations and therapeutic procedures carried out by twelve (12)
nuclear medicine centres in Malaysia from 2005 to 2007. The survey was completed
with demographic data covering different aspects including the equipment, personnel
and patients information, as well as the dosimetry data taking into account types and
activities of the radiopharmaceuticals used. In order to estimate the effective dose for
different procedures, internal dosimetry formalism recommended by the Medical
Internal Radiation Dosimetry (MIRD) Committee of the United States Society of
Nuclear Medicine was followed. On the basis of above mentioned data, estimations
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Methodology
78
were carried out based on the frequency of examinations and the relative contribution
(%) of each procedure to the total effective collective dose. From this survey, we
could also estimate the total effective collective dose (man Sv) and per capita
effective dose (mSv).
3.2.2 Nuclear Medicine Techniques
Whereas the broad aim in diagnostic radiology is the imaging of anatomy, the
practice of nuclear medicine is more closely linked to the investigation of patho-
physiological processes. In essence, radioisotopes are used as a biological tracer by
incorporating them into a pharmaceutical appropriate to the nature of an investigation.
Following administration of the radiopharmaceutical to the patient, the resulting
biodistribution and localization is dictated by the pharmaceutical preparation used
with the radionuclide label providing the means of detection. Most procedures
involve some types of measurement concerning the retention or excretion of the
tracer so as to quantify organ or tissue function. Probe detectors can be used to
measure uptake in particular organs such as the thyroid whereas imaging is carried
out by using a single or double head gamma camera with the large field of view.
Diagnostic technique with radiopharmaceuticals are widely utilized in
medicine; clinical applications include oncology, cardiology, neurology, psychiatry,
endocrinology, as well as the investigation of infection and inflammation and various
biological systems (musculo-skeletal, respiratory, gastrointestinal and genitourinary).
In oncology, important roles for nuclear medicine include detecting unknown
primary sites of cancer, differentiating between benign and malignant disease,
staging the extent of disease (local, nodal and metastases), planning and assessing the
response to therapy and detecting recurrence. The activities administered are
determined by the diagnostic information required within the chosen period of the
procedure. International and national guidance levels are available concerning the
techniques and typical activities for common procedures.
In practice, a range of radioisotopes are used in diagnostic nuclear medicine
that meet the necessary requirements for effective and efficient imaging. All are
produced artificially, using four principal routes of manufacture: cyclotron
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Methodology
79
bombardment [e.g. Gallium-67 (Ga-67), Indium-111 (In-111), Fluorin-18 (F-18)];
reactor irradiation [e.g. Chromium-51 (Cr-51), I-131]; fission products [e.g. I-131,
Strontium-90 (Sr-90)]; and generators that provide secondary decay products from
longer-lived parent radioisotopes (e.g. Mo-99 generator to generate Tc-99m). Among
all the available radioisotopes, Tc-99m is the most commonly used radionuclide in
diagnostic nuclear medicine because of its highly suitable physical characteristics for
a wide range of applications. It therefore forms the basis for over 80% of the
radiopharmaceuticals used in nuclear medicine.
In addition to conventional planar imaging, nuclear medicine applications
have also been developed to allow emission tomography. Two basic modalities have
evolved. The more common is Single Photon Emission Computed Tomography
(SPECT). This utilizes conventional gamma-emitting radiopharmaceuticals and is
often performed in combination with planar imaging. SPECT imaging requires a
scanning system incorporating a circular array of detectors or, more often, a rotating
gamma camera system. The second modality is the more specialized technique of
Positron Emission Tomography (PET). This is based on the simultaneous detection
of the pairs of photons (511 keV) arising from positron annihilation and mostly uses
the short-lived biologically active radioisotopes such as Oxygen-15 (O-15), Carbon
(C-11), F-18 and Nitrogen-13 (N-13). The more recent developments in nuclear
medicine include the hybrid PET/CT and SPECT/CT imaging. These innovations led
to fusion imaging of PET or SPECT with CT to provide information about the
anatomy and physiology without requiring a more invasive procedure or surgery.
Following the innovation of PET imaging, the radiopharmaceutical, F-18-FDG has
been widely used in PET or PET/CT imaging because of its similar structure to
glucose, which can be used for the assessment of glucose metabolism in various
organs in the body as well as for tumour imaging in oncology.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Methodology
80
3.2.3 Overall Study Design
A research team consisting of various assistant directors, scientific officers and
research assistants from the Engineering Services Division, MOH was established in
order to carry out this survey.
A complete volume of the research methodology along with six volumes of
literature compilations had been published in the beginning of the project. These
publications were referred to as the guidance protocols. Along with that, three
training courses had been organized by the MOH in collaboration with the University
of Malaya to provide training and guidance to the research assistants who would be
involved directly in the dose survey. Following these activities, five echo courses
were organized in five different zones in Malaysia (Northern Zone, Western Zone,
Eastern Zone, Central & Southern Zone and Sabah & Sarawak Zone) to the staff
members (mostly radiographers, technologists and physicists) representing the
participating hospitals. These courses aimed to explain the design and methodology
of the study as well as to introduce the research team members to the participating
hospitals.
A computer database with authorized access was developed to store and
manage the data. This database was completed with automatic edit checks to detect
the duplication of data and the abnormal variables input. Automatic backup system
was also utilized daily to prevent the loss of data.
Several meetings and three project reviews were held during the period of the
study. These meetings allowed the research assistants to discuss the difficulties and
limitations in running the survey as well as to find the best solution for all the parties
involved. Figure 3.1 presents the flow chart of the overall operation of the study.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Methodology
81
Figure 3.1: The flow chart of operation of study.
1. Project Design and Planning
4. Development of Survey Methodology
2. Determination of Sampling Sizes
3. Identification of Participating Sites & Sites Visit
10. Data De-duplication
8. Data Standardization, Data Review & Coding
5. Training Courses and Pilot Run
6. Data Collection
7. Visual Review
9. Data Entry / Verification & Update
11. Initial Data Analysis
12. Database Lock
13. Final Data Analysis
14. Draft Report
15. Dissemination
16. Final Report
End
Start R
eject Data /
Query G
eneration
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Methodology
82
3.2.4 Data Collection
The data collected in the nuclear medicine discipline were divided into two
main categories: diagnostic nuclear medicine examinations (included PET/CT) and
nuclear medicine therapeutic procedures. Figure 3.2 shows the types of diagnostic
examinations and therapeutic procedures in nuclear medicine which were included in
this study. Positron Emission Tomography (PET) examination is not available in
Malaysia but all the examinations involved with PET scanner came from the PET/CT
examinations. Only four (4) centres were involved with PET/CT examinations,
namely Penang Hospital, Prince Court Medical Centre, Sime Darby Medical Centre
and Wijaya International Medical Centre (Beacon International Specialist Centre Sdn.
Bhd.). Penang Hospital is located in the Northern zone whereas the other three
centres are located in the Central Zone.
There were eleven (11) types of diagnostic examinations and five (5) types of
therapeutic procedures as listed in Figure 3.2. Other diagnostic examinations include
the tumour localization imaging using Ga-67 or I-131 MIBG, and white blood cell
leucocyte scintigraphy using Tc-99m. Other therapeutic procedures include the Y-90
liver metastasis and Y-90 synovitis.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Methodology
83
3.2.5 Data Collection Protocols
The data collection in nuclear medicine was divided into three (3) surveys:
Background information survey, radiation dose survey and questionnaire survey.
Figure 3.3 shows the structure of the overall data collection methodology. The
following sessions elaborate the specific objectives and protocols for the different
survey.
Diagnostic Examinations
1. Bone
2. Brain
3. Cardiac
4. Gastroenterology
5. Liver or Spleen
6. Lung perfusion
7. Lung ventilation
8. Renal
9. Thyroid
10. Others
11. PET/CT
Therapeutic Procedures
1. Bone metastases
2. Hyperthyroidism
3. Polycythaemia vera
4. Thyroid malignancy
5. Others
NUCLEAR MEDICINE
Figure 3.2: Types of diagnostic examinations and therapeutic procedures in nuclear medicine.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Methodology
84
Figure 3.3: The structure of data collection methodology.
(a) Background Information Survey
The background information provides general information of the hospitals or
centres, including the number of personnel and the equipment information. The staffs
at the nuclear medicine centre/department consist of nuclear medicine physicians,
medical physicists and nuclear medicine technologists. According to the current
practice in Malaysia, the nuclear medicine physicians are qualified after undergoing
specific Master in Medicine (Nuclear Medicine) training or other qualified specialist
who have undergone specific period of training in nuclear medicine, and the nuclear
medicine technologists may be a qualified radiographer, assistant medical officer or
medical laboratory technologist. All nuclear medicine centers in the MOH, have their
own nuclear medicine physicists but most of the nuclear medicine centers other than
in MOH in Malaysia are sharing the medical physicists with other department such
as radiotherapy or the radiology department. This background survey aim to provide
information of the total number of personnel at nuclear medicine centres or
departments from 2005 to 2007 according to different categories.
Nuclear Medicine Medical Radiation Dose Survey
Part A Background
Information Survey
Part B Radiation Dose Survey
Gamma Camera or SPECT Imaging
PET/CT Imaging
Therapeutic Procedures
Equipment Information
Part C Questionnaire
Survey
Personnel Information
• Demographic • Frequency • Dosimetry
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Methodology
85
Other than personnel information, the background information also includes
the modality or equipment information. For each centre, general information and
equipment specific data such as room or location of the equipment, model,
manufacturer, serial number and year of purchase were recorded. Generally there are
two (2) major equipment or modality used for diagnostic imaging in nuclear
medicine, namely Gamma Camera (or SPECT), and PET/CT. There are also other
equipment available in nuclear medicine such as gamma counter, rectilinear scanner
and gamma probe but they are not included in this survey because they are not
mainly used for the diagnostic purposes. The SPECT camera is basically a gamma
camera which acquires multiple planar views to be processes mathematically to
create the 3D cross-sectional views of the organ. The basic design for SPECT camera
is similar to that of a planar camera but with two additional features. First the SPECT
camera is constructed so that the head can rotate either stepwise or continuously
about the patient to acquire multiple views. Second, it is equipped with a computer
that integrates the multiple images to produce the cross-sectional views of the organ.
The more advanced SPECT camera designs have more than one head or are
constructed with a ring of detectors. SPECT utilizes the single photon emitted by
gamma-emitting radioisotopes such as Tc-99m, Ga-67, In-111 and I-123. This is in
contrast to PET which utilizes the paired 511 keV photons arising from positron
annihilation. In Malaysia, PET scanner alone is unavailable but all the PET scanner
were came with the integration of CT scanner and they are called PET/CT scanner.
A background information survey form was prepared and distributed to all the
research assistants for data collection as in Appendix F.
(b) Radiation Dose Survey
For each procedure, basic patient demographics (age and gender) were
acquired from the respective hospital’s database. This was added to the pool of
information on national patient demographics. For each patient, the following
parameters were recorded: ethnic group, age, weight and height to demonstrate the
patient demographic. Other than the patient demographic data, the dosimetry
information was obtained through the type of radiopharmaceutical used, activity
administered to the patients and patient age group.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Methodology
86
The principle of the internal radiation dosimetry is rather complicated as it
involves a number of parameters such as the energy emitted per radioactive decay,
the fraction of the emitted energy that is absorbed in various target organs, the
masses of these organs, and both the physical decay and biologic clearance of the
injected radioactive material [Toohey et. al., 2000]. These radiation doses are
received from the radioactive materials within the body, so they are normally
referred to as internal doses. Unlike radiation doses received from external sources
such as medical x-ray, internal doses can never be directly measured; rather, they are
calculated from standardized assumptions and procedures [Stabin et. al., 1999].
Although several methodologies exist to calculate internal doses, the schema
developed by the Medical Internal Radiation Dose (MIRD) Committee of the Society
of Nuclear Medicine is normally used to calculate doses from radiopharmaceuticals.
The MIRD schema uses a unique set of symbols and quantities to calculate the
absorbed dose of radiation in any target organ per radioactive decay in any source
organ. A few of computer program such as MIRDose and OLINDA/EXM was
therefore developed by the MIRD Committee to calculate the dose per unit
administered activity of various radiopharmaceuticals. In this particular survey, we
were using the online dose calculator supplied by the Radiation Dose Assessment
Resource (RADAR) to calculate the internal radiation dose from nuclear medicine
patients. However, this program only allow the calculation of internal radiation dose
from nuclear medicine diagnostics procedures but not for the therapeutic procedures.
Therefore, no effective dose was calculated for nuclear medicine therapeutic
procedures but the dosage was compared in term of activity administered (MBq).
The dose survey forms are attached in the Appendix G.
(i) Radiation Dose Survey Protocols for Diagnostic Nuclear Medicine
1. Fill in the hospital name and date of survey.
2. Fill in the date of examination and examination name. The type of
examination and its abbreviation can be reffered to the legend at the bottom
of the form.
3. Record the scanning room number, patient identification, gender, age, ethnic
group, weight (kg) and height (cm).
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Methodology
87
4. Record the radiopharmaceutical which is administered into the patient during
the examination.
5. Record the activity (in mCi) of the radiopharmaceutical administered to the
patient at the time of dosing.
6. Ignore the column of the Effective Dose (mSv) as this is the radiation dose
that will be calculated using the MIRD method. This column will be filled in
after the data collection and dose calculation.
7. Note down the remarks if there is any additional information / remarks
observed from the cases.
(ii) Radiation Dose Survey Protocols for Therapeutic Nuclear Medicine
1. Fill in the hospital name and date of survey.
2. Fill in the date of treatment and treatment name. The type of treatment and its
abbreviation can be referred to the legend at the bottom of the form.
3. Record the treatment room number, patient identification, gender, age, ethnic
group, weight (kg) and height (cm).
4. Record the radiopharmaceutical which is administered into the patient for
treatment purposes.
5. Record the activity (in mCi) of the radiopharmaceutical administered to the
patient at time of dosing.
6. Ignore the column of the Effective Dose (mSv) as this is the radiation dose
that will be calculated using the MIRD method. This column will be filled in
after the data collection and dose calculation.
7. Note down any additional information observed from the cases.
(iii) Radiation Dose Survey Protocols for PET-CT
1. Fill in the hospital name, room and date of survey.
2. Record the date of examination, patient identification, gender, age, ethnic
group, weight (kg) and height (cm).
3. Record the clinical indication as mentioned in the patient’s record or as
advised by the physician.
4. Record the activity (in mCi) of the radiopharmaceutical (only F-18 FDG is
used in this case) which is administered to the patient during the examination.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Methodology
88
5. Record the parameters for the CT scan, such as kV, mAs, rotation time (s),
nominal slice thickness, pitch, scan length (mm) and scan region. The groups
and abbreviation of the scan regions can be referred to the legend at the
bottom of the form. The formulas to obtain nominal slice thickness, pitch and
scan length are also listed in the legend.
6. Ignore the column of the Effective Dose (mSv) as this is the radiation dose
that will be calculated using the MIRD and CT Expo method. This column
will be filled in after the data collection and dose calculation.
(c) Questionnaire Survey
The questionnaire survey aimed to collect information on the annual average
level of practice in nuclear medicine from 2005 to 2007. The questionnaire survey
forms recorded the estimated number of procedures performed annually, the most
commonly used radiopharmaceutical for the specific examination or treatments and
the percentage, mean activity administered for different procedures and the
frequency of procedures performed according to the age and distribution. The
dosimetric data should represent typical or average values per examination or
treatment, giving the range in minimum and maximum activity (in MBq). The
distribution of ages was divided into three (3) groups: 0-15 years old, 16-40 years
old, >40 years old. It is also important to know how many examinations are
undertaken on male and female patients separately. The questionnaire survey forms
are designed based on the original UNSCEAR survey forms with some minor
modifications to suit the local conditions. The questionnaire survey forms are
attached in the Appendix H.
3.2.6 National Medical Radiation Exposure Database
A national medical radiation exposure database was designed and developed to
store all the raw data from this survey. This database was created using the Hypertext
Preprocessor (PHP) programming script. The design was kept to be simple,
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Methodology
89
straightforward and unambiguous for the convenience of the users. Figure 3.4 shows
the screen shot of the login page of the database. For security purposes, the database
was protected by restricting the access to authorized users only, therefore username
and password were needed in order to login to the database. Different menu were
installed in the database by following the hierarchy of the data flow. The menu
includes the system parameters, user maintenance, hospital maintenance, case, data
upload and inquiry, as shown in Figure 3.5. In the “System Parameter” (Figure 3.6),
different parameters regarding the disciplines, modality, examination types,
multipurpose parameters, etc. were stored. Figure 3.7 shows the menu for “Hospital
Maintenance” where the information regarding the hospital, examination rooms,
equipment, personnel and specific machine parameters were stored. Figure 3.8 and
3.9 shows the “Case” menu where the data for every single case were stored. Finally,
the database was also designed with the “Inquiry” menu (Figure 3.10), where a quick
search on the total number of cases and the cases data can be obtained instantly. The
users can also easily download the data based on the cases selected and export them
into Excel or other file format for analysis. The flow and the relationships of the
database design are presented in Figure 3.11 to 3.13. The data collection flow chart is
presented in Figure 3.14.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Methodology
90
Figure 3.4: Screen shot of the login page of the database.
Figure 3.5: Screen shot of the database main page showing the organization of the database main and sub-menu.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Methodology
91
Figure 3.6: Screen shot of the database “System Parameter” menu.
Figure 3.7: Screen shot of the database “Hospital Maintenance” menu.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Methodology
92
Figure 3.8: Screen shot of the database “Case” menu for diagnostic examination entry.
Figure 3.9: Screen shot of the database “Case” menu for PET/CT data entry.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Methodology
93
Figure 3.10: Screen shot of the database “Inquiry” menu.
Parameter Tables Relationship
Figure 3.11: Parameter tables relationship of the database.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Methodology
94
Hospital Tables Relationship
Figure 3.12: Hospital tables relationship of the database.
Figure 3.13: Overall relationship of the database.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Methodology
95
Figure 3.14: Radiation dose survey protocol for Nuclear Medicine procedures.
Data Collection – identify cases and fill in the appropriate forms: UNSCEAR:Forms/Nuclear Medicine: Diagnostic/1.1
UNSCEAR : Forms/Nuclear Medicine : Therapeutics/1.1 UNSCEAR : Forms/Nuclear Medicine : PET-CT/1.1
Start
Make a copy of the forms, keep in file (JKN)
Send complete forms to MOH HQ
Calculate the effective dose (mSv) using the online MIRD software
Enter data into database
Data screening and analysis
End
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Data Analysis
96
3.3 DATA ANALYSIS
3.3.1 Introduction
This survey provides qualitative and quantitative information on the doses for
diagnostic examinations and therapeutic procedures in nuclear medicine, to assess
medical radiation exposure in Malaysia and to allow comparison between data from
the countries worldwide and to explore temporal or regional trends in the usage of
radiation in medicine. The survey on the nuclear medicine facilities represents the
first attempt in Malaysia to assess the actual usage of the procedures in the country.
The results of the survey provide the basis for optimization procedures and
guidelines for radiation protection as well as the establishment of national diagnostic
reference levels (DRLs) of the country.
A centralized computer database was designed and developed for the data
management. Figure 3.15 shows the Medical Radiation Exposure Survey Database
Management System. The data from the background information survey and dose
survey were stored in the database in the study. This database was also built in with
the MIRD calculation formula based on the reference from the RADAR® online
software (http://www.doseinfo-radar.com), hence the effective dose would be
calculated automatically and stored in the database as long as the types of
radiopharmaceutical and the administered activity were given.
Data analysis was done using the Statistical Package for the Social Sciences
(SPSS) version 16. SPSS is an established statistical analysis software used for
descriptive statistics, bivariate statistics, prediction for numerical outcomes and
prediction for identifying groups. Generally, the data analysis in this survey could be
divided into two (2) main categories, which are descriptive statistics and dosimetric
analysis. Descriptive statistics including the analysis of number of personnel, number
of equipment, frequency of examinations performed and patient demographics
statistics; whereas the dosimetry analysis including the numerical calculation for the
radiation exposure such as mean, minimum, maximum, standard deviation, medium,
first quartile (1st quartile) and third quartile (3rd quartile). The analysis outputs are
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Data Analysis
97
generally displayed in tables and pie charts for descriptive statistics, and tables as
well as box plots for the dosimetric analysis. Histograms were also included in the
analysis to demonstrate the distribution or proportion of cases that fall into each of
several categories.
Figure 3.15: Medical Radiation Exposure Survey Database Management System.
3.3.2 Data Screening
Prior to data analysis, the data was screened several times to identify errors and
outliers. The errors could be from human mistakes such as typographical error,
calculation mistakes, unit conversion errors, misplaced variables, etc. These data
were either corrected or excluded from analysis depending on the validity of the data,
i.e. year 20005 was reentered as year 2005; 500 kg was reentered as 50 kg. Suspected
errorneous data of which the cause could not be ascertained were excluded.
Medical
Radiation Exposure
Survey Central
Database
Dose Calculation
Program
Background Information
Survey
Radiation Dose Survey
Statistical Analysis
Output / Result
Input Dose
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Data Analysis
98
Data screening will also figure out the missing values and outliers in the
numerical data. In cases where the data was suspect or missing (blank data) it was
not included in the data analysis. During screening of the dosimetric data, initially
values less than 2% and more than 98% from the mean were excluded (this is the
first step of data screening to avoid being affected by extreme values), and a new
mean was calculated. The values which were smaller, or larger than 2 standard
deviations from the new mean were considered as outliers and were excluded.
Overall the number of data that was excluded from the final analysis
represented less than 5% of the entire data collection.
3.3.3 Descriptive Statistics
(a) Number of Personnel
The United Nations defined four levels of health care in the world based on
population per physician [UNSCEAR, 1988]. At the highest level of health care
(Level 1), there are one or more physicians for each 1,000 population; Level II has
one physician for each 1,000 to 3,000 population; Level III has one physician for
3,000 to 10,000 population, and for Level IV has one physician for more than 10,000
population. The Background Information Survey allows the analysis of the number
of personnel, including physicians, medical physicists and nuclear medicine
technologists per 1,000 population. In this survey, the trend of personnel growth in
nuclear medicine was monitored from 2005 to 2007. Malaysia with 27.17 million
population in 2007, and an average of 1,429 population per physician is classified as
health care Level II country.
(b) Number of Equipment or Facilities
The number of equipment or facilities provides useful information on the
machine to population ratio of the country. The results were compared to the survey
in other countries worldwide to estimate the trend of growth of human resources in
Malaysia. The major equipment in nuclear medicine comprises gamma camera
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Data Analysis
99
(SPECT) and PET/CT. This analysis establishes the major trends in the frequency of
different nuclear medicine facilities from 2005 to 2007, as well as the imaging
techniques used.
(c) Frequency of Examinations and Therapeutic Procedures
The frequency of diagnostic examinations and therapeutic procedures were
analyzed. Annual examination or therapeutic procedure, annual effective dose per
capita and collective effective dose of the population were analysed. The population
statistics in Malaysia from 2005 to 2009 is shown in Figure 3.16. The trend and
frequencies of examinations and therapeutic procedure were analyzed according to
the age group distribution. This information was used to compare the statistics of this
survey to the relevant international and regional published studies.
In addition, the combination statistics of examination frequency and number of
equipment enables the estimation of medical equipment utilization levels in the
nation.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Data Analysis
100
Figure 3.16: Statistics of Malaysian population from 2005 to 2009 (Department of Statistics
Malaysia, 2009).
(d) Patient Demographics Statistics
For each procedure, basic patient demographics such as age, gender, height and
weight data were acquired from the respective hospital database. This data will add
to the pool of knowledge on national nuclear medicine patient demographics.
Descriptive statistics such as mean, median, range, 1st quartile and 3rd quartile
histogram were tabulated. The study of age-distribution revealed the average
population that underwent different examinations and procedures whereas the study
of gender-distribution of patients demonstrated the prevalence of certain disease in a
certain gender. The analysis would provide insight into the frequency of
examinations and radiation dose distribution with respect to gender and ethnic group
distribution.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Data Analysis
101
3.3.4 Dosimetric Analysis
The radiation doses to patients resulting from administrations of
radiopharmaceuticals are determined by a range of physical and biological factors
which included the amount and form of the radioactive material administered, the
route of administration, the biokinetics and physiological fate of the
radiopharmaceutical, and the decay scheme of the radionuclide [UNSCEAR, 2000].
Absorbed doses to the various organs and tissues are generally estimated using the
dosimetric formalism developed by the Medical Internal Radiation Dose Committee
of the United States Society of Nuclear Medicine (MIRD). Broadly, this approach
involves knowledge of the cumulative activities in each source organ, together with
estimates and summation of the absorbed fractions of energy in every target organ
from each source organ. Cumulative activities were derived on the basis of
quantification of organ uptake in human studies using SPECT and PET imaging.
Specific absorbed fractions are estimated by Monte Carlo calculations using
anthropomorphic mathematical phantoms; values are available for standardized
phantoms representing typical adult, paediatric and pregnant patients. More realistic
voxel phantoms are also being developed for use in internal dosimetry [Stabin,
1996]. The MIRD formalism is shown in the following equation:
rkD - The mean dose (rads) for a target organ, rk
∑h
- The sum of all the source organs, rh, where the units are rads
hA~ - The accumulated activity (μCi·hr) for each source organ, rh
)( hk rrS ← - The absorbed dose (rads/μCi·hr) in the target organ, rk per unit of cumulated activity in each source organ (S factor is specific for each pair of source – target organs. Acquired from published tables).
( )∑ ←=h
hkhr rrSADk
~
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Data Analysis
102
Coefficients derived using this methodology have been published that allow
the estimation of organ and effective doses to adults and children from administered
activities for a wide range of commonly used radiopharmaceuticals. Data are also
available for some new radiopharmaceuticals and for other computational
techniques. The administration of radiopharmaceuticals to patients also gives rise to
the exposure of other population groups, such as breast-feeding infants, although
these doses are not considered further in this survey. The average doses to specific
organs provided by conventional macroscopic dosimetry can grossly underestimate
radiation exposures to individual cells. New methods of cellular dosimetry are being
developed for assessing the risks associated with new pharmaceuticals that target
specific cells and cellular components with short-range radiations, such as Auger
electrons.
Patient doses for common types of procedure are summarized principally in
this survey in terms of the administered activities (MBq) for each
radiopharmaceutical, as well as the effective dose (mSv) for diagnostic examinations.
The collective effective dose to the Malaysian population and the relative
contributions of different procedures were also tabulated in this survey. Inter
comparison was made in national and international level.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Result and Discussion
103
3.4 RESULT AND DISCUSSION
3.4.1 Descriptive Analysis
This session includes the analysis for number of personnel (number of staffs eg.
nuclear medicine physicians, medical physicists and nuclear medicine technologists),
number of equipment or facilities (eg. gamma cameras or SPECT and PET/CT
scanners), and the frequency of diagnostic examinations and therapeutic procedures
performed in nuclear medicine centre / department / unit / section (hereafter referred
as “sites”) in Malaysia from year 2005 to 2007.
(a) Number of Personnel
The staff at nuclear medicine sites are generally represented by the nuclear
medicine physicians, medical physicists and nuclear medicine technologists. Table
3.2 summarizes the total number of staff in nuclear medicine sites in Malaysia from
year 2005 to 2007. The total number of nuclear medicine physicians up to 2007 was
8. The number of medical physicists was the same in year 2005 and 2006 (total
number = 14) but in year 2007 there was a slight increase to 16. The number of
nuclear medicine technologists increased every year; there were 24 technologists in
year 2005, 28 in year 2006 and 39 in year 2007, respectively.
Table 3.2: Total number of personnel in nuclear medicine sites in Malaysia from year 2005-2007.
Personnel 2005 2006 2007
†Nuclear Medicine Physicians 7 8 8
Medical Physicists 14 14 16
‡Nuclear Medicine Technologists 24 28 39
†Nuclear medicine physicians in some centres are also qualified as specialist with sub specialization training in nuclear medicine. ‡Nuclear medicine technologists in some centres are also qualified as radiographers, medical assistants and medical laboratory technologist.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Result and Discussion
104
(b) Number of Equipment
There are three (3) different types of equipment used for diagnostic imaging in
nuclear medicine, namely Gamma Camera, PET and PET/CT. However, the stand-
alone PET scanner was unavailable in Malaysia up to the date of this report, so they
were excluded from the survey. Therefore, there were only two (2) types of
equipment available for analysis in nuclear medicine: Gamma Camera, and PET/CT.
Table 3.3 shows the total number of Gamma Camera and PET/CT available in
Malaysia from 2005 to 2007. The gamma camera camera increased consistently with
one (1) unit each year from 2005 to 2007; whereas the PET/CT scanner increased
from three (3) units in 2005 to five (5) units in 2007.
Table 3.3: Total number of nuclear medicine equipment in Malaysia from 2005-2007.
Equipment/Modality 2005 2006 2007
Gamma Camera 14 15 16
PET/CT 3 4 5
(c) Frequency of Examinations or Therapeutic Procedures
The use of radiopharmaceuticals in medical diagnosis is less widespread than
the use of x-rays. There are large variations in practice from state to state, with
nuclear medicine examinations not being performed at all in some states in the
country. Annual number of diagnostic and therapeutic administration of
radiopharmaceuticals performed in Malaysia from 2005 to 2007 are summarized in
Table 3.4 (a) to (c) and Figure 3.17 (a) to (c) by types of examinations and
therapeutic procedures.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Result and Discussion
105
Table 3.4 (a): Annual number of nuclear medicine diagnostic examinations in Malaysia from 2005-2007 according to examination types.
Diagnostic Examinations Year Total2005 2006 2007
Bone 5650 5790 6028 17468
Brain 21 18 15 54
Cardiac 2275 5020 4566 11861
Gastroenterology 67 86 67 220
Liver or Spleen 148 141 118 407
Lung Perfusion 83 58 42 183
Lung Ventilation 82 59 65 206
Renal 2790 3163 3193 9146
Thyroid 1691 2194 2006 5891
Others 2 9 2 13
Total 12809 16538 16102 45449
Table 3.4 (b): Annual number of nuclear medicine therapeutic procedures in Malaysia from 2005-2007 according to disease types.
Therapeutic Procedures Year Total
2005 2006 2007
Bone metastases 0 0 1 1
Hyperthyroidism 606 858 702 2166
Polycythaemia vera 2 1 1 4
Thyroid malignancy 268 382 404 1054
Others 0 5 8 13
Total 876 1246 1116 3238
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Result and Discussion
106
Table 3.4 (c): Annual number of PET/CT examinations in Malaysia from 2005-2007.
PET/CT Examination Year Total
2005 2006 2007
PET/CT 100 385 650 1135
Figure 3.17 (a): Bar chart showing the frequency of nuclear medicine diagnostic examinations in Malaysia from 2005 to 2007 according to different examination types.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Result and Discussion
107
Figure 3.17 (b): Bar chart showing the frequency of nuclear medicine therapeutic procedures in Malaysia from 2005 to 2007 according to different disease types.
Figure 3.17 (c): Bar chart showing the frequency of PET/CT in Malaysia from 2005 to 2007.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Result and Discussion
108
Generally, both diagnostic examinations and therapeutic procedures show
small, increasing trends from 2005 to 2007. The first PET/CT scanner was installed
at Penang Hospital in 2005. One (1) PET/CT scanner was installed at Sime Darby
Medical Centre and one (1) at Wijaya International Medical Centre in the same year,
making the total number of PET/CT scanners in Malaysia in 2005 to three (3). The
total number of cases performed in 2005 was 100, all done in Penang Hospital. The
total number of cases performed in 2006 was 385. In 2007, the total number of
PET/CT examinations increased to 650 cases after the Sime Darby Medical Centre
and Prince Court Medical Centre started their services. During the survey period of
2005 to 2007, a total of 1135 cases were performed. The percentage contributions of
each type of diagnostic examinations and therapeutic procedures to the total
frequency are given in Table 3.5 (a) and (b) and Figure 3.18 (a) to (b).
Table 3.5 (a): Percentage contributions by types of examinations to total number of diagnostic examinations (2005-2007).
Diagnostic Examinations Frequency Percentage to Total (%)
Bone 17468 38.4
Brain 54 0.1
Cardiac 11861 26.1
Gastroenterology 220 0.5
Liver or Spleen 407 0.9
Lung Perfusion 183 0.4
Lung Ventilation 206 0.5
Renal 9146 20.1
Thyroid 5891 13.0
Others 13 < 0.1
Total 45449 100.0
* PET/CT examination is not included
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Result and Discussion
109
Table 3.5 (b): Percentage contributions by types of diseases to total number of therapeutic procedures (2005-2007).
Therapeutic Procedures Frequency Percentage to Total (%)
Bone metastases 1 <0.1
Hyperthyroidism 2166 66.9
Polycythaemia vera 4 0.1
Thyroid malignancy 1054 32.6
Others 13 0.4
Total 3238 100.0
Figure 3.18 (a): Pie chart showing the frequency distribution of different disease in diagnostic nuclear medicine (2005-2007).
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Result and Discussion
110
Figure 3.18 (b): Pie chart showing the frequency distribution of different disease in therapeutic nuclear medicine (2005-2007).
(d) Exposed Populations
The distributions by age and gender of patients undergoing various types of
diagnostic and therapeutic nuclear medicine procedures from 2005 to 2007 are
presented in Table 3.6 (a) to (c) and Figure 3.19 (a) to (b). This analysis uses the
same three broad ranges of patient age that were used for x-ray examinations.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Result and Discussion
111
Table 3.6 (a): Gender and age distribution of patients undergoing diagnostic examinations in nuclear medicine (2005-2007).
Diagnostic
Examinations
Gender and Age Distribution
Female Male
0-15 16-40 >40 Total
No.
0-15 16-40 >40 Total
No.
Bone 203 1670 9468 11341 287 868 4972 6127
Brain 1 3 20 24 2 8 20 30
Cardiac 45 159 3808 4012 54 315 7480 7849
Gastroenterology 4 35 59 98 9 39 74 122
Liver or Spleen 100 47 38 185 161 29 32 222
Lung Perfusion 6 56 58 120 6 25 32 63
Lung Ventilation 0 38 52 90 0 50 66 116
Renal 1571 633 1924 4128 1902 897 2219 5018
Thyroid 202 1503 1874 3579 151 792 1369 2312
Others 0 0 6 6 0 1 6 7
Total 2132 4144 17307 23583 2572 3024 16270 21866
Table 3.6 (b): Gender and age distribution of patients undergoing therapeutic procedures in nuclear medicine (2005-2007).
Therapeutic
Procedures
Gender and Age Distribution
Female Male
0-15 16-40 >40 Total
No.
0-15 16-40 >40 Total
No.
Bone metastases 0 0 1 1 0 0 0 0Hyperthyroidism 15 625 935 1575 4 199 388 591Polycythaemia vera 0 0 0 0 0 1 3 4Thyroid malignancy 11 333 449 793 6 83 172 261Others 0 2 0 2 0 2 9 11
Total 26 960 1385 2371 10 285 572 867
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Result and Discussion
112
Table 3.6 (c): Gender and age distribution of patients undergoing PET/CT examination in nuclear medicine (2005-2007).
PET/CT
Examination
Gender and Age Distribution
Female Male
0-15 16-40 >40 Total
No.
0-15 16-40 >40 Total
No.
PET-CT 20 133 399 552 14 121 448 583
Figure 3.19 (a): Bar chart showing the frequency of nuclear medicine diagnostic examinations in Malaysia according to age groups (2005-2007).
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Result and Discussion
113
0.0
66.3
0.2
32.0
0.4
0
0.6
0
0.5
0
0.0 20.0 40.0 60.0 80.0
Bone metastasis
Hyperthytoidism
Polycythaemia vera
Thyroid malignancy
Others
Percentage
Ther
apeu
tic P
roce
dure
s
Frequency of Nuclear Medicine Therapeutic Procedures in Malaysia (2005-2007)
Paediatrics
Adult
Figure 3.19 (b): Bar chart showing the frequency of nuclear medicine therapeutic procedures in Malaysia according to age groups (2005-2007).
In the diagnostic nuclear medicine examinations, most of the cases were
dominated by the age group >40 years, particularly for bone, cardiac, renal and
thyroid examinations. Among all the diagnostic examinations, only renal, bone and
liver or spleen studies composed the highest percentage of paediatrics (0-15 years)
patients. There was no lung ventilation cases performed in paediatrics over the three
years. However, there were a few cases (12) of lung perfusion performed in
paediatrics, equally distributed between the male and female. Other uncommon cases
on in the paediatrics age group were in the gastroenterology group. In term of
gender-distribution, the numbers of male patients were more than the female patients
in all of the diagnostic examinations except in bone, lung perfusion, and thyroid. The
number of female patients underwent bone examination was almost double the
number of male patients in 2005 to 2007.
In therapeutic procedures, all of the cases are dominated by the age group >16
years. In the therapeutic procedures for paediatrics, there were a few cases of
hyperthyroidism (19) and thyroid malignancy (17) performed on patients <16 years
old. In term of gender-distribution, female patients far outnumbered the male
patients in hyperthyroidism (73%) and thyroid malignancy (75%). For bone
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Result and Discussion
114
metastases treatment, there was only one case performed in the period of 2005 to
2007. This case should probably be excluded from the survey, however, in order to
figure out the number of bone metastases treatment in Malaysia compared to other
countries, we decided to include this number in our data. Another uncommon
therapeutic procedure in nuclear medicine was polycythaemia vera (4).
In PET/CT examination, again, the cases were dominated by the age group >16
years. Male patients were slightly more than the female patients in receiving the
PET/CT examinations in 2005 to 2007. PET/CT for paediatrics was uncommon as
there were only 34 cases performed in three years.
3.4.2 Dosimetric Analysis
(a) Administered Activity (MBq)
The samples mean, median, minimum and maximum, 1st quartile and 3rd
quartile of administered activities in different types of diagnostic examinations and
therapeutic procedures from all the nuclear medicine sites in Malaysia from 2005 to
2007 are presented in Table 3.7 (a) to (e). The dosage for paediatrics (age <16) and
adults (age ≥16) were compared separately. Table 3.7 (a), Table 3.7 (b) and Figure
3.25 3.20 (a) show the administered activities according to different diagnostic
examination types for paediatrics and adults and Table 3.7 (c), Table 3.7 (d) and
Figure 3.20 (b) shows the administered activities according to different therapeutic
procedures for paediatrics and adults. Table 3.7 (e) shows the administered activities
for PET/CT examinations.
Table 3.7 (a): Administered activities (MBq) in different types of diagnostic examinations for paediatrics <16 years (2005-2007).
Diagnostic Examinations (Age <16)
Radio-pharmaceutical
Administered activity (MBq)
Mean Median Min Max Std. Dev.
Q1 Q3
Bone Tc-99m MDP/HDP 574 518 234 1110 206 407 732 Phosphate 292 356 151 370 122 254 363 Brain Tc-99m HMPAO 326 350 185 444 131 267 397 Cardiac Tc-99m MIBI, Rest 497 497 222 771 388 359 634
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Result and Discussion
115
Tc-99m Tetrofosmin,
Rest
509 444 333 925 150 370 592
Tc-99m Tetrofosmin,
Stress
359 370 167 518 104 315 407
Gastro-
enterology
Ga-67 Citrate 163 148 148 204 26 148 176
Tc-99m Sn Colloid 381 381 381 381 - 381 381
Liver or
Spleen
Tc-99m HIDA 69 60 37 289 33 46 84
Tc-99m Sn Colloid 197 204 93 296 102 148 250
Lung
Perfusion
Tc-99m MAA 307 333 130 333 60 324 333
Renal Tc-99m DMSA 177 126 20 970 129 75 244
Tc-99m MAG 3 74 59 37 265 52 37 78
Tc-99m DTPA 294 300 122 531 110 185 407
Thyroid I-131 NaI 183 185 74 370 102 81 204
Tc-99m TcO4 202 179 110 555 83 137 259
Table 3.7 (b): Administered activities (MBq) in different types of diagnostic examinations for adults ≥16 years (2005-2007).
Diagnostic Examinations (Age ≥16)
Radio-pharmaceutical
Administered activity (MBq)
Mean Median Min Max Std. Dev.
Q1 Q3
Bone Tc-99m MDP/HDP
832 798 370 1295 140 740 925
Phosphate 579 555 507 666 49 555 601 Brain Tc-99m
HMPAO 769 740 233 1369 310 555 962
Tc-99m TcO4 436 407 333 555 78 370 509 Cardiac Tc-99m MIBI,
Rest 832 925 380 1058 150 744 925
Tc-99m MIBI, Stress
638 555 264 1110 242 481 870
Tc-99m Tetrofosmin, Rest
850 925 370 1406 206 733 1036
Tc-99m Tetrofosmin, Stress
699 555 333 1432 238 503 925
Gastro-enterology
Ga-67 Citrate 238 185 148 444 94 178 370
In-111 230 224 218 248 16 221 236
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Result and Discussion
116
Pentetreotide
Tc-99m Sn Colloid
388 429 137 614 150 304 470
Liver or Spleen
Tc-99m HIDA 244 222 90 407 92 185 311
Tc-99m Sn Colloid
379 370 185 592 103 348 407
Lung Perfusion
Tc-99m MAA 308 333 148 444 70 259 333
Lung Ventilation
Tc-99m DTPA 1023 1036 740 1332 188 845 1192
Tc-99m Technegas 396 370 148 555 92 370 444
Renal Tc-99m DMSA 354 296 148 1110 173 189 485 Tc-99m MAG 3 219 210 148 259 35 185 259 Tc-99m DTPA 365 297 185 818 164 203 490 Thyroid I-131 MIBG 19 19 19 19 0 19 19 I-131 NaI 172 185 74 400 42 185 185 Tc-99m TcO4 349 278 185 740 165 212 555 Others 561 555 185 925 223 398 740
Table 3.7 (c): Administered activities (MBq) in different types of therapeutic procedure for paediatrics <16 years (2005-2007). Therapeutic
Procedures
(Age <16)
Radionuclide Administered activity (MBq)
Mean Median Min Max Std.
Dev. Q1 Q3
Hyperthyroidism I-131 448 444 111 740 166 370 555
Thyroid malignancy
I-131 3169 2960 1110 5550 1330 2220 3689
Table 3.7 (d): Administered activities (MBq) in different types of therapeutic procedures for adults ≥16 years (2005-2007). Therapeutic
Procedures
(Age ≥16)
Radionuclide Administered activity (MBq)
Mean Median Min Max Std.
Dev. Q1 Q3
Hyperthyroidism I-131 419 370 111 1295 146 296 555
Polycythaemia
vera
P-32 305 333 185 370 87 268 370
Thyroid
malignancy
I-131 4480 3700 1110 9620 1950 2960 5550
Others Y-90 860 888 555 1147 179 694 967
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Result and Discussion
117
Table 3.7 (e): Administered activities (MBq) in PET/CT (2005-2007).
Procedures Radio-pharmaceutical
Administered activity (MBq)
Mean Median Min Max Std.
Dev. Q1 Q3
PET/CT F-18-FDG 411 401 117 629 58 382 433
Figure 3.20 (a): Box plot showing the administered activities for different examination types in diagnostic nuclear medicine (2005-2007).
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Result and Discussion
118
Figure 3.20 (b): Box plot showing the administered activities for different disease types in therapeutic nuclear medicine (2005-2007).
For diagnostic examinations, the highest mean administered activity to the
nuclear medicine paediatrics patients was from the bone studies (Tc-99m MDP/HDP,
574 MBq). The highest mean administered activity to the nuclear medicine adult
patients was from the lung ventilation studies (Tc-99m DTPA, 1023 MBq). This was
followed by cardiac, gastroenterology, brain, lung perfusion, renal, thyroid and liver
or spleen, for paediatrics; cardiac, bone, renal, brain, others, gastroenterology, liver
or spleen, lung perfusion and thyroid for adults. There was no lung ventilation
performed on the paediatrics age group.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Result and Discussion
119
For therapeutic procedures, the highest mean administered activity was for
treatment of thyroid malignancy for both the paediatric (3169 MBq) and the adult
group (4480 MBq). In both groups, the administered activity for treatment of thyroid
malignancy was 7 to 9 times the administered activity for treatment of
hyperthyroidism. For the adults group, the other disease types during 2005 to 2007
comprised of bone metastases, polycythaemia vera and others. Most of the “Others”
therapy were from the Y-90 therapy for liver metastases and synovitis. There was no
other disease type besides for thyroid malignancy and hyperthyroidism for the
paediatric group. Bone metastases treatment using radionuclide is not common in
Malaysia. There was only a case performed in 2007 by Sime Darby Medical Centre
with administered activity of 148 MBq. As such, no comparative analysis with other
centres were analysed.
(b) Effective Dose (mSv)
The mean effective doses calculated using MIRD method for different types of
diagnostic examination are shown in Table 3.8 (a), Table 3.8 (b) and Figure 3.21.
Table 3.8 (a): Mean effective dose (mSv) calculated for different types of diagnostic examination for paediatrics <16 years (2005-2007).
Diagnostic Examinations (Age <16)
Mean Effective Dose (mSv) Mean Median Min Max Std.Dev.
Bone 2.85 2.73 0.86 6.30 1.19Brain 3.03 3.25 1.72 4.13 1.22Cardiac 3.66 3.09 1.17 7.03 1.24Gastroenterology 1.85 1.48 1.48 3.57 0.63Liver or Spleen 1.19 1.02 0.63 4.91 0.57Lung Perfusion 3.37 3.66 1.42 3.66 0.66Renal 1.09 0.98 0.18 8.52 0.63Thyroid 2.92 2.41 1.43 13.54 1.73
Table 3.8 (b): Mean effective dose (mSv) calculated for different types of diagnostic examinations for adults ≥16 years (2005-2007).
Diagnostic Examinations (Age ≥16)
Mean Effective Dose (mSv) Mean Median Min Max Std.Dev.
Bone 3.91 4.00 1.25 7.35 1.23Brain 6.75 6.54 2.17 12.73 2.59Cardiac 5.69 5.90 2.08 10.68 1.80Gastroenterology 3.84 3.70 1.28 18.50 3.26Liver or Spleen 4.07 3.65 1.53 6.92 1.51Lung Perfusion 3.38 3.66 1.63 4.88 0.77Lung Ventilation 5.35 5.55 2.22 8.33 1.19
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Result and Discussion
120
Renal 1.87 1.63 0.91 7.77 0.93Thyroid* 7.62 7.22 2.41 15.80 3.75Others 6.11 6.11 1.72 10.18 2.55
Figure 3.21: Box plot showing the effective dose for different examination types in diagnostic nuclear medicine (2005-2007).
For the paediatric group, the highest mean effective dose was from the
examinations of cardiac (3.66 mSv) and the lowest was from the renal examinations
(1.09 mSv). Renal studies had the highest frequency of examinations, however, the
study had relatively low mean effective dose (1.09 mSv). The range for the effective
dose among the paediatric patients was from 0.18 to 13.54 mSv.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Result and Discussion
121
For the adult group, the highest mean effective dose recorded was from the
examinations of thyroid (7.62 mSv) and the lowest was from the renal studies (1.87
mSv). The range for the effective dose among the adult patients was from 0.91 to
18.50 mSv.
The comparison of mean administered activity and mean effective dose for
paediatrics (age <16) and adults (age ≥16) for different diagnostic examination types
is presented in Table 3.9.
Table 3.9: Comparison of mean administered activity and mean effective dose for paediatrics (age <16) and adults (age ≥16) for different diagnostic examinations.
Diagnostic
Examinations
Paediatrics (Age <16) Adults (Age ≥16)
Mean
Activity
(MBq)
Mean
Eff. Dose
(mSv)
Mean
Activity
(MBq)
Mean
Eff. Dose
(mSv)
Bone 573 2.85 832 3.91
Brain 326 3.03 678 6.75
Cardiac 484 3.66 776 5.69
Gastroenterology 196 1.85 358 3.84
Liver or Spleen 71 1.19 262 4.07
Lung Perfusion 307 3.37 308 3.38
Lung Ventilation - - 795 5.35
Renal 177 1.09 354 1.87
Thyroid 190 2.92 256 7.62
Others - - 561 6.11
There is a general correlation between the average administered activity (MBq)
and the calculated mean effective dose (mSv) (with the exception of lung ventilation
and ‘other’ examination types), although the actual relationship is not immediately
clear as the mean effective dose takes into account different organ sensitivities
towards radiation and the amount of radiopharmaceutical uptake into the particular
organ, among other factors.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Result and Discussion
122
In summary, for diagnostic examinations in nuclear medicine, examinations
which constantly had high effective dose were cardiac, lung perfusion and brain for
the paediatric group (all were above 3.00 mSv). The constantly high effective dose in
the adult age group were from the thyroid, brain and ‘others’ examinations (all were
above 6.00 mSv). In both groups, renal examinations typically recorded one of the
lowest mean effective dose. The average administered activity for adults is usually
1.5 to 2 times higher than the administered activity for paediatrics. The administered
activities are generally scaled according to body surface area or weight. When
calculated by weight, the resultant effective doses to the paediatrics in general will be
roughly the same as those to an adult. The average mean effective doses calculated
for the adults were found to be mostly slightly higher for each examination type
compared to the paediatrics. The analysis of patient exposures is also complicated by
the variety of different radiopharmaceuticals in use for each type of procedure.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Result and Discussion
123
3.4.3 Data Comparisons with Published Literature
The results from this survey were compared with the previously published
papers. The main source for the comparison is from the UNSCEAR 2000 report
(refer UNSCEAR 2000 Annex D in Appendix I). The data comparisons were
presented in the following tables. The main parameters for comparison are the
number of equipment per population, frequency of procedure per population, mean
effective dose per procedure, annual collective effective dose and the annual per
caput effective dose.
The dosimetric data collected from this survey were compared to the
Diagnostic Reference Levels (DRLs) recommended by different international
organizations, eg. IAEA, NRPB, EC and ARSAC. One of the main objectives of this
survey was to develop a local DRL in the relevant diagnostic imaging disciplines to
outfit the local population and conditions. Furthermore, we also compared the data
from this survey to other national surveys carried out by different countries.
(a) Data Comparisons with UNSCEAR 2000 Report
Table 3.10 to Table 3.16 and Figure 3.22 to Figure 3.25 represent the
comparisons between the data collected from this survey with the published
UNSCEAR 2000 report.
Table 3.10: Comparison of number of nuclear medicine diagnostic imaging equipment per million population with UNSCEAR 2000 report.
Nuclear
Medicine
Equipment
Diagnostic Imaging Equipment per Million Population
Level
I
Level
II
Level
III
Level
IV
Malaysia
(2007)
Gamma Cameras 7.19 0.32 0.13 0.03 0.59
PET or PET/CT 0.2 0.002 0 0 0.18
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Result and Discussion
124
Table 3.11: Comparison of number of procedures per 1000 population with UNSCEAR 2000 report (Table 46).
Procedure
No. of Procedures per 1,000 Population
Level
I
Level
II
Level
III
Level
IV
World Malaysia
(2007)
Bone 4.5 0.24 0.053 0.001 1.3 0.21
Cardiovascular 2.7 0.17 0.018 0.00002 0.8 0.16
Lung Perfusion 1.8 0.023 0.007 0.0001 0.49 0.0012
Lung Ventilation 0.34 0.011 0.0003 0.00002 0.095 0.001
Thyroid Scan 4.1 0.3 0.16 0.003 1.3 0.0355
Renal 0.89 0.16 0.02 0.002 0.32 0.089
Liver/Spleen 2.1 0.09 0.005 0.0002 0.59 0.0043
Brain 1.3 0.05 0.01 0.003 0.37 0.0006
Total 19 1.1 0.28 0.02 5.6 0.5016
Table 3.12: Comparison of effective dose per procedure with UNSCEAR 2000 report (Table 46).
Procedure Effective Dose Per Procedure (mSv)
Level
I
Level
II
Level
III
Level
IV
World Malaysia
(2007)
Bone 4.5 4.5 4 4 4.5 3.91
Cardiovascular 8 8 12 12 8 5.69
Lung Perfusion 1.5 2 2 2 1.5 3.38
Lung Ventilation 1 1 1 1 1 5.35
Thyroid Scan 2 10 30 30 3.4 7.62
Renal 1.5 3 3 3 1.9 1.87
Liver/Spleen 1.7 2 2 2 1.7 4.07
Brain 6 6 6 6 6 6.75
Average Effective
Dose Per
Procedure (mSv)
4.3 6.7 20 20 4.6 4.83
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Result and Discussion
125
Table 3.13: Comparison of annual collective dose per procedure with UNSCEAR 2000 report (Table 46).
Procedure
Annual Collective Dose (man Sv)
Level
I
Level
II
Level
III
Level
IV
World Malaysia
(2007)
Bone 31000 3300 140 3 35000 22.314
Cardiovascular 33000 4150 140 0.1 37000 25.178
Lung Perfusion 4150 140 9 0.1 4300 0.115
Lung Ventilation 520 35 0.2 0.01 600 0.144
Thyroid Scan 12500 9300 3200 55 25000 7.353
Renal 2000 1500 40 4 3500 4.533
Liver/Spleen 5300 600 6 0.2 5900 0.480
Brain 12000 900 40 9 13000 0.101
Total 123000 23000 3500 200 150000 60.218
Average Effective
Dose Per Caput
(mSv)
0.081 0.008 0.006 0.0003 0.026 0.0022
Table 3.14: Comparison of percentage contribution to total annual frequency with UNSCEAR 2000 report (Table 47).
Procedure Contribution to total annual frequency (%)
Level
I
Level
II
Level
III
Level
IV
World Malaysia
(2007)
Bone 24 21 19 8 24 41.61
Cardiovascular 14 15 6 0.1 14 32.26
Lung Perfusion 10 2 2 0.4 9 0.25
Lung Ventilation 2 1 0.1 0.1 2 0.20
Thyroid Scan 22 27 59 19 22 7.04
Renal 5 14 7 13 6 17.67
Liver/Spleen 11 8 2 1 11 0.86
Brain 7 4 4 16 7 0.11
Total 100 100 100 100 100 100
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Result and Discussion
126
Table 3.15: Comparison of percentage contribution to total annual collective dose with UNSCEAR 2000 report (Table 47).
Procedure Contribution to total annual collective dose (%)
Level
I
Level
II
Level
III
Level
IV
World Malaysia
(2007)
Bone 25 14 4 2 23 37.04
Cardiovascular 27 18 4 0.1 25 41.80
Lung Perfusion 3 0.6 0.3 <0.1 3 0.19
Lung Ventilation 0.4 0.1 <0.1 <0.1 0.4 0.24
Thyroid Scan 10 40 89 28 17 12.24
Renal 2 6 1 2 2 7.52
Liver/Spleen 4 2 0.2 0.1 4 0.80
Brain 10 4 1 5 8 0.17
Total 100 100 100 100 100 100
Table 3.16: Summary of the data comparison between this survey and UNSCEAR 2000 report (Table 50).
Health-Care Level
Population (millions)
Annual per caput Effective Dose
(mSv)
Annual Collective Effective Dose
(man Sv)
I 1530 0.08 123000
II 3070 0.008 23000
III 640 0.006 3500
IV 565 0.0003 200
World 5800 0.03 150000
Malaysia (2007) 27.17 0.0022 60.218
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Result and Discussion
127
Effective Dose per Procedure (mSv)
0 5 10 15 20 25 30 35
Bone
Cardiovascular
Lung Perfusion
Lung Ventilation
Thyroid Scan
Renal
Liver/Spleen
BrainEx
amin
atio
n Ty
pes
Effective dose per procedure (mSv)
Malaysia (2007)Level IVLevel IIILevel IILevel I
Figure 3.23 3.22: Comparison of effective dose per procedure with different healthcare levels.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Result and Discussion
128
Comparison of Annual Collective Effective Dose (manSv)
602003500
23000
123000
0
20000
40000
60000
80000
100000
120000
140000
Level I Level II Level III Level IV Malaysia (2007)
Ann
ual C
olle
ctiv
e Ef
fect
ive
Dos
e (m
anSv
)
Figure 3.23: Comparison of annual collective effective dose with different healthcare levels.
Comparison of Annual per Caput Effective Dose (mSv)
0.00030.0022
0.0060.008
0.08
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
Level I Level II Level III Malaysia (2007) Level IV
Ann
ual p
er C
aput
Effe
ctiv
e D
ose
(mSv
)
Figure 3.24: Comparison of annual per caput effective dose with different healthcare levels.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Result and Discussion
129
(b) Data Comparisons with Recommended DRLs
Table 3.17 (a) and Table 3.17 (b) present the comparisons between the data
collected from this survey with the recommended DRLs by international
organizations.
Table 3.17 (a): Comparison of average administered activity (MBq) of different types of diagnostic examination with difference recommended DRLs (Adults ≥ 16 years old).
Diagnostic Exam.
Radio-pharmaceutical
Average Administered Activity (MBq) This
survey
1IAEA 1996
2ARSAC 2006
3RSNA 2008
4EC 1999a
5SSK 2000
Bone Tc-99m MDP/HDP 832 800 800 1110 600 750Brain Tc-99m HMPAO 769 800 500 740 N/A N/ACardiac Tc-99m MIBI, Rest 832 800 800 1100 N/A N/A
Tc-99m MIBI, Stress 638 600 800 1100 N/A N/A
Tc-99m Tetrofosmin, Rest
850 800 800 1500 N/A N/A
Tc-99m Tetrofosmin, Stress
699 600 800 1500 N/A N/A
Gastro-enterology
Ga-67 Citrate 238 N/A 150 150 N/A N/A
In-111 Pentetreotide 230 N/A 220 222 N/A N/A
Tc-99m Sn Colloid 388 200 400 N/A N/A N/A
Liver or Spleen
Tc-99m HIDA 244 150 150 N/A 150 150Tc-99m Sn Colloid 379 200 200 222 80 N/A
Lung Perfusion
Tc-99m MAA 308 200 200 185 100 200
Lung Ventilation
Tc-99m DTPA 1023 N/A 80 1300 N/A N/A
Tc-99m Aerosol 396 N/A 400 740 N/A N/A
Renal Tc-99m DMSA 354 160 80 370 80 70Tc-99m MAG3 219 100 100 370 100 200Tc-99m DTPA 365 350 300 370 300 150
Thyroid I-131 MIBG 19 20 20 25 N/A N/AI-131 NaI 172 400 N/A N/A N/A N/A
TcO4- 349 200 80 370 N/A N/A
1. International Atomic Energy Agency. International Basic Safety Standards protection against ionizing radiation and for the safety of radiation sources. Safety Series No. 115. IAEA. 1996.
2. Administration of Radioactive Substances Advisory Committee. Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources. Health Protection Agency, UK, 2006.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Result and Discussion
130
3. Fred AM, Walter H, Terry TY, Mahadevappa M. Effective doses in radiology and diagnostic nuclear medicine: A catalog. Radiology. 2008, 246(1).
4. European Commission. Radiation Protection 109: Guidance on diagnostic reference levels (DRLs) for medical exposures. Directorate-General Environment, Nuclear Safety and Civil Protection. 1999.
5. Strahlenschutzkommission (SSK). Diagnostic Reference Levels in Nuclear Medicine. Recommendation of the Radiation Protection Commission (Session 167) (Germany). 2000.
Table 3.17 (b): Comparison of average administered activity (MBq) of different types of diagnostic examination with difference recommended DRLs (Paediatrics < 16 years old).
Diagnostic Exam.
Radio-pharmaceutical
Average Administered Activity (MBq) This
survey
1ARSAC 2006
2EANM 1990
3Iran 2005
4Ireland2008
Bone Tc-99m MDP/HDP 574 40 40 457 40-549Brain Tc-99m HMPAO 326 100 100 537 N/ACardiac Tc-99m Sestamibi,
Rest 497 N/A N/A N/A N/A
Tc-99m Tetrofosmin, Rest
509 N/A N/A N/A N/A
Tc-99m Tetrofosmin, Stress
359 N/A N/A N/A N/A
Gastro-enterology
Ga-67 Citrate 163 10 10 103 N/A
Tc-99m Sn Colloid 381 10 10 119 N/A
Liver or Spleen
Tc-99m HIDA 69 N/A 20 117 N/A
Tc-99m Sn Colloid 197 15 15 119 N/A
Lung Perfusion
Tc-99m MAA 307 N/A 10 106 N/A
Renal Tc-99m DMSA 177 15 15 79 15-91Tc-99m MAG3 74 15 15 N/A 15-91Tc-99m DTPA 294 20 20 256 20-201
Thyroid I-131 NaI 183 3 3 1.32 N/A Tc-99m TcO4
- 202 10 10 457 10-731. Administration of Radioactive Substances Advisory Committee. Notes for guidance on the clinical
administration of radiopharmaceuticals and use of sealed radioactive sources. Health Protection Agency, UK, 2006.
2. European Association of Nuclear Medicine, 1990. 3. Neshandar Asli I., Tabeie F. Paediatric radiation exposure from diagnostic nuclear medicine
examinations in Tehran. Iran J. Radiol. 2005, 3(1). 4. Gray L, Torreggiani W, O’Reilly G. Paediatric diagnostic reference levels in nuclear medicine
imaging in Ireland. Br J Radiol. 2008, 81(971): 918-9.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Result and Discussion
131
(c) Data Comparisons with Surveys From Other Countries
Table 3.18 and Table 3.19 present the comparisons between the data collected
from this survey with the data published by other national (countries) surveys.
Table 3.18: Comparison of average administered activity (MBq) of different types of diagnostic examinations with survey from other countries (Adults ≥ 16 years old).
Diagnostic Exam.
Radio-pharmaceutical
Average Administered Activity (MBq) This
Survey
1ARG 2BRA 3CUB 4NHS 5GRC 6TWN 7USA
Bone Tc-99m MDP/ HDP
832 860 1016 740 682 536.5 560 740
Brain Tc-99m HMPAO 769 640 1009 N/A N/A N/A 420 740Cardiac Tc-99m MIBI,
Rest 832 600 589 N/A N/A N/A 540 N/A
Tc-99m MIBI, Stress
638 600 589 N/A N/A N/A 540 N/A
Tc-99m Tetrofosmin, Rest
850 700 N/A N/A N/A N/A 540 N/A
Tc-99m Tetrofosmin, Stress
699 700 N/A N/A N/A N/A 540 N/A
Gastro-enterology
Ga-67 Citrate 238 190 N/A N/A N/A 129.5 110 N/A
In-111 Pentetreotide
230 N/A N/A N/A N/A N/A N/A N/A
Tc-99m Sn Colloid
388 720 N/A N/A N/A 18.5 150 N/A
Liver or Spleen
Tc-99m HIDA 244 N/A N/A 222 N/A 263 140 N/ATc-99m Sn Colloid
379 220 510 N/A N/A 114.7 150 185
Lung Perfusion
Tc-99m MAA 308 280 421 N/A 100 172 120 185
Lung Ventilation
Tc-99m DTPA 1023 938 894 N/A N/A N/A N/A N/A
Tc-99m Aerosol 396 N/A N/A N/A N/A N/A N/A N/A
Renal Tc-99m DMSA 354 230 234 222 77 92.5 150 N/A
Tc-99m MAG3 219 400 N/A N/A 89 N/A N/A N/A
Tc-99m DTPA 365 220 N/A N/A 204 370 150 N/AThyroid I-131 MIBG 19 470 N/A 3.7 N/A 25.9 0.8 N/A I-131 NaI 172 180 4.4 74 75 N/A 20 3.7
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 3: Nuclear Medicine, Result and Discussion
132
TcO4- 349 210 426 222 N/A 114.7 80 185
1. Bomben AM, Chiliutti CA. Radiopharmaceutical activities administered for diagnostic and
therapeutic procedures in nuclear medicine in Argentine: Results of a national survey. International Congress on the International Radiation Protection Association. 2004.
2. Khoury HJ, Pereira MA, Stabin MG, Hazin CA, Drexler G. Assessment of population dose from nuclear medicine procedures in Pernambuco (Brazil) during the period 1990-1994.
3. Flores OB, Caballero AB, Sanchez OL, Estrada AM, Garcia JH. Population effective collective dose from nuclear medicine examination in Cuba. Radiat Prot Dosimetry. 2006, 121(4): 438-444.
4. NHS: Procedure for Use of Diagnostic Reference Levels for Radiodiagnosis, Hull & East Yorkshire. Hospitals Radiation Protection Service.
5. Papadopoulos G, Okkalides D. Dose to patients through nuclear medicine procedures in a department in northern Greece. European Journal of Nuclear Medicine. 1990, 17: 212-215.
6. Lai SY, Sabol J, Weng PS. Assessment of the population effective doses from the diagnostic use of radiopharmaceuticals in Taiwan. Radiat Prot Dosimetry. 1995, 62(4): 255-261.
7. Mettler FA, Christie JH, Williams AG, Moseley RD. Population characteristics and Absorbed dose to the population from nuclear medicine: United States – 1982. Health Phys. 1986, 50(5): 619-628.
Table 3.19 : Comparison of average administered activity (MBq) of different types of radionuclide therapy with other survey from other countries (Adults ≥ 16 years old).
Countries Average Administered Activity (MBq) I-131 Y-90 P-32 Sr-89
Malaysia (This survey)
1741 860 305 148
Austria 3500 10 0.2 7.5Germany 41426 1025 23 13Hungry 951 9.3 N/A 1.5Israel 1000 740 N/A N/A
Norway 932 1.9 0.33 9.4Portugal 1194 0.74 1.66 3Slovakia 4000 55 15 15Slovenia 582 7.59 1.3 2Spain 10000 N/A N/A N/A
Switzerland 1690 31 11 8The Netherlands 2900 75 18 42Turkey 2080 N/A 0.45 2.22UK 16695 88 94.96 57.06Source: Hoefnagel, C. A., Clarke, S. E., Fischer, M., Chatal, J. F., Lewington, V. J., Nilsson, S., Troncone, L. and Vieira, M. R. 1999 'Radionuclide therapy practice and facilities in Europe. EANM Radionuclide Therapy Committee', Eur J Nucl Med 26(3): 277-82.
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 4: Summary, Conclusions and Recommendations
133
The main objective of this study was to develop a national database of patient
dose in diagnostic imaging in view of establishing the DRL in Malaysia. The study
was carried out under the actual clinical settings and did not consider the potential
factors that might affect the dose measured, namely exposure parameters and
performance of the machine. This study was limited to adult patients with age greater
than 16 years. However in nuclear medicine, the patients involves were categorised
from age 0-15, 16-40 and >40 years old.
The results of this study are comparable to the published studies from other
international surveys, except in the field of interventional cardiology. Nonetheless, it
should be noted that common practice for interventional cardiology in this country is
to perform both diagnostic and therapeutic interventional procedures at the same
sitting.
The proposed DRLs were based on the third quartile value of the dose
distribution collected in this study. These DRLs will be useful in providing guidance
to the professional and regulatory bodies on national reference dose levels for
various examinations and procedures involving ionising radiation.
To improve the management of patient’s doses involving ionising radiation,
radiation exposure data must be recorded and systematically compared to the DRLs.
For radiology and nuclear medicine, MOH recommends that the medical facilities in
the country to adopt these DRLs as a guidance in order to compare with their local
practices. If doses exceed the DRLs, a review is considered to ensure the optimized
protection of patients and maintaining appropriate level of good practice.
Nevertheless, if the DRLs are exceeded, this does not necessarily mean that the
examination has been improperly conducted. Exposures exceeding the DRLs may be
expedient in order, for example, to achieve image quality which is better than usual.
On the other hand, corrective action should be taken as necessary if exposures do not
CHAPTER 4: SUMMARY, CONCLUSIONS AND RECOMMENDATIONS
Medical Radiation Exposure Study in Malaysia
__________________________________________________________________________________________________ Chapter 4: Summary, Conclusions and Recommendations
134
provide useful diagnostic information and do not yield the expected medical benefit
to patients.
This study presents the results of an updated and broad review of medical
radiation exposures in Malaysia. It involves both, public and private sectors that
covers diagnostic radiology, dental radiology and nuclear medicine. However, there
are some areas in which the study could be further improved or explored. This
includes the following:
i. General x-ray, dental x-ray and mammography examinations dose survey
carried out in this study involved conventional imaging modalities. Thus, it
would be of interest to carry out a study involving digital imaging modalities,
i.e., examinations using general x-ray machine, dental x-ray machine, and full
field digital mammography (FFDM).
ii. In this study, the dose survey for mammography carried out using real
patients and calculation to get the MGD values. In the future, a study using
phantom can be performed. Thus, the results would be comparable with other
published studies.
iii. PET/CT consists of two components: PET and CT. Each component will
contribute to the dose received by the patient. Thus, future studies would
include the total effective dose for PET/CT, i.e., the total dose received by the
patient due to administered activity and CT examination.
Medical Radiation Exposure Study in Malaysia
_______________________________________________________________________________________________________ References 135
REFERENCES
Department of Statistics Malaysia. 2009. Key Statistics: Population (Updated 31
July 2009). Available at http://www.statistics.gov.my. Accessed on 18 Nov
2009.
European Commission (EC). 1999. Radiation Protection 109: Guidance on
diagnostic reference levels (DRLs) for medical exposures. Environment,
Nuclear Safety and Civil Protection, European Commission.
International Atomic Energy Agency. 2005. Radiation oncology physics: A
handbook for teachers and students. Austria, Vienna: IAEA.
International Atomic Energy Agency (IAEA). 2006. Developing and using dose
guidance (reference) levels in radiology and nuclear medicine examinations.
Contributed papers, pages 403-487, in Radiological Protection of Patients in
Diagnostic and Interventional Radiology, Nuclear Medicine and Radiotherapy
International Commission on Radiological Protection (ICRP). 1996. Radiological
protection and safety in medicine. ICRP Publication 73. Annals of the ICRP
26, No. 2. Oxford: Pergamon Press.
National Radiological Protection Board/Royal College of Radiologists. 1990.
Patient dose reduction in diagnostic radiology. In: Documents of the NRPB.
London: HMSO; 1(3).
Ng KH, Abdullah BJ and Sivalingam S. 1999. Medical radiation exposures for
diagnostic radiology in Malaysia. Health Phys; 77(1): 33-6.
Ng KH, Rassiah P, Wang HB, Hambali AS, Muthuvellu P and Lee HP. 1998.
Doses to patients in routine X-ray examinations in Malaysia. Br J Radiol;
71(846): 654-60.
Medical Radiation Exposure Study in Malaysia
_______________________________________________________________________________________________________ References 136
Stabin MG. 1996. MIRDOSE: personal computer software for internal dose
assessment in nuclear medicine. J Nucl Med; (37): 538-46.
Stabin MG, Tagesson M, Thomas SR, Ljungberg M and Strand SE. 1999.
Radiation dosimetry in nuclear medicine. Appl Radiat Isot; (50): 73-87.
Toohey RE, Stabin MG and Watson EE. 2000. The AAPM/RSNA physics tutorial
for residents: internal radiation dosimetry: principles and applications.
Radiographics; 20: 533-46.
United Nations Scientific Committee on the Effects of Atomic Radiation: Sources,
Effects and Risks of Ionizing Radiation. 1993. UNSCEAR 1993 Report to
the General Assembly, with annexes. New York. United Nation.
United Nations Scientific Committee on the Effects of Atomic Radiation: Sources,
Effects and Risks of Ionizing Radiation. 2006. UNSCEAR 2006 Report to
the General Assembly, with annexes. New York. United Nation.
United Nations Scientific Committee on the Effects of Atomic Radiation: Sources,
effects and risks of ionizing radiation. UNSCEAR 1988 Report to the
General Assembly, with Scientific Annexes. New York. United Nation.
United Nations Scientific Committee on the Effects of Atomic Radiation
(UNSCEAR). 2000. UNSCEAR 2000 Report: Effects of ionizing radiation,
Vol II, Annex D. New York. United Nation.
US National Council on Radiation Protection & Measurements. 2009. Report No.
160 - Ionizing Radiation Exposure of the Population of the United States
(2009). NRPB, United States.
Wall, B., Harrison, R. and Spiers, F. W. 1988. Patient Dosimetry Techniques in
Diagnostic Radiology. UK: The Institute of Physical Science in Medicine.
World Nuclear Association. 2009. Radioisotopes in nuclear medicine. Available at
http://www.world-nuclear.org. Accessed on 15 Nov 2009.
Medical Radiation Exposure Study in Malaysia
_______________________________________________________________________________________________________ References 137
http://www.doseinfo-radar.com
www.syque.com/quality_tools/toolbook/Variation/measuring_centering.htm
MINISTRY OF HEALTH UNSCEAR SURVEY PROJECT Diagnostic Radiology
Hospital:
Radiologist: Years Radiologist
2007 (a) (b) (c) (d) (e)
2008 (a) (b) (c) (d) (e)
2009 (a) (b) (c) (d) (e)
Personnel:
Number of Personnel
2007 2008 2009
Radiologist
Interventional Radiologists
Interventional Cardiologists
Medical Physicists
Radiographers/ Radiation Technologists
Modality:
X-Ray Unit
Model Manufacturer
Appendix A
UNSCEAR: Forms/Background/Diagnostic/1.0 1 of 2
Computed Tomography (CT)
Model Manufacturer
Mammography Unit
Model Manufacturer
Fluoroscopy Unit
Model Manufacturer
Bone Mineral Density Unit
Model Manufacturer
Name of individual completing the form
e-mail address
UNSCEAR: Forms/Background/Diagnostic/1.0 2 of 2
MINISTRY OF HEALTH UNSCEAR SURVEY PROJECT Dental Examinations
Hospital:
Dentists: Years Radiologist
2007 (a) (b) (c) (d) (e)
2008 (a) (b) (c) (d) (e)
2009 (a) (b) (c) (d) (e)
Personnel:
Number of Personnel
2007 2008 2009
Dentists
Medical Physicists
Radiographers
Modality:
Dental X-Ray Unit
Model Manufacturer
Dental CT Unit
Model Manufacturer
UNSCEAR: Forms/Background/Dental/1.0 1 of 2
Name of individual completing the form
e-mail address
UNSCEAR: Forms/Background/Dental/1.0 2 of 2
General X-ray Measurement of entrance Surface Air Kerma per study Hospital: ………………………………….. Room: …………….
Date
Type of examination
Patient Data:
Patient ID
Ethnic Group M/ C/ I/ O
Sex Male / Female
Age
Weight kg
Height cm
Study Parameters:
Image No.
Projection (AP/PA/LAT/Oblique)
FFD (cm)
kVp mAs AEC used
(*Y/N)
Cassette size (cm x cm)
TLD ID Entrance Surface Air Kerma (mGy)
Remark
1
2
3
4
5 Y – Yes, N – No
UNSCEAR: Forms/Diagnostic/GenXray/ 1.0
Fluoroscopy Measurement of dose-area-product and entrance skin dose per study Hospital: ………………………………….. Room: …………….
Date
Type of examination Angiography (Diagnostic): Cardiac / Non-cardiac
Conventional: Upper Gastrointestinal / Lower Gastrointestinal / MCU / ERCP
Interventional: Cardiac (PTCA) / Cerebral / Vascular / ESWL / Others
Patient Data:
Patient ID
Ethnic Group M/ C/ I/ O
Sex Male / Female
Age
Weight kg
Height cm
Study Parameters:
Series No.
Study kV (mean)
mA Time (s)
mAs Frame Rate (fps)
Total Time
(s)
No. of Acquisition
DAP (mGy.m2)
Gafchromic Film Label
Remark
1
2
3
4
5 Y – Yes, N – No
UNSCEAR: Forms/Diagnostic/Fluoro/ 1.0
Computed Tomography (CT) Measurement of CTDI and effective dose per study Hospital: Room:
Date
Type of examination
Patient Data:
Patient ID
Ethnic Group M / C / I / O
Sex Male / Female
Age
Weight kg
Height cm
Information: FOV Field of View (cm x cm) Matrix Size eg. 512 x 512 , 1024 x 1024 TF (Table Feed) distance/rotation (mm) P Pitch Collimation/ Detector Selection Eg. 16 x 0.625, 4 x 2.5.
For single sliced CT, leave this empty. No. of Phases Number of scan with same parameters (only for
multiple phases)
*Study Parameters:
Series No.
Scan Area kV mA mAs Time (s)
FOV Matrix size
TF (mm)
P Collimation/Detector Selection
Recon Slice
Thickness (mm)
Scan Length (cm)
Spiral Mode (Y/N)
Remark (e.g. No.
of Phases)
1
2
3
4
5
*Do not record scout scan
UNSCEAR: Forms/Diagnostic/CT/ 1.0
Mammography Measurement of Mean Glandular Dose per study Hospital: ………………………………….. Room: …………….
Date
Type of examination Screening / Clinical Diagnosis
Patient Data:
Patient ID
Ethnic Group M / C / I / O
Age
Weight kg
Height cm
Information: CC Cranial-caudal view MLO Mediolateral oblique view FFD Focus-to-Film Distance Target/Filter eg., Mo/Mo, Mo/Rh, Rh/Rh, W/W AEC Automatic Exposure Control
Study Parameters:
Series No.
Projection (CC/MLO)
FFD (cm)
Target/ Filter kVp mAs(exp) AEC used (*Y/N)
Compressed Breast
Thickness (mm)
Mean Glandular Dose (mGy)
Remark
1
2
3
4
5 Y – Yes, N – No
UNSCEAR: Forms/Diagnostic/Mammo/ 1.0
Bone Mineral Density Examinations Measurement of entrance surface dose per study Hospital: ………………………………….. Room: …………….
Date
Patient Data:
Patient ID
Ethnic Group M / C / I / O
Sex Male / Female
Age
Weight kg
Height cm
Information: Projection AP Spine / Left Hip / Right Hip Scan Mode Hi-Res, Fast / Hi-Res, Med / Low-Res, Med
Study Parameters:
Image No.
Projection (AP Spine / Left Hip /
Right Hip)
kVp mA Time (s)
Scan Mode TLD label Entrance Surface Dose
(mGy)
Remark
1
2
3
4
5 Y – Yes N – No
UNSCEAR: Forms/Diagnostic/BMD/ 1.0
Dental Examinations Measurement of entrance surface dose per study Hospital: ………………………………….. Room: …………….
Date
Type of examination Intraoral / Panoramic / Dental CT
Patient Data:
Patient ID
Ethnic Group M / C / I / O
Sex Male / Female
Age
Weight kg
Height cm
Study Parameters:
Image No.
FFD (cm)
kVp mAs AEC used
(*Y/N)
Film size (cm x cm)
TLD label Entrance Surface Dose
(mGy)
Remark
1
2
3
4
5 Y – Yes N – No
UNSCEAR: Forms/Diagnostic/Dental/ 1.0
Diagnostic X-ray Examinations (Year 2005)
UNSCEAR: Forms/Survey/Diagnostic/2005 1 of 3
General X-ray Estimated number of
examinations performed annually (a)
Estimated average patient dose
Estimated effective dose (mSv)(If
available) Age and sex distribution (%)
0-15 years 16-40 years >40 years Examination Conven-
tional Digital
Entrance surface Dose (mGy)
±SD Mean ±SD Male Female Male Female Male Female
Chest Radiography Chest PA Chest LAT Limbs & Joints Upper Extremities: Hand, Wrist, Radius, Ulna, Elbow, Humerus, Shoulder
Lower Extremities: Foot, Ankle, Tibia, Fibula, Femur, Knee
Spine Lumbo-sacral AP Lumbo-sacral LAT Thoracic AP Thoracic LAT Cervical AP Cervical LAT Pelvis/Hip Skull AP Lat Others (Towne, Caldwell, etc)
Abdomen/KUB
Diagnostic X-ray Examinations (Year 2005)
UNSCEAR: Forms/Survey/Diagnostic/2005 2 of 3
Mammography Estimated number of
examinations performed annually (a)
Estimated average patient dose
Estimated effective dose (mSv)(If available) Age and sex distribution (%)
Examination
Conventional Digital Mean
glandular dose(mGy)
±SD Mean ±SD 16-40 years >40 years
Screening
Clinical diagnosis
Fluoroscopy
Estimated average patient dose Estimated effective
dose (mSv)(If available)
Age and sex distribution (%)
0-15 years 16-40 years >40 years Examination
Estimated number of
examinations performed annually (a)
Peak Skin Dose (mGy)
±SD
Kerma Area
Product (Gycm2)
±SD Mean ±SD Male Female Male Female Male Female
Angiography (Diagnostic) Cardiac Non-cardiac
Conventional Studies Upper Gastrointestinal Lower Gastrointestinal MCU ERCP Cholecystography Urography
Interventional Cardiac (PTCA) Cerebral Vascular ESWL Others
Diagnostic X-ray Examinations (Year 2005) Computed Tomography (CT)
Estimated average patient dose
Estimated effective dose (mSv)(If available) Age and sex distribution (%)
0-15 years 16-40 years >40 years Examination
Estimated number of examinations
performed annually (a) CTDI(vol) ±SD Mean ±SD
Male Female Male Female Male Female Brain Spine/Musculo-skeletal (Cervical, thorax, lumbo-sacral spine)
Chest Abdomen Pelvis Cardiac CT Other: …………………………
TOTAL of all medical examinations
Bone Mineral Density (BMD)
Estimated average patient dose
Estimated effective dose (mSv)(If
available) Age and sex distribution (%)
0-15 years 16-40 years >40 years Examination
Estimated number of examinations
performed annually (a)
Entrance surface Dose (mGy)
±SD Mean ±SD Male Female Male Female Male Female
AP Spine Left Hip / Right Hip
(a) If the conventional/digital mix is not known, please check the box and put entries in the Conventional column
UNSCEAR: Forms/Survey/Diagnostic/2005 3 of 3
Diagnostic X-ray Examinations (Year 2006)
UNSCEAR: Forms/Survey/Diagnostic/2006 1 of 3
General X-ray Estimated number of
examinations performed annually (a)
Estimated average patient dose
Estimated effective dose (mSv)(If
available) Age and sex distribution (%)
0-15 years 16-40 years >40 years Examination Conven-
tional Digital
Entrance surface Dose (mGy)
±SD Mean ±SD Male Female Male Female Male Female
Chest Radiography Chest PA Chest LAT Limbs & Joints Upper Extremities: Hand, Wrist, Radius, Ulna, Elbow, Humerus, Shoulder
Lower Extremities: Foot, Ankle, Tibia, Fibula, Femur, Knee
Spine Lumbo-sacral AP Lumbo-sacral LAT Thoracic AP Thoracic LAT Cervical AP Cervical LAT Pelvis/Hip Skull AP Lat Others (Towne, Caldwell, etc)
Abdomen/KUB
Diagnostic X-ray Examinations (Year 2006)
UNSCEAR: Forms/Survey/Diagnostic/2006 2 of 3
Mammography Estimated number of
examinations performed annually (a)
Estimated average patient dose
Estimated effective dose (mSv)(If available) Age and sex distribution (%)
Examination
Conventional Digital Mean
glandular dose(mGy)
±SD Mean ±SD 16-40 years >40 years
Screening
Clinical diagnosis
Fluoroscopy
Estimated average patient dose Estimated effective
dose (mSv)(If available)
Age and sex distribution (%)
0-15 years 16-40 years >40 years Examination
Estimated number of
examinations performed annually (a)
Peak Skin Dose (mGy)
±SD
Kerma Area
Product (Gycm2)
±SD Mean ±SD Male Female Male Female Male Female
Angiography (Diagnostic) Cardiac Non-cardiac
Conventional Studies Upper Gastrointestinal Lower Gastrointestinal MCU ERCP Cholecystography Urography
Interventional Cardiac (PTCA) Cerebral Vascular ESWL Others
Diagnostic X-ray Examinations (Year 2006) Computed Tomography (CT)
Estimated average patient dose
Estimated effective dose (mSv)(If available) Age and sex distribution (%)
0-15 years 16-40 years >40 years Examination
Estimated number of examinations
performed annually (a) CTDI(vol) ±SD Mean ±SD
Male Female Male Female Male Female Brain Spine/Musculo-skeletal (Cervical, thorax, lumbo-sacral spine)
Chest Abdomen Pelvis Cardiac CT Other: …………………………
TOTAL of all medical examinations
Bone Mineral Density (BMD)
Estimated average patient dose
Estimated effective dose (mSv)(If
available) Age and sex distribution (%)
0-15 years 16-40 years >40 years Examination
Estimated number of examinations
performed annually (a)
Entrance surface Dose (mGy)
±SD Mean ±SD Male Female Male Female Male Female
AP Spine Left Hip / Right Hip
(a) If the conventional/digital mix is not known, please check the box and put entries in the Conventional column
UNSCEAR: Forms/Survey/Diagnostic/2006 3 of 3
Diagnostic X-ray Examinations (Year 2007)
UNSCEAR: Forms/Survey/Diagnostic/2007 1 of 3
General X-ray Estimated number of
examinations performed annually (a)
Estimated average patient dose
Estimated effective dose (mSv)(If
available) Age and sex distribution (%)
0-15 years 16-40 years >40 years Examination Conven-
tional Digital
Entrance surface Dose (mGy)
±SD Mean ±SD Male Female Male Female Male Female
Chest Radiography Chest PA Chest LAT Limbs & Joints Upper Extremities: Hand, Wrist, Radius, Ulna, Elbow, Humerus, Shoulder
Lower Extremities: Foot, Ankle, Tibia, Fibula, Femur, Knee
Spine Lumbo-sacral AP Lumbo-sacral LAT Thoracic AP Thoracic LAT Cervical AP Cervical LAT Pelvis/Hip Skull AP Lat Others (Towne, Caldwell, etc)
Abdomen/KUB
Diagnostic X-ray Examinations (Year 2007)
UNSCEAR: Forms/Survey/Diagnostic/2007 2 of 3
Mammography Estimated number of
examinations performed annually (a)
Estimated average patient dose
Estimated effective dose (mSv)(If available) Age and sex distribution (%)
Examination
Conventional Digital Mean
glandular dose(mGy)
±SD Mean ±SD 16-40 years >40 years
Screening
Clinical diagnosis
Fluoroscopy
Estimated average patient dose Estimated effective
dose (mSv)(If available)
Age and sex distribution (%)
0-15 years 16-40 years >40 years Examination
Estimated number of
examinations performed annually (a)
Peak Skin Dose (mGy)
±SD
Kerma Area
Product (Gycm2)
±SD Mean ±SD Male Female Male Female Male Female
Angiography (Diagnostic) Cardiac Non-cardiac
Conventional Studies Upper Gastrointestinal Lower Gastrointestinal MCU ERCP Cholecystography Urography
Interventional Cardiac (PTCA) Cerebral Vascular ESWL Others
Diagnostic X-ray Examinations (Year 2007) Computed Tomography (CT)
Estimated average patient dose
Estimated effective dose (mSv)(If available) Age and sex distribution (%)
0-15 years 16-40 years >40 years Examination
Estimated number of examinations
performed annually (a) CTDI(vol) ±SD Mean ±SD
Male Female Male Female Male Female Brain Spine/Musculo-skeletal (Cervical, thorax, lumbo-sacral spine)
Chest Abdomen Pelvis Cardiac CT Other: …………………………
TOTAL of all medical examinations
Bone Mineral Density (BMD)
Estimated average patient dose
Estimated effective dose (mSv)(If
available) Age and sex distribution (%)
0-15 years 16-40 years >40 years Examination
Estimated number of examinations
performed annually (a)
Entrance surface Dose (mGy)
±SD Mean ±SD Male Female Male Female Male Female
AP Spine Left Hip / Right Hip
(a) If the conventional/digital mix is not known, please check the box and put entries in the Conventional column
UNSCEAR: Forms/Survey/Diagnostic/2007 3 of 3
Dental Radiology (Year 2005)
UNSCEAR: Forms/ Survey /Dental/2005 1 of 3
Dental Radiology
Estimated average patient dose
Estimated effective dose (mSv)(If available) Age and sex distribution (%)
0-15 years 16-40 years >40 years Examination
Estimated number of examinations
performed annually (a)
Entrance surface Dose
(mGy) ±SD Mean ±SD
Male Female Male Female Male Female Intraoral Panoramic Dental CT
Dental Radiology (Year 2006)
UNSCEAR: Forms/Survey/Dental/2006 1 of 3
Dental Radiology
Estimated average patient dose
Estimated effective dose (mSv)(If available) Age and sex distribution (%)
0-15 years 16-40 years >40 years Examination
Estimated number of examinations
performed annually (a)
Entrance surface Dose
(mGy) ±SD Mean ±SD
Male Female Male Female Male Female Intraoral Panoramic Dental CT
Dental Radiology (Year 2007)
UNSCEAR: Forms/Survey/Dental/2007 1 of 3
Dental Radiology
Estimated average patient dose
Estimated effective dose (mSv)(If available) Age and sex distribution (%)
0-15 years 16-40 years >40 years Examination
Estimated number of examinations
performed annually (a)
Entrance surface Dose
(mGy) ±SD Mean ±SD
Male Female Male Female Male Female Intraoral Panoramic Dental CT
UNSCEAR: Forms/Equipment list/ 1.1
MINISTRY OF HEALTH UNSCEAR SURVEY PROJECT Equipment List Hospital:
No. Location (Room #) Model Manufacturer
Serial No.
Year of Purchase Other Specifications
1 2 3 4 5 6 7 8 9
General X-ray
10
1 No. of Slice = 2 No. of Slice = 3 No. of Slice = 4 No. of Slice =
Computer Tomography
5 No. of Slice =
1 2 3 4 5
Fluoroscopy
6
UNSCEAR: Forms/Equipment list/ 1.1
7 8 9
10
1 HVL = ESAK =
2 HVL = ESAK =
3 HVL = ESAK =
4 HVL = ESAK =
Mammography
5 HVL = ESAK =
1 2 3 4
Bone Mineral Density
5
1 2 3 4
Dental
5
Radionuclide Studies
Code Study Purpose EquipmentSkeletalS1 99m-Tc MDP WB Bone Planar scintigraphy To detect skeletal lesions at the earliest possible SPECT Gamma camera with
time, monitor the course of skeletal disease and planar collimator.evaluate metabolic activity of skeletal lesions.
S2 99m-Tc MDP Localised Bone Planar scintigraphy same as above same as aboveS3 99m-Tc MDP Localised Bone SPECT same as above same as aboveS4 99m-Tc Bilateral Hip Planar scintigraphy same as above same as aboveS5 99m-Tc MDP Bilateral Hip SPECT same as above same as aboveS6 99m-Tc Sn colloid WB Bone Marrow study To detect marrow space disease processes. same as aboveS7 99m-Tc Sn colloid Localised Bone Marrow study same as above same as aboveS8 99m-Tc MDP Bone Pinhole scintigraphy same as item S1 Gamma camera with
pinhole collimator.S9 99m-Tc MDP Flow & Equi. Bone Planar scintigraphy same as item S1 Gamma camera with planar
collimator.
CardiovascularC1 99m-Tc MIBI Exercise Myocardial Perfusion study To assess regional and global myocardial perfusion SPECT Gamma camera with
for diagnosis and management of coronary artery planar collimator.disease.
C2 99m-Tc MIBI DP Stress Myocardial Perfusion study same as above same as aboveC3 99m-Tc MIBI Rest Myocardial Perfusion study same as above same as aboveC4 99m-Tc RBC Rest Gated Ventriculography To examine the function of the heart's chambers SPECT Gamma camera with
including ventricular size, configuration and wall planar collimator.motion.
C5 99m-Tc RBC Exercise Gated Ventriculography same as above same as aboveC6 99m-Tc RBC Rest Gated SPECT Ventriculography same as above same as aboveC7 99m-Tc Cardiac First Pass study To provide quantitative, semi-quantitative and Gamma camera with planar
qualitative indices of cardiac function and anatomic collimator.information.
C8 99m-Tc Cardiac Gated First Pass study same as above same as aboveC9 99m-Tc PYP Myocardial Infarct Planar scintigraphy Localization of acute myocardial infarction. same as aboveC10 99m-Tc PYP Myocardial Infarct SPECT scintigraphy same as item C9 SPECT Gamma camera with
planar collimator.C11 201-Tl Exercise Myocardial Perfusion study same as item C1 same as aboveC12 201-Tl DP Stress Myocardial Perfusion study same as item C1 same as aboveC13 201-Tl Redistribution Myocardial Perfusion study same as item C1 same as aboveC14 201-Tl 24hr Redistribution Myocardial Perfusion study same as item C1 same as aboveC15 201-Tl 24hr (Re-inj) Redistr. Myocardial Perfusion same as item C1 same as above
Code Study Purpose Equipmentstudy
C16 99m-Tc TET Exercise Myocardial Perfusion study same as item C1 same as aboveC17 99m-Tc TET DP Stress Myocardial Perfusion study same as item C1 same as aboveC18 99m-Tc TET Rest Myocardial Perfusion study same as item C1 same as above
Central Nervous SystemB1 99m-Tc HMPAO Cerebral Perfusion SPECT To diagnose abnormalities of regional cerebral blood SPECT Gamma camera with
flow. planar collimator.B2 99m-Tc Brain Blood Flow study Assess cerebral function. Gamma camera with planar
collimator.B3 99m-Tc WBC Cerebral SPECT Detection of sites of focal infection. SPECT Gamma camera with
planar collimator.B4 99m-Tc DTPA Planar Cisternography Assess CSF hydrodynamics, determination of Gamma camera with planar
patency of shunts or intraventricular blocks. collimator.B5 99m-Tc DTPA SPECT Cisternography same as above SPECT Gamma camera with
planar collimator.
Gastrointestinal & HepatobiliaryG1 99m-Tc Sn colloid Oesophageal Transit study Quantitate the motor function of oesophagus. Gamma camera with planar
collimator.G2 99m-Tc DTPA Gastric Emptying Time study Quantitating gastric emptying. same as aboveG3 99m-Tc Meckel's Diverticulum scintigraphy Localization of bleeding site in ectopic gastric same as above
mucosa.G4 99m-Tc Sn colloid Acute Gastrointestinal Bleed Localization of bleeding site. same as above
scintigraphyG5 99m-Tc RBC Gastrointestinal Bleed scintigraphy same as above same as aboveG6 99m-Tc BRIDA Hepatobiliary scintigraphy Assess biliary tree function. same as aboveG7 99m-Tc Sn colloid Accessory Spleen scintigraphy To detect presence of accessory spleen following same as above
scintigraphy splenectomy.G8 99m-Tc Heat Damaged RBC Accessory Spleen same as above same as above
scintigraphyG9 99m-Tc Sn colloid Gastrointestinal Reflux study Evaluate reflux oesophagitis. same as aboveG10 99m-Tc Sn colloid Liver/Spleen Planar scintigraphy To delineate various states of liver/spleen disease. same as aboveG11 99m-Tc Sn colloid Liver/Spleen SPECT scintigraphy same as above SPECT Gamma camera with
planar collimator.G12 99m-Tc RBC Liver Blood Pool Planar scintigraphy Localization of hemangiomas. Gamma camera with planar
collimator.G13 99m-Tc RBC Liver Blood Pool SPECT scintigraphy same as above SPECT Gamma camera with
planar collimator.G14 99m-Tc Sn colloid Peritoneal Shunt study To detect obstruction of LeVeen shunt. Gamma camera with planar
Code Study Purpose Equipmentcollimator.
Infection & OncologyI1 99m-Tc HMPAO Leucocyte Planar scintigraphy Detect sites of abscess and inflammation. Gamma camera with planar
collimator.I2 99m-Tc WBC Leucocyte scintigraphy same as above same as aboveI3 67-Ga WB Planar scintigraphy Detect sites of infection and tumours. same as aboveI4 67-Ga Localised SPECT same as above SPECT Gamma camera with
planar collimator.I5 67-Ga Localised Planar scintigraphy same as above Gamma camera with planar
collimator.I6 131-I WB Planar scintigraphy To detect metastasis from thyroid cancers. same as aboveI7 131-I Localised Planar scintigraphy same as above same as aboveI8 131-I Localised SPECT same as above SPECT Gamma camera with
planar collimator.I9 75-Se Selenomethyl Norcholestenol Adrenal Localization of adrenocortical and sympathomedulla Gamma camera with planar
scintigraphy disease. collimator.I10 131-I MIBG WB Planar scintigraphy Detect presence of adrenal pheochromocytoma, same as above
extra-adrenal metastatic deposits and catecholaminie secreting tumours.
I11 131-I MIBG Localised SPECT same as above SPECT Gamma camera withplanar collimator.
I12 131-I MIBG Localised Planar scintigraphy same as above Gamma camera with planarcollimator.
I13 99m-Tc V-DMSA WB Planar scintigraphy To detect medullary carcinoma. same as aboveI14 131-I Localised Pinhole scintigraphy Delineate thyroid gland Gamma camera with pinhole
collimator.I15 67-Ga Localised Pinhole scintigraphy same as item I5 same as aboveI16 99m-Tc HMPAO Leucocyte SPECT same as item I1 SPECT Gamma camera with
planar collimator.I17 99m-Tc HMPAO Leucocyte WB Planar scintigraphy same as item I1 Gamma camera with planar
collimator.I18 99m-Tc HMPAO Leucocyte Pinhole scintigraphy same as item I1 Gamma camera with pinhole
collimator.I19 111-In Pentetreotide Localised SPECT Localization of primary and metastatic neuro- SPECT Gamma camera with
endocrine tumours bearing somatostatin receptors. planar collimator.I20 111-In Pentetreotide WB Planar scintigraphy same as above Gamma camera with planar
collimator.I21 111-In Pentetreotide Localised Planar scintigraphy same as above same as aboveI22 99m-Tc Tetrofosmin Osteosarcoma scintigraphy To detect osteosarcoma same as above
Code Study Purpose EquipmentI23 201-Tl Osteosarcoma scintigraphy same as above same as aboveI24 99m-Tc TET Tumour WB scintigraphy Localization of malignant tumours. same as aboveI25 99m-Tc TET Tumour SPECT same as above SPECT Gamma camera with
planar collimator.I26 99m-Tc TET Tumour Planar scintigraphy same as above Gamma camera with planar
collimator.I28 99m-Tc TET Cancer Breast SPECT Localization of malignant breast tissue. same as aboveI29 99m-Tc Nanocolloid Lymphoscintigraphy Demonstrate historeticular tissue of retroperitoneal, same as above
axillary, parasternal and cervical lymph nodes.I30 99m-Tc Scintimun Granulocyte same as item I1 same as above
Lacrymal & SalivaryL1 99m-Tc Dacryo Planar scintigraphy Define patency of lacrymal duct. Gamma camera with planar
collimator.L2 99m-Tc Salivary Gland scintigraphy To establish function of salivary gland. same as aboveL3 99m-Tc Salivary Gland Pinhole scintigraphy same as above Gamma camera with pinhole
PulmonaryP1 99m-Tc Technegas Lung Ventilation study To distinguish COPD related perfusion defects from Gamma camera with planar
those secondary to pulmonary embolization. collimator.P2 99m-Tc MAA Lung Perfusion study Evaluation of pulmonary arterial blood flow. same as aboveP3 99m-Tc DTPA Radioaerosol Lung Ventilation study same as item P1 same as aboveP4 99m-Tc Technegas Lung Ventilation SPECT same as item P1 SPECT Gamma camera with
planar collimator.P5 99m-Tc MAA Perfusion SPECT same as item P2 same as above
Renal & Urinary TractR1 99m-Tc DTPA Diuretic Renal study Provide sensitive indices of relative renal blood flow, Gamma camera with planar
glomerular filtration, tubular function and urinary collimator.excretion.
R2 99m-Tc DTPA Renal Transplant study same as above same as aboveR3 99m-Tc DTPA Captopril Enhanced Renal study same as above same as aboveR4 99m-Tc DMSA Renal Planar study Evaluation of functioning cortical renal parenchyma same as aboveR5 99m-Tc DMSA Renal SPECT same as above SPECT Gamma camera with
planar collimator.R6 99m-Tc DTPA Micturating Cystoscintigraphy Management of vesicoureteral reflux Gamma camera with planar
(Direct method) collimator.R7 99m-Tc DTPA Micturating Cystoscintigraphy same as above same as above
(Indirect method)R8 99m-Tc MAG3 Renal study same as item R1 same as above
Code Study Purpose EquipmentR9 99m-Tc DTPA Glomerular Filtration Rate Estimation of glomerular filtration rate Gamma well counterR10 99m-Tc/51-Cr EDTA GFR same as above same as above
Thyroid & ParathyroidT1 99m-Tc Thyroid scintigraphy To define functioning benign thyroid tissue and to Gamma camera with planar
detect presence and location of metastases from collimator.thyroid cancer.
T2 131-I Thyroid scintigraphy same as aboveT3 131-I Thyroid Uptake study Evaluate thyroid gland functionT4 131-I Thyroid Perchlorate Discharge test To detect defects in intrathyroidal iodide Thyroid uptake probe
organification.T5 201-Tl/99m-Tc Parathyroid scintigraphy To detect functioning parathyroid adenomas Gamma camera with planar
collimator.T6 131-I/99m-Tc TET Parathyroid scintigraphy same as above same as aboveT7 99m-Tc Thyroid SPECT same as item T1 SPECT Gamma camera with
planar collimator.T8 99m-Tc MIBI Parathyroid scintigraphy same as item T5 Gamma camera with planar
collimator.
OthersO1 Schilling Test (Vitamin B12 malabsorption) To differentiate malabsorption syndrome from Gamma well counter
pernicious anaemia.O2 51-Cr RBC Blood Volume study To estimate total blood volume and red cell mass. same as aboveO3 125-I Plasma Volume study To estimate plasma volume same as aboveO4 51-Cr Red Cell Survival & Sequestration study To determine functional half clearance time of 51Cr Gamma well counter & uptake
labelled isologous red cells and life span of red cells probe.in haemolytic anaemia.
Radionuclide TherapyZ1 131-I therapy for thyrotoxicosis Treatment of Graves' disease Radionuclide dose calibratorZ2 90-Sr Beta irradiation of Pterygium Prophylactic post-operative irradiation to reduce Strontium-90 ophthalmic
recurrence. applicator.Z3 89-Sr therapy for bone pains Control of bone pain in metastatic bone disease. Radionuclide dose calibratorZ4 153-Sm therapy same as above same as aboveZ6 131-I High Dose ablation Treatment of thyroid cancer same as aboveZ7 90-Y Zevalin therapy Treatment for relapsed or refractory, low grade or same as above
follicular B-cell non Hodgkin's lymphoma.Z8 90-Y microspheres therapy Selective internal radiation therapy for liver cancer. same as aboveZ9 188-Re therapy Treatment for disseminated skeletal metastasis. same as above
UNSCEAR: Forms/Background/Nuclear Medicine/1.0 1 of 2
MINISTRY OF HEALTH UNSCEAR SURVEY PROJECT
Nuclear Medicine
Hospital:
Nuclear Medicine Physicians: Years Nuclear Medicine Physicians
2005 (a)
(b)
(c)
(d)
(e)
2006 (a)
(b)
(c)
(d)
(e)
2007 (a)
(b)
(c)
(d)
(e)
Personnel:
Number of Personnel
2005 2006 2007
Nuclear Medicine Physicians:
Medical Physicists
Nuclear Medicine Technologist
Modality:
Gamma Camera
Model Manufacturer
PET
Model Manufacturer
UNSCEAR: Forms/Background/Nuclear Medicine/1.0 2 of 2
PET/CT
Model Manufacturer
Name of individual completing the form
E-mail address
NUCLEAR MEDICINE: DIAGNOSTIC DOSE SURVEY FORM
Hospital:
Date of Survey:
Patient Data:
Date of examination (dd/mm/yy)
Exam Name Scanning Room
No
Patient ID Sex / Age Ethnic group
Weight / Height
( kg / cm)
Radio-pharmaceutical
Activity (mCi)
Effective Dose (mSv)
Remarks
/ /
/ /
/ /
/ /
/ /
/ /
/ /
/ /
/ /
/ /
Legend: Exam name: BO - Bone, BR - Brain, C - Cardiac, G - Gastroenterology, LP - Lung Perfusion, LV - Lung Ventilation, R - Renal, T - Thyroid, others
Sex: M-male, F-female Ethnic group: M-Malay, C-Chinese, I-Indian, O-others
UNSCEAR: Forms/Nuclear Medicine: Diagnostic/1.1
NUCLEAR MEDICINE: THERAPEUTIC DOSE SURVEY FORM
Hospital:
Date of Survey:
Patient Data:
Date of Treatment (dd/mm/yy)
Treatment Name Treatment Room No
Patient ID Sex / Age Ethnic group
Weight / Height
( kg / cm)
Radio-pharmaceutical
Activity (mCi)
Effective Dose (mSv)
Remarks
/ /
/ /
/ /
/ /
/ /
/ /
/ /
/ /
/ /
/ /
Legend: Treatment name: BM - Bone metastases, HT - Hyperthyroidism, PV - Polycythaemia vera, SY - Synovitis, TM - Thyroid malignancy, others
Sex: M-male, F-female Ethnic group: M-Malay, C-Chinese, I-Indian, O-others
UNSCEAR: Forms/Nuclear Medicine: Therapeutic/1.1
NUCLEAR MEDICINE: PET-CT DOSE SURVEY FORM
Hospital:
Room: Date of survey:
Patient Data:
CT protocol Date of exam.
(dd/mm/yy)
Patient ID Sex / Age
Ethnic group
Weight / Height
( kg / cm)
Clinical indication
Activity of 18-FDG (mCi)
kV mAs Rot. Time (s)
Nom S/thick
Pitch Scan length (mm)
Scan region
Effective Dose (mSv)
/ /
/ /
/ /
/ /
/ /
/ /
/ /
/ /
/ /
/ /
Legend: Sex: M-male, F-female Ethnic group: M-Malay, C-Chinese, I-Indian, O-others
Nom. S/thickness for SSCT = slice thickness, for MSCT = no. of slice X slice thickness
Pitch = table travel distance / nom S/thickness Scan length = end scan – start scan. Minus sign must be included
Scan region: A - Abdomen, AP - Abdomen Pelvis, BPF - Brain posterior fossa, BR - Brain, C - Chest, PF - Posterior fossa, N - Neck, P - Pelvis, others
UNSCEAR: Forms/Nuclear Medicine: PET-CT/1.1
Nuclear Medicine Procedures (Year 2005)
Age and sex distribution (%) Activity administered (MBq)
0-15 years 16-40 years >40 years Examination or
treatment
Estimated number of procedures performed annually
Most common radio-
pharmaceutical
Percentage of examinations
performed using this material
Mean Min Max Male Female Male Female Male Female
DIAGNOSTIC EXAMINATIONS
Bone
C ardiac
Lung perfusion
Lung ventilation
Thyroid
Renal
Gastroenterology
Brain
PET
PET/CT combined
TOTAL of all examinations
THERAPEUTIC TREATMENTS
Thyroid malignancy
Hyperthyroidism
Polycythaemia vera
Bone metastases
Synovitis
Other: e.g. 90YCl
TOTAL of all treatments
UNSCEAR: Forms/Survey/Nuclear Medicine/2005 1 of 1
Nuclear Medicine Procedures (Year 2006)
Age and sex distribution (%) Activity administered (MBq)
0-15 years 16-40 years >40 years Examination or
treatment
Estimated number of procedures performed annually
Most common radio-
pharmaceutical
Percentage of examinations
performed using this material
Mean Min Max Male Female Male Female Male Female
DIAGNOSTIC EXAMINATIONS
Bone
C ardiac
Lung perfusion
Lung ventilation
Thyroid
Renal
Gastroenterology
Brain
PET
PET/CT combined
TOTAL of all examinations
THERAPEUTIC TREATMENTS
Thyroid malignancy
Hyperthyroidism
Polycythaemia vera
Bone metastases
Synovitis
Other: e.g. 90YCl
TOTAL of all treatments
UNSCEAR: Forms/ Survey /Nuclear Medicine/2006 1 of 1
Nuclear Medicine Procedures (Year 2007)
Age and sex distribution (%) Activity administered (MBq)
0-15 years 16-40 years >40 years Examination or
treatment
Estimated number of procedures performed annually
Most common radio-
pharmaceutical
Percentage of examinations
performed using this material
Mean Min Max Male Female Male Female Male Female
DIAGNOSTIC EXAMINATIONS
Bone
C ardiac
Lung perfusion
Lung ventilation
Thyroid
Renal
Gastroenterology
Brain
PET
PET/CT combined
TOTAL of all examinations
THERAPEUTIC TREATMENTS
Thyroid malignancy
Hyperthyroidism
Polycythaemia vera
Bone metastases
Synovitis
Other: e.g. 90YCl
TOTAL of all treatments
UNSCEAR: Forms/ Survey /Nuclear Medicine/2007 1 of 1
Tab
le15
Typ
ical
effe
ctiv
ed
ose
sto
pat
ien
tsu
nd
erg
oin
gso
me
com
mo
nty
pes
of
dia
gn
ost
icm
edic
ala
x-ra
yp
roce
du
res
(199
1�19
96)
Dat
afr
omU
NS
CE
AR
Sur
vey
ofM
edic
alR
adia
tion
Usa
gean
dE
xpos
ures
unle
ssot
herw
ise
indi
cate
d
PA
RT
A
Cou
ntry
Typi
cale
ffect
ive
dose
per
proc
edur
eb
(mSv
)
Che
stLi
mbs
and
join
ts
Spin
eP
elvi
san
dhi
ps
Hea
dA
bdom
enG
Itr
act
Cho
le-
cyst
o-gr
aphy
Rad
io-
grap
hyP
hoto
-flu
orog
raph
yF
luor
o-sc
opy
Lum
bar
Thor
acic
Cer
vica
lU
pper
Low
er
Hea
lth
-car
ele
velI
Aus
tral
ia0.
025
(±0.
008)
�
c�
�2
(±1)
��
0.6
�1
(±0.
7)�
��
Bel
arus
0.25
(30 �
50%
)0.
5(3
0�50
%)
1.0
(30-
50%
)0.
2(3
0-50
%)
1.1
(30-
50%
)1.
6(±
30-5
0%)
1.1
(30-
50%
)1.
1(3
0-50
%)
0.12
(30-
50%
)1.
4(3
0-50
%)
0.6
(30-
50%
)1
(30-
50%
)0.
2(3
0-50
%)
Bul
gari
a0.
16(0
.04-
0.18
)0.
91(0
.77 �
1.05
)1.
85(1
.6�
2.1)
��
��
��
��
��
Chi
na,T
aiw
anPr
ov.
0.02
��
�0.
48�
��
�0.
193.
84.
1�
Cze
chR
epub
lic0.
050.
7�
�2
1.76
0.28
1.26
0.28
33
8.5
1.26
Finl
and
0.1
��
�2.
31
0.2
1.3
0.1
2.2
99.
7�
Ger
man
y0.
3(0
.01 �
5.5)
��
0.06
(0.0
01-0
.5)
20.
70.
20.
8(0
.1-4
.8)
0.03
(0.0
01-0
.7)
1.2
(0.1
-5.3
)8.
3(0
.1-3
8)17
.7(0
.2-8
5)7.
1(0
.7-3
6)
Japa
n0.
057
0.05
31.
14�
1.45
0.65
0.26
0.58
0.09
0.24
3.33
2.68
0.88
Net
herl
ands
0.06
(±0.
08)
��
�2
11
10.
11
6.4
(±3.
4)4.
7(±
2.4)
�
New
Zea
land
��
��
��
��
��
510
�
Nor
way
0.13
0.23
��
1.1
0.5
0.2
0.5
0.2
14
8�
Pana
ma
0.02
1(±
0.01
3)�
�0.
003
(±0.
003)
2.17
(±1.
0)1.
20(±
0.43
)0.
07(±
0.01
)0.
44(±
0.13
)0.
045
(±0.
02)
0.30
(±0.
12)
6.9
(±2.
9)3.
12(±
0.76
)0.
87(±
0.14
)
Pola
nd0.
110.
824.
10.
024.
333.
03�
0.61
0.1
2.2
1422
.7�
Rom
ania
0.25
(±0.
11)
0.63
(±0.
3)0.
95(±
0.4)
0.08
(±0.
03)
3(±
1.4)
2.1
(±1.
2)0.
21(±
0.1)
2.6
0.17
(±0.
12)
1.9
(±1)
4.1
(±1.
9)9
(±3.
8)1.
6(±
0.9)
ANNEX D: MEDICAL RADIATION EXPOSURES374
Tab
le15
(con
tinue
d)
Cou
ntry
Typi
cale
ffect
ive
dose
per
proc
edur
eb
(mSv
)
Che
stLi
mbs
and
join
ts
Spin
eP
elvi
san
dhi
ps
Hea
dA
bdom
enG
Itr
act
Cho
le-
cyst
o-gr
aphy
Rad
io-
grap
hyP
hoto
-flu
orog
raph
yF
luor
o-sc
opy
Lum
bar
Thor
acic
Cer
vica
lU
pper
Low
er
Rus
sian
Fede
ratio
n0.
40.
67�
��
��
��
�3.
3�
�
Swed
en0.
15�
�0.
13
10.
21.
50.
12.
53
86
Switz
erla
nd0.
1(±
0.03
)0.
5(±
0.2)
0.2
(±0.
1)0.
05(±
0.05
)1.
5(±
0.5)
0.8
(±0.
5)0.
2(±
0.2)
1(±
0.5)
0.1
(±0.
1)0.
5(±
0.3)
5(±
4)5
(±4)
8(±
4)
Uni
ted
Ara
bE
mir
ates
0.05
90.
018
(0.0
11-0
.028
)�
�0.
470.
350.
280.
35(0
.11-
0.67
)1.
060.
434.
49.
8�
Uni
ted
Kin
gdom
0.02
��
�1.
30.
7�
0.7
0.04
0.7
2.6
7.2
�
Ave
rage
d0.
140.
651.
080.
061.
81.
40.
270.
830.
070.
533.
66.
42.
3
Hea
lth
-car
ele
velI
I
Bra
zil
0.05
3�
��
��
��
�0.
5(±
0.36
)�
��
Mal
aysi
a[N
26]
0.03
��
0.04
1.04
0.46
0.03
0.74
0.04
1.05
6�
1.5
Ave
rage
0.05
��
0.04
1.0
0.46
0.03
0.74
0.04
0.62
6�
1.5
PA
RT
B
Cou
ntry
Typi
cale
ffect
ive
dose
per
proc
edur
e(m
Sv)
Uro
grap
hyM
amm
ogra
phy
Com
pute
dto
mog
raph
yA
ngio
grap
hyP
TCA
Tota
lofa
llm
edic
alex
amin
atio
nsSc
reen
ing
Clin
ical
All
Hea
dB
ody
All
Cer
ebra
lC
ardi
acA
ll
Hea
lth�
care
leve
lI
Aus
tral
ia�
��
0.4
(±0.
16)
2.6
(±2.
0)10
.6(±
7.5)
6.9
��
��
1.33
Bel
arus
2(±
30-5
0%)
��
��
��
��
��
�
Bul
gari
a�
��
��
��
��
��
1.28
Can
ada
��
��
��
��
��
�1.
05
ANNEX D: MEDICAL RADIATION EXPOSURES 375
ANNEX D: MEDICAL RADIATION EXPOSURES376
Tab
le15
(con
tinue
d)
Cou
ntry
Typi
cale
ffect
ive
dose
per
proc
edur
e(m
Sv)
Uro
grap
hyM
amm
ogra
phy
Com
pute
dto
mog
raph
yA
ngio
grap
hyP
TCA
Tota
lofa
llm
edic
alex
amin
atio
nsSc
reen
ing
Clin
ical
All
Hea
dB
ody
All
Cer
ebra
lC
ardi
acA
ll
Chi
na,T
aiw
anPr
ov.
��
��
��
��
��
�0.
43
Cze
chR
epub
lic2.
04�
0.5
�1.
19.
23.
82.
83.
67.
3�
�
Den
mar
k�
��
��
��
��
��
0.7
Finl
and
4.5
0.1
0.2
�1.
37.
93.
8�
14.8
��
0.64
Ger
man
y4.
9(0
.2�
19)
��
0.5
(0.1�
2)2.
6(1�
5)15
.4(4�
50)
11.3
��
12.3
(1�
190)
23(1�
190)
1.5
(0.0
01�
190)
Japa
n2.
47�
��
��
��
5.56
��
�
Net
herl
ands
40.
1e
0.1
0.1
e1.
7e
10.2
e6.
7e
�5
e5
e5
e1.
0e
New
Zea
land
��
0.07
(±0.
02)
�2.
2(±
1.1)
7.8
(±4)
��
12.3
(±5.
4)�
16.2
(±9.
2)�
Nor
way
2�
0.12
�2
106.
5�
��
��
Pana
ma
2.07
(±0.
39)
��
0.24
(±0.
11)
1.06
(±0.
12)
3.8
(±0.
51)
2.1
3.7
(±1.
1)�
��
�
Pola
nd3.
1�
�1
(±0.
3)�
�3.
5�
�25
71.
2
Port
ugal
��
��
��
��
��
�0.
83
Rom
ania
5.8
(±2.
9)�
�0.
62(±
0.3)
��
��
�0.
22�
1.35
(±0.
63)
Rus
sian
Fede
ratio
n�
��
0.56
0.4
5.8
��
��
�0.
73
Swed
en5
0.1
0.2
�2
105.
81
129.
222
1.2
Switz
erla
nd4
(±2)
��
0.1
(±0.
1)2
(±1)
5(±
2)3.
92
(±1)
10 (±1)
6.7
100.
8(±
0.4)
Ukr
aine
��
��
��
��
��
�0.
83
Uni
ted
Ara
bE
mir
ates
2.66
0.13
0.11
(0.0
1 �0.
14)
�2.
62(1
.75 �
3.3)
9.83
(6.8�
11.8
)�
��
��
�
Uni
ted
Kin
gdom
2.4
0.06
��
29
6�
��
��
Tab
le15
(con
tinue
d)
Cou
ntry
Typi
cale
ffect
ive
dose
per
proc
edur
e(m
Sv)
Uro
grap
hyM
amm
ogra
phy
Com
pute
dto
mog
raph
yA
ngio
grap
hyP
TCA
Tota
lofa
llm
edic
alex
amin
atio
nsSc
reen
ing
Clin
ical
All
Hea
dB
ody
All
Cer
ebra
lC
ardi
acA
ll
aE
xclu
ding
dent
alx-
ray
exam
inat
ions
.b
Var
iatio
nssh
own
inbr
acke
ts(s
tand
ard
devi
atio
n,co
effi
cien
tofv
aria
tion
orra
nge)
.c
No
data
avai
labl
e.d
Freq
uenc
y-w
eigh
ted
aver
age
ofna
tiona
lval
ues.
eT
hese
revi
sed
data
wer
ere
ceiv
edby
the
Com
mitt
eeaf
ter
com
plet
ion
ofth
egl
obal
anal
ysis
.
Uni
ted
Kin
gdom
2.4
0.06
��
29
6�
��
��
Uni
ted
Stat
es�
��
��
��
��
��
0.52
Ave
rage
3.7
0.07
0.21
0.51
2.3
13.3
8.8
2.0
7.3
12.4
220.
83
Hea
lth
-car
ele
velI
I
Bra
zil
3.89
(±2.
8)�
��
��
��
��
�0.
26
Chi
na[Z
10]
��
��
��
��
��
�0.
57
Mal
aysi
a[N
26]
2.4
�0.
10.
12.
87.
84.
96.
86.
8�
�0.
28
Ave
rage
3.9
�0.
10.
12.
87.
84.
96.
86.
8�
�0.
56
The
entr
ies
inth
isT
able
are
qual
ifie
das
follo
ws:
Bra
zil:
Surv
eyda
tafo
rPa
raná
Stat
e(w
itha
popu
latio
nof
9m
illio
nan
da
soci
alan
dec
onom
icpr
ofile
abov
eth
eav
erag
efo
rB
razi
l).
Chi
na(T
aiw
an):
Dat
afo
rlu
mba
rsp
ine,
GI
trac
tand
tota
lofa
llm
edic
alex
amin
atio
nsfr
omre
fere
nce
[L23
].G
erm
any:
Mea
nef
fect
ive
dose
for
gene
ralc
lass
ific
atio
nof
spin
eis
1.2
mSv
(ran
ge:0
.1�
20m
Sv).
Mal
aysi
a:D
ata
for
ches
t,sp
ine
and
head
refe
rto
AP/
PApr
ojec
tions
.Dat
afo
r‘G
Itr
act’
rela
teto
both
‘Upp
er’
and
‘Low
er’
cate
gori
es.
Nor
way
:D
ata
from
natio
nals
urve
yin
volv
ing
abou
t50
hosp
itals
and
5000
mea
sure
men
ts.
Rom
ania
:A
dditi
onal
surv
eyda
tain
rela
tion
to‘C
hest
fluo
rosc
opy’
:mea
nen
tran
cesu
rfac
edo
seof
13.4
mG
yan
dm
ean
dose
-are
apr
oduc
tof3
.6m
Gy
cm2
[I28
].R
ussi
a:A
dditi
onal
surv
eyda
tain
rela
tion
toef
fect
ive
dose
sfr
om‘C
hest
fluo
rosc
opy’
:dos
era
tes
with
outa
ndw
ithel
ectr
onic
imag
ein
tens
ific
atio
nof
1.4
mSv
per
min
ute
and
0.9
mSv
per
min
ute,
resp
ectiv
ely.
Dat
ash
own
for
‘GI
trac
t’re
late
tobo
th‘U
pper
’an
d‘L
ower
’ca
tego
ries
.Eff
ectiv
edo
sera
tes
from
fluo
rosc
opy
with
outa
ndw
ithel
ectr
onic
imag
ein
tens
ific
atio
nof
4.2
mSv
per
min
ute
and
2.3
mSv
per
min
ute,
resp
ectiv
ely
duri
ngup
per
GI
exam
inat
ions
,and
3.6
mSv
per
min
ute
and
2.2
mSv
per
min
ute,
resp
ectiv
ely,
duri
nglo
wer
GI
exam
inat
ions
.Dat
afo
r‘C
T-B
ody’
refe
rto
exam
inat
ions
ofth
eab
dom
en;m
ean
effe
ctiv
edo
sefo
rC
Tch
esti
s2.
8m
Sv.
Uni
ted
Ara
bE
mir
ates
:Su
rvey
data
from
one
hosp
ital,
exce
ptth
ose
for
ches
trad
iogr
aphy
and
pelv
is/h
ip(f
rom
seve
nho
spita
ls),
and
ches
tpho
tofl
uoro
grap
hy(f
rom
four
units
attw
oho
spita
ls).
ANNEX D: MEDICAL RADIATION EXPOSURES 377
Tab
le16
Pat
ien
td
ose
fro
md
iag
no
stic
x-ra
yex
amin
atio
ns
Dat
afr
omU
NS
CE
AR
Sur
vey
ofM
edic
alR
adia
tion
Usa
gean
dE
xpos
ures
unle
ssot
herw
ise
indi
cate
d
PA
RT
A
Cou
ntry
/are
aSc
ope
ofda
taD
ose
quan
tity
a
Mea
nva
lue
ofdo
sequ
antit
ype
rra
diog
raph
b
Skul
lC
hest
Thor
acic
spin
eLu
mba
rsp
ine
Abd
omen
Pel
vis
AP
/PA
LAT
PA
LAT
AP
LAT
AP
LAT
LSJ
AP
AP
Hea
lth
-car
ele
velI
Aus
tral
ia[B
29]
Stat
eE
SD1.
9(0
.9�
2.7)
1.2
(0.5�
2.3)
0.12
(0.0
2-0.
21)
0.63
(0.2
2-1.
42)
�
c�
6.1
(2.3�
19.7
)15
.1(3
.7�
32.5
)22
.4(5
.3�
43.3
)4.
2(1
.4�
7.3)
3.9
(1.5�
7.0)
Arg
entin
a[I
4]3
hosp
itals
ESD
ESD
��
0.38
(pre
)(0
.24-
0.48
)0.
33(p
ost)
(0.3
1-0.
34)
��
��
��
5.10
(pre
)
3.31
(pos
t)
�
Can
ada
Reg
iona
lE
SD
ESD
�0.
68(m
an.)
(±0.
23)
0.74
(aut
o.)
(±0.
21)
0.11
(man
.)(±
0.03
)0.
13(a
uto.
)(±
0.04
)
�1.
82(m
an.)
(±0.
6)1.
50(a
uto.
)(±
0.05
)
�3.
34(m
an.)
(±1.
0)3.
69(a
uto.
)(±
1.3)
��
2.35
(man
.)(±
0.5)
1.64
(aut
o.)
(±0.
5)
�
Chi
na,T
aiw
anPr
ovin
ce[Y
9]N
atio
nal
E�
�0.
040
(±0.
12)
��
��
��
0.21
(±0.
10)
�
Cze
chR
epub
lic[I
4]3
hosp
itals
ESD
ESD
��
0.41
(pre
.)(0
.08-
0.99
)0.
12(p
ost.)
(0.1
-0.1
3)
��
�8.
36(p
re.)
(5.5
6-10
.8)
5.64
(pos
t.)3.
87-8
.39)
��
�6.
37(p
re.)
(5.5
9-6.
99)
4.12
(pos
t.)3.
09-6
.99)
Est
onia
[S29
]4
hosp
itals
ESD
15.1
(2.2�
30.1
)8.
1(1
.1�
14.3
)0.
30(0
.15-
0.49
)0.
86�
�13
.8(0
.84-
31.7
)30
.3(7
.3�
61.0
)�
14.0
(2.2�
26.8
)15
.8(2
.5�
29.9
)
Finl
and
[R11
]N
atio
nal
ESD
DA
P
E
3.37
(1.0
6-8.
53)
1.63
(020
-5.8
2)0.
12(0
.03-
0.42
)
1.93
(0.5
7-8.
01)
0.24
(0.0
6-3.
28)
0.44
(0.0
8-3.
47)
0.10
(0.0
3-1.
10)
0.73
(0.1
5-4.
44)
4.89
(0.4
9-11
.3)
4.14
(1.1
0-22
.2)
1.02
(0.2
3-3.
92)
11.6
(2.1
0-26
.2)
8.80
(0.4
9-43
.5)
8.25
(0.8
8-68
.8)
2.27
(0.2
5-11
.4)
18.2
(2.1
0-11
1)�
7.08
(0.7
6-19
.0)
6.90
(0.8
6-20
.8)
2.22
(0.6
0-5.
89)
6.15
(2.0
2-22
.0)
3.80
(0.7
9-16
.0)
1.25
(0.3
1-4.
49)
Ger
man
y[B
9]N
atio
nal
DA
P1.
071.
373.
519.
323.
623.
62
Gre
ece
[O3]
1ho
spita
lE
SD E
3.5
(±1.
95)
0.09
4
2.68
(±1.
49)
0.03
4
0.69
(±0.
4)0.
11
2.94
(±1.
57)
0.22
8.25
(±4.
63)
0.74
10.9
(±8.
1)0.
33
18.9
(±6.
76)
1.88
44.9
(±22
.9)
0.94
�11
.2(±
7.3)
1.45
12.5
(±6.
85)
1.35
ANNEX D: MEDICAL RADIATION EXPOSURES378
Tab
le16
(con
tinue
d)
Cou
ntry
/are
aSc
ope
ofda
taD
ose
quan
tity
a
Mea
nva
lue
ofdo
sequ
antit
ype
rra
diog
raph
b
Skul
lC
hest
Thor
acic
spin
eLu
mba
rsp
ine
Abd
omen
Pel
vis
AP
/PA
LAT
PA
LAT
AP
LAT
AP
LAT
LSJ
AP
AP
Irel
and
[J10
]N
atio
nal
ESD
��
0.22
(0.0
2-0.
65)
��
�6.
47(0
.27-
20.3
)16
.9(1
.8�
67.1
)36
.9(1
.5�
102)
4.75
(0.5�
18.3
)5.
63(1
.2�
26.5
)
Lith
uani
aN
atio
nal
ESD
2.11
2.73
0.81
1.39
��
22.8
35.5
37.4
20.4
321
.43
Nor
way
[O6]
Nat
iona
lD
AP
E�
�0.
640.
12�
��
��
�7.
613.
48
Pana
ma
Nat
iona
lE
SD�
�0.
17(±
0.10
)�
��
��
�2.
33(±
0.91
)3.
28(±
1.0)
Pola
ndN
atio
nal
ESD E
��
0.20
(0.1
6-2.
76)
0.06
(0.0
6-0.
49)
0.88
0.10
5.1
(0.7
-18.
5)0.
9(0
.63-
12.6
)
8.3
(1.2
-23.
2)2.
13(0
.98-
8.9)
7.50
(1.3
8-25
.3)
3.43
(0.7
7-11
.5)
12.0
(3.4
5-38
.4)
0.9
(0.7
1-2.
27)
�4.
7(0
.75-
23.2
)2.
18(0
.12-
7.12
)
2.54
(1.9
7-25
.8)
0.61
(0.4
0-10
.3)
Rom
ania
[I28
]21
hosp
itals
ESD
11.0
(1.0�
31)
9.4
(1.2�
28)
1.7
(0.3�
6.0)
4.2
(0.7�
13)
11.2
(2.0�
41)
24.0
(3.5�
97)
17.6
(2.0�
71)
42.0
(4.4�
162)
�10
.9(2
.1�
37)
13.2
(1.9�
35)
Rus
sian
Fede
ratio
nN
atio
nal
E�
�0.
40.
60.
80.
31.
71.
2�
�0.
75
New
Zea
land
Nat
iona
lE
SD
DA
P
E
3.0
(±2.
04)
0.96
(±0.
65)
0.03
(±0.
02)
1.56
(±1.
04)
0.57
(±0.
37)
0.02
(±0.
05)
0.22
(±0.
25)
0.17
(±0.
2)0.
03(±
0.03
)
1.24
(±1.
92)
0.62
(±0.
67)
0.1
(±0.
11)
4.32
(±2.
67)
1.54
(±1.
01)
0.44
(±0.
26)
13.3
(±9.
72)
3.53
(±2.
68)
0.31
(±0.
21)
5.47
(±2.
89)
1.88
(±1.
16)
0.6
(±0.
33)
18.9
(±11
.6)
3.92
(±2.
33)
0.47
(±0.
29)
31.2
(±21
.8)
3.83
(±2.
79)
0.36
(±0.
24)
4.57
(±2.
57)
2.67
(±1.
61)
0.58
(±0.
33)
3.98
(±2.
33)
2.37
(±1.
49)
0.63
(±0.
38)
Slov
enia
Loc
alE
SD E�
�0.
290.
051.
020.
064.
890.
377.
220.
216.
110.
6315
.65
0.48
15.0
00.
143.
520.
044.
720.
65
Sout
hA
fric
a[M
22,H
29]
Nat
iona
lE
SD6.
43.
61.
53.
213
.135
.627
.359
.1�
13.1
15.4
Uni
ted
Ara
bE
mir
ates
Loc
alE
0.68
0.38
0.02
0(0
.005
-0.
028)
0.03
9(0
.008
4 �0.
094)
��
��
��
�
Uni
ted
Kin
gdom
[H11
]N
atio
nal
ESD E
3.0
(0.5�
10.0
)0.
03
1.5
(0.5
6-4.
43)
0.01
0.16
(0.0
1-0.
94)
0.02
0.57
(0.1
1�2.
6)0.
04
4.7
(1.3�
18.0
)0.
40
13.0
(1.3�
43.0
)0.
29
6.1
(1.4�
31.0
)0.
69
16.0
(3.9�
75.0
)0.
29
29.0
(4.2�
84.0
)0.
29
5.6
(0.7
5-16
.6)
0.7
4.4
(1.0�
16.0
)0.
66
Uni
ted
Stat
esN
atio
nal
ESD
��
0.15
��
��
��
��
ANNEX D: MEDICAL RADIATION EXPOSURES 379
Tab
le16
(con
tinue
d)
Cou
ntry
/are
aSc
ope
ofda
taD
ose
quan
tity
a
Mea
nva
lue
ofdo
sequ
antit
ype
rra
diog
raph
b
Skul
lC
hest
Thor
acic
spin
eLu
mba
rsp
ine
Abd
omen
Pel
vis
AP
/PA
LAT
PA
LAT
AP
LAT
AP
LAT
LSJ
AP
AP
Hea
lth
-car
ele
velI
I
Bra
zil
3ho
spita
lsE
SD E
4.55
(3.0
8-7.
34)
�0.
33
0.02
1(±
0.01
)
1.01
0.03
2(±
0.02
)
��
6.82
(4.3
6 �9.
38)
��
7.88
5.28
(4.3
5-6.
20)
Cos
taR
ica
1ho
spita
lE
SD4.
45(±
2.3)
2.92
(±2.
4)1.
97(±
2.3)
5.33
(±5.
3)7.
14(±
4.6)
12.4
(±8.
9)10
.6(±
12.0
)27
.9(±
18.1
)�
7.74
(±5.
3)6.
39(±
3.3)
Iran
(Isl
am.R
ep.o
f)[I
4]2
hosp
itals
ESD
ESD
��
0.21
(pre
.)(0
.19-
0.26
)0.
06(p
ost.)
(0.0
4-0.
09)
��
��
��
3.57
(pre
.)(2
.83-
4.25
)1.
87(p
ost.)
1.47�
2.08
)
�
Mal
aysi
a[N
15,N
26]
12ho
spita
lsE
SD E4.
780.
043.
340.
040.
280.
031.
400.
097.
030.
4616
.510
.61.
0418
.7�
10.0
8.41
Peru
�E
SD3.
5(±
1.0)
�0.
4(±
0.3)
��
�7.
0(±
3.0)
��
8.5
(±2.
0)6.
0(±
3.0)
Tur
key
Loc
alE
SD4.
27(±
0.88
)�
0.32
(±0.
05)
0.70
(±0.
20)
7.45
(±0.
54)
�2.
81(±
1.49
)�
�10
.73
(±2.
01)
19.3
5(±
1.16
)
Hea
lth�
care
leve
lIII
Egy
pt[H
28]
14ho
spita
lsE
SD0.
3�
0.5
��
�3.
3�
�1.
51.
5
Gha
na[S
39]
12ho
spita
lsE
SD E
5.7
(2.7�
9.1)
0.08
(±38
%)
�0.
74(0
.1�
1.5)
0.10
(±61
%)
��
�9.
2(3
.1�
16.0
)1.
61(±
52%
)
��
�7.
9(2
.0�
13.1
)1.
71(±
40%
)
Indo
nesi
a[L
19]
4ho
spita
lsE
SD3.
61(±
1.24
)3.
52(±
1.48
)0.
51(±
0.18
)�
��
6.30
(±1.
50)
9.36
(±3.
0)9.
57(±
6.22
)�
3.72
(±1.
23)
Mor
occo
�E
SD9.
39(±
2)�
0.23
(±0.
2)0.
72(±
0.2)
��
12.3
��
�10
.2
Tha
iland
[L19
]4
hosp
itals
ESD
ESD
1.37
(pre
.)(±
0.76
)0.
72(p
ost.)
(±0.
26)
1.10
(pre
.)(±
0.64
)0.
52(p
ost.)
(±0.
17)
0.26
(pre
.)(±
0.16
)0.
16(p
ost.)
(±0.
09)
0.97
(pre
.)(±
0.48
)0.
52(p
ost.)
(±0.
27)
��
2.81
(pre
.)(±
2.1)
1.21
(pos
t.)(±
0.65
)
7.97
(pre
.)(±
5.3)
4.08
(pos
t.)(±
3.5)
��
1.52
(pre
.)(±
1.09
)0.
93(p
ost.)
(±0.
47)
ANNEX D: MEDICAL RADIATION EXPOSURES380
Tab
le16
(con
tinue
d)
Cou
ntry
/are
aSc
ope
ofda
taD
ose
quan
tity
a
Mea
nva
lue
ofdo
sequ
antit
ype
rra
diog
raph
b
Skul
lC
hest
Thor
acic
spin
eLu
mba
rsp
ine
Abd
omen
Pel
vis
AP
/PA
LAT
PA
LAT
AP
LAT
AP
LAT
LSJ
AP
AP
aE
SD:e
ntra
nce
surf
ace
dose
with
back
scat
ter
(mG
y);D
AP:
dose
-are
apr
oduc
t(G
ycm
2 );E
:eff
ectiv
edo
se(m
Sv).
bV
aria
tions
show
nin
brac
kets
(sta
ndar
dde
viat
ion
orra
nge)
.c
No
data
avai
labl
e.
Hea
lth�
care
leve
lIV
Eth
iopi
a[I
4]2
hosp
itals
ESD
ESD
��
1.34
(pre
.)(0
.94-
1.74
)0.
57(p
ost.)
(0.4
3-0.
70)
��
��
��
�5.
26(p
re.)
5.11�
5.41
)10
.57(
post
)(9
.74-
11.4
)
Uni
tdR
ep.o
fT
anza
nia
[M37
]5
hosp
itals
ESD
��
0.5
(±0.
3)�
��
7.7
(±3.
8)17
.5(±
8.5)
�8.
3(±
5.6)
6.4
(±4.
5)
PA
RT
B
Cou
ntry
Scop
eof
data
Dos
equ
antit
ya
Mea
nva
lue
ofdo
sequ
antit
ype
rex
amin
atio
nb
Upp
erG
Itr
act
Low
erG
Itr
act
Uro
grap
hyE
RC
PV
enog
ram
Swal
low
Mea
lE
nem
aC
olon
osco
py
Hea
lth�
care
leve
lI
Ger
man
y[B
9]N
atio
nal
DA
P13
.05
35.9
61.5
�20
.333
.77.
8
Icel
and
[W42
]5
hosp
itals
DA
P�
�(4
3.6�
77.4
)�
��
�
New
Zea
land
Nat
iona
lE
�3
90.
4�
4�
Nor
way
[O6]
Nat
iona
lD
AP
E7.
41 1.5
24.8
5.9
49.1
13.7
�18
.13.
831
.88.
3�
Rom
ania
[I18
]
[I28
]
5ho
spita
ls
21ho
spita
ls
DA
PE
DA
P
�37
.7(±
17.5
)3.
722
.0(2�
100)
32.2
(±3.
3)8.
1234
.7(2�
116)
��
��
Switz
erla
nd[M
45]
�D
AP
13.5
(±10
.2)
68.5
(±42
.9)
��
�37
.1(±
32.8
)�
Uni
ted
Kin
gdom
[H11
][B
56]
Nat
iona
lR
egio
nal
DA
PD
AP
9.3
5.63
13.0
7.60
25.8
15.7
�13
.4�
� 9.0
3.8
1.92
ANNEX D: MEDICAL RADIATION EXPOSURES 381
ANNEX D: MEDICAL RADIATION EXPOSURES382
Tab
le16
(con
tinue
d)
The
entr
ies
inth
isT
able
are
qual
ifie
das
follo
ws:
Arg
entin
a:Pa
irs
ofva
lues
repr
esen
tsur
veys
befo
rean
daf
ter
the
intr
oduc
tion
ofa
prog
ram
me
ofqu
ality
cont
rol.
Inte
rhos
pita
lvar
iatio
nin
brac
kets
.B
razi
l:Su
rvey
data
for
Para
náSt
ate
(with
apo
pula
tion
of9
mill
ion
and
aso
cial
and
econ
omic
prof
ileab
ove
the
aver
age
for
Bra
zil)
;dat
afo
rsk
ull,
lum
bar
spin
e,an
dpe
lvis
from
refe
renc
e[I
4].
Bra
zil:
Pair
sof
valu
esre
pres
ents
urve
ysbe
fore
and
afte
rth
ein
trod
uctio
nof
apr
ogra
mm
eof
qual
ityco
ntro
l.In
terh
ospi
talv
aria
tion
inbr
acke
ts.
Can
ada:
Surv
eyda
tafr
omM
anito
ba(4
%of
Can
adia
npo
pula
tion)
for
stan
dard
pres
sed
woo
dph
anto
ms
(uni
tden
sity
)un
der
man
uala
ndau
tom
atic
expo
sure
cont
rola
ndfo
rra
re�
eart
hin
tens
ifyi
ngte
chni
ques
.C
osta
Ric
a:D
ata
from
Hos
pita
lCal
deró
nG
uard
ia(s
ervi
ngon
e �th
ird
ofth
epo
pula
tion)
.C
zech
Rep
ublic
:Pa
irs
ofva
lues
repr
esen
tsur
veys
befo
rean
daf
ter
the
intr
oduc
tion
ofa
prog
ram
me
ofqu
ality
cont
rol.
Inte
rhos
pita
lvar
iatio
nin
brac
kets
.E
gypt
:M
axim
umre
com
men
ded
dose
sde
rive
dfr
omth
efo
llow
ing
publ
ishe
dm
axim
umen
tran
cesu
rfac
eex
posu
res:
26m
Rsk
ull;
45m
Rch
est;
272
mR
lum
bar
spin
e;12
5m
Rab
dom
en;1
25m
Rpe
lvis
[H28
].E
ston
ia:
Inte
rhos
pita
lvar
iatio
nin
brac
kets
.E
thio
pia:
Pair
sof
valu
esre
pres
ents
urve
ysbe
fore
and
afte
rth
ein
trod
uctio
nof
apr
ogra
mm
eof
qual
ityco
ntro
l.In
terh
ospi
talv
aria
tion
inbr
acke
ts.
Fin
land
:D
AP
and
Eda
tare
pres
entm
ean
valu
esfo
rco
mpl
ete
exam
inat
ions
.G
erm
any:
DA
Pda
tare
fer
toco
mpl
ete
exam
inat
ions
(rat
her
than
dose
spe
rra
diog
raph
).G
hana
:D
ata
for
AP
pelv
isal
soin
clud
esra
diog
raph
yof
the
abdo
men
.Ic
elan
d:D
ata
for
bari
umen
ema
exam
inat
ions
refe
rto
rang
eof
mea
nD
AP
valu
esob
serv
edin
surv
eyof
5ho
spita
ls.
Iran
(Isl
amic
Rep
.of)
:Pa
irs
ofva
lues
repr
esen
tsur
veys
befo
rean
daf
ter
the
intr
oduc
tion
ofa
prog
ram
me
ofqu
ality
cont
rol.
Inte
rhos
pita
lvar
iatio
nin
brac
kets
.Li
thua
nia:
Dat
afr
omV
ilniu
sU
nive
rsity
Hos
pita
l.M
oroc
co:
Dat
afr
omIA
EA
Coo
rdin
ated
Res
earc
hPr
ogra
mm
e.N
orw
ay:
Dat
afo
r‘U
pper
GI-
Mea
l’an
d‘L
ower
GI-
Ene
ma’
refe
rto
doub
leco
ntra
stte
chni
que
(cor
resp
ondi
ngda
tafo
rsin
gle
cont
rast
tech
niqu
e:14
.0G
ycm
2&
3.4
mSv
,and
32.3
Gy
cm2
&9.
0m
Sv,r
espe
ctiv
ely)
.P
eru:
Dat
am
ayre
fer
toco
mpl
ete
exam
inat
ions
.R
oman
ia:
Pair
sof
valu
esre
pres
ents
urve
ysbe
fore
and
afte
rth
ein
trod
uctio
nof
apr
ogra
mm
eof
qual
ityco
ntro
l.In
ter �
hosp
italv
aria
tion
inbr
acke
ts.
Sout
hA
fric
a:D
eriv
edfr
omfr
ee�
in�
air
data
calc
ulat
edfo
rav
erag
eex
posu
reco
nditi
ons.
Uni
ted
Rep
.of
Tanz
ania
:Su
rvey
data
for
500
patie
nts
per
exam
inat
ion
spre
adov
er4
refe
rral
hosp
itals
and
1re
gion
alho
spita
l;th
ese
hosp
itals
are
colle
ctiv
ely
resp
onsi
ble
for
near
ly50
%of
the
annu
alna
tiona
ltot
alof
patie
nts
exam
ined
with
x �ra
ys.
Thai
land
:Pa
irs
ofva
lues
repr
esen
tsur
veys
befo
rean
daf
ter
the
intr
oduc
tion
ofa
prog
ram
me
ofqu
ality
cont
rol.
Turk
ey:
Surv
eyda
tafr
omA
nkar
aU
nive
rsity
Hos
pita
land
Gül
hane
Mili
tary
Hos
pita
l.U
nite
dA
rab
Em
irat
es:
Surv
eyda
tafo
r‘H
ead’
exam
inat
ions
from
one
hosp
ital,
data
for
‘Che
st’
from
seve
nho
spita
ls.
Uni
ted
Kin
gdom
:In
ter �
hosp
italv
aria
tion
inbr
acke
ts.D
ata
from
refe
renc
e[B
56]
repr
esen
tmed
ian
valu
esfr
omre
gion
alsu
rvey
.U
nite
dSt
ates
:O
nth
eba
sis
ofen
tran
cesu
rfac
eex
posu
reof
0.12
mG
yfr
omN
EX
Tpr
ogra
mm
efo
r19
94.
ANNEX D: MEDICAL RADIATION EXPOSURES 383
a Mean values of parameters (with range, standard deviation, or coefficient of variation in parentheses).b Ages 0.01-12 years. Calculated entrance surface doses: mean 99 mGy, range 10-526 mGy.c Mean length of cine film 28 m (maximum 85 m).d Range of cine film length: 25-100 m.e Mean time of cinefluorography (25-30 frames per second) was 60 seconds (standard deviation 30 seconds).f Mean number of frames: 689.g Range of cine film length: 16-43 m.h 61% of total DAP from radiography.i Data refer to right and left heart angiography.j Mean contributions to effective dose: 67% from fluoroscopy, 26% from cut films, and 7% from DSA.k Maximum dose to right ocular lens of 125 mGy; maximum dose to thyroid of 88 mGy.
Table 17Patient dose per procedure from diagnostic angiographic examinations
ProcedureTechnique Fluoroscopy time a
(min)Dose-area product a
(Gy cm2)Effective dose a
(mSv)Ref.
Coronary Children b
Cine film c
Cine film d
-Cinefluorography e
---Digital cine f
-No. frames a: 878 (302 SD)Cine film g
�
8 (70 max.)4.3 (1.5�15)
3.97 (SD 3.6)
�
9.8 ( ± 65%)�
5.7�
3.6 (3.3 SD)(3.1�5.6)
13.3 (1.4�98)41 (228 max.)
(21�40)16.1 h
�
55.930.4 ( ± 57%)
38.947.758.7 i
39.3 (18 SD)(23�79)
�
�
(2�9)3.1 (1�12)
10.6�
5.68.99.4�
�
(4.6�15.8)
[B48][H6][C22][L3][K5][Z12][B3][O6][B54][W41][P20][N29]
Cerebral DSA�
DSA/conventional j
Carotid (DSA)DSA/conventionalDigital�
�
Carotid
4.7�
�
3.9 (1.2�11.8)15 ( ± 10)
12.1 (2.9�36)�
�
7.8 (3.1�17.9)
48.5�
�
27.4 (9.5�80)59 (12�120)74 (21�196)
55.250
98 (44�208)
3.6Eye/thyroid data k
10.6 (2.7�23.4)4 (1�12)
�
7.4 (2.1�19.6)1.6�
�
[M9][H24][F15][S3]
[K23][M34][O6][V14][M46]
Abdominal Hepatic (DSA)Renal (DSA)Renal (DSA)Mesenteric and/or coeliac art.DSA/conventionalDigitalRenal angiographyRenal angiographyDigitalAortagramMesenteric
10.3 (2.3�28.6)12.1 (5.5�21)
5.114.7
1.0 ( ± 0.5)8.0 (1.8�27)5.1 (2.9�7.6)2.8 (0.5�9.3)6.7 ( ± 6.5)
�
�
137 (28�279)95 (41�186)
4365
57 (31�89)118 (21.6�301)39.8 (17.4�72)177 (90�327)
61 (8�192)98 (297 max.)
112 (352 max.)
23 (4�48)16 (6�34)
610�
18.9 (3.5�48)6.4 (2.8�11.5)
�
8.2�
�
[S3][S3]
[K26][K26][K23][M34][M34][M46][R17][W32][W32]
Peripheral Femoral (DSA)Aorto�iliac + 1 legAorto�iliac + 2 legsAorto�iliac + thighsAortogram/femoral runoffFemoral arteriogramFemoral (DSA/conventional)Femoral (DSA)Femoral (DSA)FemoralFemoralLower limbsLower limbs (arteries)Lower limbs (veins)Lower limbVenography (arm)
3.7 (1.2�19)2.9 ( ± 2.8)4.5 ( ± 1.2)1.2 ( ± 0.4)
3.9 (1.8�10.8)2.4 ( ± 1.9)1.7 (0.4�6.7)2.3 (0.9�13.7)
�
7.2 (1.8�17.2)2.4 (13�8.3)3.7 ( ± 3.1)
�
�
�
�
42.9 (13�122)13 (2�52)
32 (19�68)47 (16�100)
�
2624.4 (5.6�100)74 (19.8�184)
1346.7 (3�114)
16 (8�91)30 (9�77)
35.54.9
78 (306 max.)23 (57 max.)
4 (1�16)�
�
�
14.0 (7.0�21.8)4
2.79.0
3.1 ( ± 1.8)7.5 (0.5�18.2)
�
6.26.40.9�
�
[S3][K23][K23][K23][C23][T8]
[H25][H25][C24][M34][M46][R17][O6][O6]
[W32][W32]
ANNEX D: MEDICAL RADIATION EXPOSURES384
Table 18Patient dose per procedure a during interventional radiology
ProcedureFluoroscopy time
(min)Localized dose to
skin (Gy)Dose-area product
(Gy cm2)Effective dose
(mSv)Ref.
PTCA (Percutaneoustransluminal coronaryangioplasty)
11.5 (2.4�28)30 (9�70)
15(56 max.)
11 (92 max.)31.3
43.8 b
31 c (8�62)43 d (3�53)
�
�
�
�
�
18.7�
21 ( ± 63%)12.4�
�
18.5 (15.5 SD)
�e
0.15 (0.05�0.3)1�
�
�
�
0.46 c
0.39 d
(1�5)0.1 (1 max.)
�
�
�
1.1�
0.038 (at spine)�
0.5 (0.01�2.2)�
0.14 (LAO proj.)
93 (33�402)28.5 (20�50.5)
�
�
42 (266 max.)�
�
�
�
�
87.5 (67�122)110 (40�340)143 (83 SD)
�
�
91.837.6 ( ± 41%)
72.2�
45.8102 (85 SD)
28.9 (7.5�57)�
10�
�
�
�
�
�
�
�
�
�
22�
�
6.914.2�
�
�
[N6][F4][P3][K5][H6][G4][G4][B6][B6][H7][V3][B9]
[B10][L4][P15][Z12][B3]
[B54][V14][W41][P20]
PTA (Percutaneoustransluminal angioplasty)
1419.7 (5.3�26)(21.8�68) f
6�
24 b (5�45)�
17.9 (6.9�57.3)(6.3�26.3)
0.4�
�
�
�
0.3b
�
�
�
7568.5 (22�150)
�
65.143.5 (5�184)
140 b (73�223)67.3 (289 max.)
68 (15�338)(19�109)
10�
�
�
�
12.5 b
�
�
�
[S14][F5][N6][F6][B9]
[H27][W32][M46][K50]
TIPS (Transjugularintrahepatic portosystemicshunt)
46�
48.4 (21.7�100)32 (9�79)
59 (26�115)48�
�
�
�
1.70.4
1.2 (5 max.)�
�
354525 (273�1131)226 (111�354)
77 (7�240)220
182 (470 max.)
�
�
83.9 (43.7�181)27 (14�44)
8 (2�40)50�
[M8][V3]
[M34][Z11][Z11][S14][W32]
Radiofrequency ablation 42 (27�108)50 (31 SD)
21.4 (142 max.)(190 max.)28 (3�109)
�
�
�
�
53 ( ± 50)�
65 (5�195)28.9�
�
�
0.9 (6.2 max.)(8.4 max.)
�
0.07 (1.4 max.)�
�
�
1.3 ( ± 1.3)0.93 ( ± 0.62)1.0 (0.08�3.1)
�
�
116 (26�217)�
�
�
103 (7�516)�
56.4 g (12�184)77.5 h (13�367)97.3 i (9�532)
�
�
�
91.143.6
�
17�
�
�
�
�
�
�
17 / 25 j
�
�
17.3�
[N6][L4][B7][C3][F6][C9][H8][H8][H8][R16][P14][N25][B54][W41]
Valvuloplasty 53 k (40�120)�
31.8
�
�
�
56 k
44 l
162
�
�
29.3
[S15][S15][B54]
Lysis 21 � � � [M8]
Embolization 2537.4 (8.1�58)
(8.4�6.4) m
(17.5�90) n
23 o (1�75)�
�
�
-----
(0.2�1.4) p
0.5 q
�
180121 (34�286)
�
�
114 o (7�394)�
81.7 q
391 (93�918)
25�
�
�
�
(6�43)�
�
[S14][F5][N6][N6][F6][B8][V3][B9]
Table 18 (continued)
ANNEX D: MEDICAL RADIATION EXPOSURES 385
ProcedureFluoroscopy time
(min)Localized dose to
skin (Gy)Dose-area product
(Gy cm2)Effective dose
(mSv)Ref.
a Mean values of parameters (with range, standard deviation, or coefficient of variation in parentheses).b Procedure carried out with laser.c Total occlusion.d Subtotal stenosis.e No data available.f Leg.g Atrioventricular.h Atrioventricular nodal reentry.i Wolff�Parkinson�White.j Values for males and females, respectively.k Children (1�16 years).l Infants (<1 year).m Liver.n Kidney.o Neurological.p Cerebral.q Hepatic.
a Reported range for survey of 22 scanners.b Published value for spine.c Reported range for survey of 4 scanners.d Published value for trunk.
Embolization (continued) 21 p (6�54)34.1 p (15.2�55.8)
43 o (31�74)24.3 m (5�48)
�
�
�
�
0.34 p (019�0.66)0.62 o (0.13�1.34)
0.44 m
�
�
�
122 p
105 p (57.2�201)116 o (29�243)79 m (55�100)
�
�
105 (352 max.)
10.6 p
10.5 p (5.7�20)1.67 o (0.44�3.44)
15.9m
20 o ( ± 14) adult68 o ( ± 51) child.
�
[M9][M34,M36]
[B17][H27][G12][G12][W32]
Biliary �
7.1 (0.6�26.3)30.4 (3.6�141)34.2 ( ± 11.5)
�
2.10.11 (0.01�0.37)
�
�
�
68.9 (30�163)43.1 (3.8�149)20.1 (1.2�122)150 (51�291)
43 (167)
�
6.9 (0.6�23.9)�
38.2�
[V3][M34,M36]
[M35][R17][W32]
Stent (superior vena cava) 17 ( ± 9) 2 (max.) 42 ( ± 29) 5.8 [O9]
Table 19Doses to patients from computed tomography
Country / area Year
Mean effective dose per procedure (mSv)
HeadCervical
spineChest Abdomen Liver Kidneys Pelvis
Lumbarspine
Health-care level I
Australia [T17]Finland [S67]Germany [B58]Japan [N16]Netherlands [V15]New Zealand [P5]Norway [O12]Sweden [S68]United Kingdom (Wales) [H33]
199519941993199419931992199319911994
2.61.32.6-
0.8-5.0 a
1.82.02.11.6
5.2-
9 b
--
3.3-6
1.5
10.45.120.5
4.6-10.8 c
6-188.911.510 d
9.7
16.711.627.4
6.7-13.3 c
6-24 a
9.712.810 d
12.0
12.7----
6.511.910 d
10.3
-----
7.69.910 d
9.1
11.0----
6.99.810 d
9.8
5.25.09 b
-2-12 a
4.74.56 b
3.3
Health-care level II
Oman [G37] 1998 2.4 3.5 3.4 9.5 - - - -
ANNEX D: MEDICAL RADIATION EXPOSURES388
a Without backscatter.b Dose range given in parentheses.c Dose-width product [N23].
a Applied potential.b Focus to skin distance.
Table 22Doses to patients from dental x-ray examinationsData from UNSCEAR Survey of Medical Radiation Usage and Exposures unless otherwise indicated
Country Year Technique Condition of measurementTypical entrance surface dose a per
exposure (mGy)
Survey mean S.D. b
Health-care level I
CanadaGreece [Y11]
Denmark [H31]
United Arab Emirates
United Kingdom [N23]
United States
19951997
1993
1997
1998
1993
IntraoralIntraoral (50 kV)Intraoral (60 kV)Intraoral (65 kV)Intraoral (70 kV)Intraoral (D speed film)Intraoral (E speed film)IntraoralIntraoralIntraoral (All)Intraoral (E speed film)Intraoral (45-55 kV)Intraoral (60-70 kV)PanoralIntraoralCephalometric
Survey of 56 units
National surveyNational survey4 unitsRVG filmless systemSample of 6344 measurementsSample of 1577 measurementsSample of 2175 measurementsSample of 3105 measurementsSample of 387 measurementsNEXT programmeNEXT programme
2.56.54.93.11.94.93.22.770.723.32.65.02.2
57.4 mGy mm c
1.90.21
(1.6�3.6)4.93.71.20.94.33.6
(2.61�3.2)�
(0.14�46)(0.14�21)(0.6�46)(0.2�9.6)
(2�328 mGy mm) c
�
�
Health-care level II
Brazil 1996 Intraoral Survey data for Paraná State 7.9 (0.9�61)
Table 23Variation with technique of the typical effective dose from dental radiography[N3]
Radiographic technique Effective dose (µSv)
Two bitewing films 70 kV a, 200 mm fsd b, rectangular collimation, E speed film70 kV, 200 mm fsd, circular collimation, E speed film50-60 kV, 100 mm fsd, circular collimation, E speed film50-60 kV, 100 mm fsd, circular collimation, D speed film
248
16
Single panoral film Rare-earth intensifying screensCalcium tungstate intensifying screens
714
ANNEX D: MEDICAL RADIATION EXPOSURES 389
a Entrance surface dose or entrance surface air kerma; backscatter factor is generally <1.1 for mammographic exposures.b Dose range given in parentheses.c Values represent surveys before and after the introduction of a programme of quality control; data from two hospitals.d Diagnostic data from four units with grid and one without grid; screening data from two units.e Without grid.f Mediolateral oblique view (mean breast thickness 57 mm).g Craniocaudal view (mean breast thickness 52 mm).h Data from one hospital. Values represent surveys (with mean breast thickness of 3 cm) before and after the introduction of a programme of quality
control.
Table 24Doses to patients from mammographyData from UNSCEAR Survey of Medical Radiation Usage and Exposures unless otherwise indicated
Country Year Technique Condition of measurement
Typical dose per film (mGy)
Entrance surfacedose a
Dose to glandulartissue
Surveymean
S.D. b Surveymean
S.D.b
Health-care level I
Argentina c [I4]
Australia [H48]Belgium [P28]
Canada[F19]
Finland [S16]France [M7]
Germany [K49]
Greece [F7]
Italy [M6]
Japan [S81]New Zealand
[B12]Norway [O10]
PanamaSloveniaSpain [C40]
SwedenUnited Arab
Emirates d
United Kingdom [Y12]
[B66]
United States [S82]
[K43]
1993
19961997
19941999199319911993199219931990
1997
1994199619931994
199519961997199719961998
1991199619951995199219971999
400 speedfilm/screenScreeningScreeningScreening
-ScreeningScreeningScreeningScreeningW anode
Mo/W anodeGrid
Non-grid--
Screening-
ScreeningNon-grid
Grid--
ScreeningScreeningScreeningScreeningClinical
Clinical e
ScreeningScreeningScreeningScreening
---
Patient surveys
Patient survey (2 units; 2051 films)24 centres (4.5 cm phantom)24 centres (patient survey)Standard breast phantomSurvey in Ontario (phantom)4.5 cm Acrylic phantomSurvey in Bas-Rhin (phantom)Survey in Bas-Rhin (phantom)Patient survey (1678 women)Patient survey (945 women)4 cm Acrylic phantom4 cm Acrylic phantomTuscany region (phantom)Tuscany region (patients)4 cm compressed breastAverage breast thicknessPatient survey in Otago (phantom)Standard phantomStandard phantom-Standard phantom4.5 cm Acrylic phantomPatient surveyStandard breast phantomStandard breast phantomStandard breast phantomStandard breast phantomStandard breast phantomStandard breast phantomPatient survey (4 633 women)Patient survey (4 633 women)Standard breast phantomStandard breast phantomSurvey of 6 000 patients (phantom)
11.08 (pre)7.26 (post)
�
7.58.0�
�
6.315.28.58.3611.08.55.27.99.5�
�
�
�
�
5.976.826.15.7�
�
�
�
�
�
�
�
�
�
�
�
�
�
2.42.9�
�
3.1�
�
4.225.05
(5�15)(1�25)�
�
�
�
�
�
�
2.702.592.02.6�
�
�
�
�
�
�
�
�
�
�
�
�
2.261.41.51.11.51.0�
�
1.592.07�
�
�
�
1.801.45�
�
�
�
�
1.31.01.52.652.710.231.281.362.0 f
1.6 g
1.491.602.6
�
�
(0.4�7.2)0.40.5
(0.36�4.68)�
0.48�
�
0.560.66�
�
�
�
�
0.47(0.7�8.5)(0.4�0.8)(0.7�2.0)
�
�
0.40.4
(0.7�3.2)(2.48�2.81)(2.66�2.76)
�
(0.6�2.6)(0.7�2.5)
�
�
�
�
�
Health-care level II
Iran (IslamicRepublic of) h [I4]Turkey
1993
1997
�
�
-
Patient surveys
Localized survey
5.45 (pre)4.27 (post)
3.29
1.94�
0.23
�
�
�
�
�
�
Table 34 (continued)
ANNEX D: MEDICAL RADIATION EXPOSURES400
a Historical data.b Categorized in health-care level II in previous analyses.c Data for 1985�1990 represent historical data for Federal Republic of Germany.d Historical data were not included in previous analyses.e These revised data were received by the Committee after completion of the global analysis.
a Frequency-weighted average of national values from survey data. Values for 1991�1996 from Table 15.
Health�care level IV
United Rep. of Tanzania � � � 0.1
Average � � � 0.1
Table 35Trends in average effective doses from diagnostic medical x-ray examinationsData from UNSCEAR Surveys of Medical Radiation Usage and Exposures
Examination
Average a effective dose per examination (mSv)
Health-care level I Health-care level II
1970�1979 1980�1990 1991�1996 1980�1990 1991�1996
Chest radiographyChest photofluoroscopyChest fluoroscopyLimbs and jointsLumbar spinePelvis and hipHeadAbdomenUpper GI tractLower GI tractCholecystographyUrographyMammographyCTAngiographyPTCA
0.250.520.720.022.22.10.501.98.99.81.93.01.81.39.2�
0.140.520.980.061.71.20.161.17.24.11.53.11.04.36.8�
0.140.651.10.061.80.830.070.533.66.42.33.70.518.81222
0.04�
0.290.042.62.00.130.221.65.01.61.7�
�
�
�
0.05�
�
0.041.00.740.040.626.06.01.53.90.14.96.8�
Tab
le41
Ave
rag
eac
tivi
ties
adm
inis
tere
din
dia
gn
ost
icex
amin
atio
ns
wit
hra
dio
ph
arm
aceu
tica
ls(1
991 �
1996
)D
ata
from
UN
SC
EA
RS
urve
yof
Med
ical
Rad
iatio
nU
sage
and
Exp
osur
esun
less
othe
rwis
ein
dica
ted
PA
RT
A
Cou
ntry
/are
a
Ave
rage
activ
ityad
min
iste
red
(MB
q)(r
ange
orst
anda
rdde
viat
ion
inpa
rent
hese
s)
Bon
eC
ardi
ovas
cula
rB
rain
99mTc
phos
phat
es99
mTc
othe
r99
mTc
MIB
I99
mTc
othe
r21
0 Tlch
lori
de99
mTc
DTP
A99
mTc
HM
PA
O99
mTc
pert
echn
etat
eO
ther
Hea
lth
-car
ele
velI
Arg
entin
aB
elar
usB
ulga
ria
Can
ada
Chi
na,T
aiw
anPr
.[L
6]C
roat
iaC
ypru
sC
zech
Rep
ublic
Den
mar
kE
cuad
orFi
nlan
dFr
ance
[E10
]G
erm
any
Irel
and
Ital
yJa
pan
[J11
]K
uwai
tL
ithua
nia
Net
herl
ands
New
Zea
land
[L28
]Pa
nam
aPo
rtug
al[E
10]
Rom
ania
Slov
akia
Slov
enia
Spai
n[E
10]
Swed
enSw
itzer
land
Uni
ted
Ara
bE
mir
ates
Uni
ted
Kin
gdom
[A20
]
�
a
�
300
(150�
450)
925
(±10
%)
545
(370�
750)
555
(100�
740)
630
730
(350
-121
0)63
7(1
80�
820)
740
(±5%
)62
0� 60
050
0(4
0 �66
0)63
0(5
55�
740)
�
925
(740
-111
0)60
0(4
00�
600)
�
674
(50�
920)
555
(292�
618)
�
660
(480�
840)
740
(260�
740)
500
(370�
740)
740
450
(60 �
600)
670
(150
-100
0)72
0(7
4 �82
0)60
0
781
a(±
192)
720
a(6
80-7
60)
� � � � � � � �
620
a
� � �
620
b(5
55�
740)
740
a
� �
500
a(4
00�
800)
� � � � � � � � � � �
� � 666
600
(±10
%)
� � � 680
615
(450�
860)
110
0(±
5%)
�
1000� �
600
(185�
740)
� � �
650
(600�
700)
688
(341
-108
0)55
5(2
92�
818)
� � �
400
(37�
555)
740
800
(400
-140
0)57
0(1
10�
740)
740
(700
-100
0)30
0(4
00SP
EC
T)
877
(±19
2)�
555
b
�
540
c
370
a(1
85�
740)
600 �
110
0�
710
c(7
3�1
110)
�
890
a
�
700
c
800
c(6
00-1
100)
�
740
a
925
c(5
55�
925)
� �
585
c(2
50�
944)
�
740
a
�
740
a
� � � � �
800
c
89(±
11)
� 74 � 7080
(70 �
111)
7590
(80 �
100)
� � 100� 75 �
90(7
4�11
1)13
1� �
125
(100�
150)
80(3
7 �11
1)� � � 10
074 �
80(6
0�12
0)80
(70 �
110)
93(8
0 �95
)80
� �
(550�
740)
� 420� � � �
110
0(±
5%)
� � � �
630
(555�
740)
740� � �
744
(710�
750)
555
(424�
686)
�
460
(330�
590)
� � � � � �
500
(800
SPE
CT
)
� � �
740
(±5%
)� � �
740
(460�
860)
667
(125�
945)
� � 750
700
575
(550�
600)
720
(555�
925)
787
555
(185�
555)
� 500
705
(450�
907)
� 600� � � 74
094
0(6
00�
100
0)61
0(3
70�
740)
740
(700�
760)
�
� � � � 420� �
650
(600�
700)
� � � � � � � � � � � 740� �
355
(210�
500)
740
(200�
740)
� � �
620
(460�
930)
� 500
866
d(±
137)
740
d(7
00�
780)
� � �
555
d(1
85�
740)
� �
1629
e(6
0-3
000)
�
655
d ;124
f
� � � �
650
a(7
40�
555)
� �
200
f
� � � � �
500
d(5
00�
740)
�
550
g(4
00�
570)
930
e
�
500
h
Ave
rage
719
�62
2�
100
482
721
419
�
ANNEX D: MEDICAL RADIATION EXPOSURES414
Tab
le41
(con
tinue
d)
Cou
ntry
/are
a
Ave
rage
activ
ityad
min
iste
red
(MB
q)(r
ange
orst
anda
rdde
viat
ion
inpa
rent
hese
s)
Bon
eC
ardi
ovas
cula
rB
rain
99mTc
phos
phat
es99
mTc
othe
r99
mTc
MIB
I99
mTc
othe
r21
0 Tlch
lori
de99
mTc
DTP
A99
mTc
HM
PA
O99
mTc
pert
echn
etat
eO
ther
Hea
lth
-car
ele
velI
I
Jord
anM
exic
oPe
ruT
urke
y
750
(±10
%)
463
(185�
740)
740
(700�
800)
851
(638
-106
4)
� � � �
�
148
(111�
185)
740
(700�
800)
122
1(8
58-1
584)
1000
a
379
b(1
11�
647)
740
c(7
00�
800)
�
75 � �
97(7
9�11
5)
�
262
(80�
444)
740
(700�
800)
�
�
262
(80�
444)
�
601
(368�
834)
� � � �
� � � �
Ave
rage
730
�74
0�
7574
060
1�
�
Hea
lth
-car
ele
velI
II
Gha
na[A
16]
Mor
occo
Suda
n
446� 56
0
�
740
a(5
55�
925)
�
� � �
�
925
a
�
�
92.5
(92.
5�11
1)�
� � �
� � �
409� �
� �
561
0d
Ave
rage
546
��
�93
��
��
Hea
lth
-car
ele
velI
V
Eth
iopi
aU
nite
dR
ep.o
fTan
zani
a55
560
0(±
5%)
� �
� �
� �
� �
666
(370�
740)
800
(±5%
)� �
666
(370�
740)
�
� �
Ave
rage
598
��
��
679
�66
6�
PA
RT
B
Cou
ntry
/are
a
Ave
rage
activ
ityad
min
iste
red
(MB
q)(r
ange
inpa
rent
hese
s)
Lung
perf
usio
nLu
ngve
ntila
tion
Live
r/sp
leen
99mTc
MA
AO
ther
99mTc
DTP
A99
mTc
aero
sol
Oth
er99
mTc
collo
id99
mTc
IDA
Oth
er
Hea
lth
-car
ele
velI
Arg
entin
aB
elar
usB
ulga
ria
Can
ada
Chi
na,T
aiw
anPr
.[L
6]C
roat
ia
� � 7418
5(±
10%
)12
014
8(1
11�
222)
181
d(±
78);
200
i
(±33
)� � � �
� � 925� � �
� � � � �
37(1
7�74
)
988
d(±
281)
� � � � �
� � 185
111
(±10
%)
150
148
(74 �
222)
� � 333� 14
0�
229
d(±
107)
120
d(1
11�
129)
� � � �
ANNEX D: MEDICAL RADIATION EXPOSURES 415
ANNEX D: MEDICAL RADIATION EXPOSURES416
Tab
le41
(con
tinue
d)
Cou
ntry
/are
a
Ave
rage
activ
ityad
min
iste
red
(MB
q)(r
ange
inpa
rent
hese
s)
Lung
perf
usio
nLu
ngve
ntila
tion
Live
r/sp
leen
99mTc
MA
AO
ther
99mTc
DTP
A99
mTc
aero
sol
Oth
er99
mTc
collo
id99
mTc
IDA
Oth
er
Cyp
rus
Cze
chR
epub
licD
enm
ark
Ecu
ador
Finl
and
Fran
ce[E
10]
Ger
man
yIr
elan
dIt
aly
Japa
n[J
11]
Kuw
ait
Lith
uani
aN
ethe
rlan
dsN
ewZ
eala
nd[L
28]
Pana
ma
Port
ugal
[E10
]R
oman
iaSl
ovak
iaSl
oven
iaSp
ain
[E10
]Sw
eden
Switz
erla
ndU
nite
dA
rab
Em
irat
esU
nite
dK
ingd
om[A
20]
150
188
(90 �
210)
112
(50 �
185)
870
(±5%
)10
5d
300
100
80(6
0 �11
0)15
0(1
11�
185)
�
111
(74�
185)
100
(80 �
100)
100
145
(56 �
286)
185
111
125
(55 �
195)
185
(80 �
185)
170
(120�
222)
�
100
(27�
150)
140
(70 �
230)
140
(111�
260)
100
(200
SPE
CT
)
� � � �
460
e
� � � �
240
d
� � � � � � � �
74a
(37�
84)
� � � � �
�
970
(600�
120
0)�
370
(±5%
)� � � 80
555
(370�
700)
740
148
0(1
110-
185
0)� �
81(3
7�13
6)92
5(6
62�
1188
)� � �
175
(84�
185)
�
200
(7�
150
0)�
222
(200�
300)
80
� �
13(7�
80)
� � � 100� � � � � � � 44
4� � � 37
024
0(1
5-1
700)
� � �
� �
396
e(2
00�
826)
�
580
d ;185
e
� � � � � � �
(450�
750
min
�1 )
j
734
e(3
70�
111
2)� � � �
140
e(1
00�
200)
� �
390
e(1
10-7
50);
220
k(1
00-3
70)
�
400e ;6
000j (m
ax)
185
148
(80�
230)
83(4
5 �21
7)37
0(±
10%
)� � �
110
(100�
130)
150
(111�
370)
�
185
(74�
185)
80(8
0 �10
0)80
196
(110�
278)
241
(110�
372)
185
140
(35 �
245)
� � 185
170
(20 �
800)
120
(20 �
160)
148
(140�
185)
80
� � � � � � 150
110
(100�
130)
� � � � � � � � � 185
180� �
100
(10�
200)
� �
� � � �
180
d
� � �
148
d(1
11�
185)
200
d
� � � � � �
9l(7
.4�
10.6
)18
5d(4
0�18
5)(2
96�
500)
d
� � � �
Ave
rage
118
�66
2�
�14
1�
�
Hea
lth
-car
ele
velI
I
Jord
anM
exic
oPe
ruT
urke
y
150
130
(74 �
185)
185
(150�
200)
159
(124�
194)
� � � �
100
046
3(1
85�
740)
� 925
� � � �
� �
185
a(1
50�
200)
�
150
111
(36 �
185)
185
(150�
200)
148
(96 �
200)
�
131
(40�
222)
� �
� � � �
Ave
rage
147
�70
3�
�15
0�
�
Hea
lth
-car
ele
velI
II
Gha
na[A
16]
Mor
occo
Suda
n
� � �
�
185
d(1
85�
259)
�
� � �
� � �
� � �
87 � 740
� � �
�
296
d(3
7�74
0)�
Ave
rage
��
��
�45
4�
�
Tab
le41
(con
tinue
d)
Cou
ntry
/are
a
Ave
rage
activ
ityad
min
iste
red
(MB
q)(r
ange
inpa
rent
hese
s)
Lung
perf
usio
nLu
ngve
ntila
tion
Live
r/sp
leen
99mTc
MA
AO
ther
99mTc
DTP
A99
mTc
aero
sol
Oth
er99
mTc
collo
id99
mTc
IDA
Oth
er
Hea
lth
-car
ele
velI
V
Eth
iopi
aU
nite
dR
ep.o
fTan
zani
a11
1�
�
118
0d(±
5%)
� �
� �
� �
111
(111�
185)
�
� �
� �
Ave
rage
111
��
��
111
��
PA
RT
C
Cou
ntry
/are
a
Ave
rage
activ
ityad
min
iste
red
(MB
q)(r
ange
inpa
rent
hese
s)
Thyr
oid
scan
Thyr
oid
upta
keR
enal
scan
99mTc
pert
echn
etat
e13
1 Iio
dide
Oth
er99
mTc
pert
echn
etat
e13
1 Iio
dide
123 I
iodi
de99
mTc
DM
SA99
mTc
DTP
A99
mTc
MA
G3
Oth
er
Hea
lth
-car
ele
velI
Arg
entin
aB
elar
usB
ulga
ria
Can
ada
Chi
na(T
aiw
an)
[L6]
Cro
atia
Cyp
rus
Cze
chR
epub
licD
enm
ark
Ecu
ador
Finl
and
Fran
ce[E
10]
Ger
man
yIr
elan
dIt
aly
Japa
n[J
11]
Kuw
ait
Lith
uani
aN
ethe
rlan
dsN
ewZ
eala
nd[L
28]
Pana
ma
Port
ugal
[E10
]R
oman
ia
248
(±10
7)11
1(1
01-1
21)
(37 �
74)
� 8014
8(1
11-2
22)
�
130
(70�
180)
150
(37 �
370)
� 130� 50
110
(27 �
130)
111
(74 �
185)
�
185
(74�
185)
�
100
(80�
180)
168
(23-
740)
463
(332
-594
)�
90(3
4�14
6)
3(±
1)� � � �
148
(74�
185)
758
(8�
12)
�
3.7
(±10
%)
� 185� �
1.1
(0.7
4-1.
85)
26 �
60(6
0�80
)�
113
(21�
200)
� �
1.6
(0.6�
2.6)
� �
(1�
10)
m
185
d(±
10%
)� �
150
d
� � � 12f
� � � �
200
d
� � 20f
� � � �
7(±
3)� � � � � � � � � � � 50
27(1
1 �72
)� 19
2� � � � � � �
2(±
1)0.
4(0
.35-
0.45
)� � 0.8
17 750.
62(0
.4�
1)86
(0.3
-370
0)3.
7(±
10%
)3� �
0.18
51.
1(0
.74-
1.85
)23
1.5
(1.1�
2.6)
� 0.2
5.5
(2�
20)
1.85�
1.3
(0.6�
2)
� � � � 20 � � � � �
6� � � � 8.8� � 20 � � � �
�
60(4
0�80
)� 15
074
(37 �
111)
7518
8(8
0 �25
0)� � � 20
075
84(2
6 �18
5)14
8(1
11�
180)
197�
150
(100�
150)
�
65(1
2�15
5)56
(30 �
82)
111�
�
185
(85�
285)
400
(±15
%)
150
74(3
7 �11
1)22
025
0(1
10�
360)
165
(20 �
350)
370
(±10
%)
�
200
(74�
740)
�
84(2
6�18
5)14
8(1
11�
180)
377
370
(185�
370)
�
(40�
350)
314
(22 �
617)
463
(432�
594)
111
300
(100�
500)
�
185
(85�
285)
� � � � �
92(3�
210)
370
(±10
%)
� 280�
84(2
6�18
5)� �
370
(185�
370)
� 8022
8(1
30�
444)
185
(107�
263)
111�
215d
(±12
2);6
n(±
2)18
5d(1
74�
196)
� � � � � � � �
9n ;1
50d
(74�
740)
f
25f
�
26n
(18.
5�37
)49
m
� � �
3.3
o(1�
5)�
111
f
1.5
n(0
.7�
2.3)
ANNEX D: MEDICAL RADIATION EXPOSURES 417
ANNEX D: MEDICAL RADIATION EXPOSURES418
Tab
le41
(con
tinue
d)
Cou
ntry
/are
a
Ave
rage
activ
ityad
min
iste
red
(MB
q)(r
ange
inpa
rent
hese
s)
Thyr
oid
scan
Thyr
oid
upta
keR
enal
scan
99mTc
pert
echn
etat
e13
1 Iio
dide
Oth
er99
mTc
pert
echn
etat
e13
1 Iio
dide
123 I
iodi
de99
mTc
DM
SA99
mTc
DTP
A99
mTc
MA
G3
Oth
er
aN
ofu
rthe
rin
form
atio
nav
aila
ble.
i67
Ga.
bPe
rtec
hnet
ate.
j81
mK
r.c
Red
bloo
dce
lls.
k12
7 Xe.
d99
mT
c.l
128 A
uco
lloid
.e
133 X
e.m
131 I,
125 I,
123 I.
f12
3 I.n
131 I.
g11
Cm
etio
min
.o
51C
rE
DT
A.
h99
mT
cE
CD
.
Slov
akia
Slov
enia
Spai
n[E
10]
Swed
enSw
itzer
land
Uni
ted
Ara
bE
mir
ates
Uni
ted
Kin
gdom
[A20
]
70(4
0 �11
0)74
(37 �
74)
�
120
(10�
220)
90(3
0 �20
0)18
5(1
48-2
60)
80
1.8
(0.1
8 �1.
8)5
(3.7�
7.4)
1.1
2(0
.1�
80)
2(1�
7)� 20
� � � �
13f(5�
20)
� �
7475
(50 �
100)
� � �
185
(148�
260)
40
(0.1
8 �1.
8)2
(1.5�
3.7)
�
2(0
.2�
6)� � 0.2
� � � � � �
2
185
(80�
370)
80 �
40(1
0�20
0)60
(20 �
130)
148
(140�
185)
80
185
(80 �
370)
185� �
360
(10�
800)
148
(140�
185)
300
� 100�
85(6
7�17
5)11
0(1
00�
150)
� 100
18.5
n
� � �
20f(5�
40)
� 3o
Ave
rage
6517
��
3.1
�14
023
612
7�
Hea
lth
-car
ele
velI
I
Jord
anM
exic
oPe
ruT
urke
y
�
130
(74�
185)
185
(150
-200
)13
4(9
9 �16
9)
�
5.6
(3.8�
7.4)
185
(150�
200)
�
� � � �
� � � �
3.7
5.6
(3.8�
7.4)
1(0
.5�
1.2)
�
� � � �
140�
370
(300
min
)16
1(1
18�
204)
740
170
(80 �
259)
740
(700�
800)
321
(167�
475)
�
170
(80�
259)
� �
� � � �
Ave
rage
136
185
��
4.4
�37
018
117
0�
Hea
lth
-car
ele
velI
II
Gha
na[A
16]
Mor
occo
Suda
n
9713
0(9
3 �16
7)56
0
� � �
� � �
� � �
� � �
� � �
� � 740
99 �
1800
� � �
�
111
d(7
4�22
2)�
Ave
rage
173
��
��
��
��
�
Hea
lth
-car
ele
velI
V
Eth
iopi
aU
nite
dR
ep.o
fTan
zani
a� �
1.7
(1.3�
2)�
� �
� 200
1.7
(1.3�
2)�
� �
74 �
� 200
� �
� �
Ave
rage
�1.
7�
�1.
7�
7420
0�
�
Tab
le41
(con
tinue
d)
The
entr
ies
inth
isT
able
are
qual
ifie
das
follo
ws:
Arg
entin
a:O
nth
eba
sis
ofda
tafr
oma
sam
ple
of25
%of
nucl
ear
med
icin
ece
ntre
s.B
one
scan
sal
sope
rfor
med
usin
g67
Ga
(204
±41
MB
q).
Can
ada:
Dat
afr
omL
ondo
nH
ealth
Scie
nces
Cen
tre,
SWO
ntar
io(r
epre
sent
ing
50%
ofth
ese
rvic
espr
ovid
edto
popu
latio
nof
abou
t1m
illio
n).
Cyp
rus
Surv
eyda
tare
latin
gto
90%
ofpo
pula
tion.
Gha
na:
Dat
afo
rth
yroi
dsc
anre
fer
toal
lthy
roid
stud
ies.
Jord
an:
Surv
eyda
tafr
omon
eho
spita
l.Li
thua
nia:
Dat
afr
omV
ilniu
sO
ncol
ogy
Cen
tre.
Mor
occo
:B
one
scan
sal
sope
rfor
med
usin
g13
1 I(m
ean
111
MB
q;ra
nge
92.5�
111
MB
q).
Per
u:Su
rvey
data
from
IPE
N(C
entr
eof
Nuc
lear
Med
icin
e,se
rvin
gpo
pula
tion
ofab
out5
mill
ion)
.P
ortu
gal:
Dat
afr
omon
ela
rge
depa
rtm
enta
ndso
me
addi
tiona
ldat
a.R
oman
ia:
Surv
eyda
tare
latin
gto
popu
latio
nba
seof
abou
t4.5
mill
ion.
Alte
rnat
ive
tech
niqu
eem
ploy
edfo
rbo
nesc
ans
usin
g99
mT
cph
osph
ates
:mea
n11
0M
Bq,
rang
e60�
160
MB
q.Sl
ovak
ia:
Surv
eyda
tare
latin
gto
popu
latio
nba
seof
abou
t2m
illio
n.Sw
itzer
land
:L
ung
vent
ilatio
nst
udie
sal
sope
rfor
med
usin
g12
7 Xe
(mea
n22
0M
Bq;
rang
e10
0�37
0M
Bq)
.Tu
rkey
:Su
rvey
data
from
Gül
hane
Mili
tary
Hos
pita
l,H
acet
tepe
Uni
vers
ityH
ospi
tala
ndSa
msu
nO
ndok
uzM
ayis
Uni
vers
ityH
ospi
tal.
Uni
ted
Ara
bE
mir
ates
:T
hyro
idup
take
done
sim
ulta
neou
sly
with
thyr
oid
scan
usin
ga
sing
ledo
se.
Uni
ted
Kin
gdom
:D
ata
repr
esen
trec
omm
ende
dm
axim
umus
uala
ctiv
ities
(dia
gnos
ticre
fere
nce
leve
ls).
Tab
le42
Typ
ical
effe
ctiv
ed
ose
sto
pat
ien
tsfr
om
com
mo
nty
pes
of
dia
gn
ost
icn
ucl
ear
med
icin
ep
roce
du
res
Cou
ntry
Effe
ctiv
edo
sepe
rpr
oced
ure
(mSv
)
Bon
ea
Car
diov
ascu
lar
Lung
perf
usio
nb
Lung
vent
ilatio
nTh
yroi
dsc
anTh
yroi
dup
take
Ren
alc
Live
r/s
plee
nc
Bra
inc
Hea
lth
-car
ele
velI
Can
ada
[A15
]4.
34.
9(99
mT
c)11
.8(20
1 Tl)
1.5
1.0
(99mT
c)1.
7(12
3 I)�
0.5
(DT
PA)
1.6
(MA
G3)
1.3
(DM
SA)
1.7
(Sco
lloid
)6.
9(H
MPA
O)
Chi
na,T
aiw
anPr
ovin
ce[L
6]3.
33.
2(99
mT
c)13
.3(20
1 Tl)
1.4
�1.
1(99
mT
c)14
.4(13
1 I)0.
841.
2(c
ollo
id)
2.1
(HID
A)
2.4
Ger
man
y[K
12]
3.5
4.6
(99mT
c)17
(201 T
l)1.
1�
0.6
(99mT
c)�
0.3
(123 I)
0.7
(DM
SA)
2.3
(HID
A)
6.6
(HM
PAO
)
Rom
ania
[I36
]3.
4�
1.4
�1.
1(99
mT
c)38
.4(13
1 I)31
.2(13
1 I)0.
1(13
1 I)1.
6(D
TPA
)9.
9(19
8 Au)
1.4
(col
loid
)2.
0
New
Zea
land
[L28
]4.
33.
9(99
mT
cR
BC
)7.
6(99
mT
cM
IBI)
1.6
0.4
(DT
PA)
2.0
(99mT
c)�
2.0
(DT
PA)
0.6
(DM
SA)
1.8
(Sn
collo
id)
4.8
(DT
PA)
ANNEX D: MEDICAL RADIATION EXPOSURES 419
Tab
le42
(con
tinue
d)
Cou
ntry
Effe
ctiv
edo
sepe
rpr
oced
ure
(mSv
)
Bon
ea
Car
diov
ascu
lar
Lung
perf
usio
nb
Lung
vent
ilatio
nTh
yroi
dsc
anTh
yroi
dup
take
Ren
alc
Live
r/s
plee
nc
Bra
inc
a99
mT
cph
osph
onat
es.
b99
mT
cM
AA
.c
99mT
c.d
35%
upta
ke.
eSP
EC
T.
fU
ptak
ean
dsc
an.
Slov
akia
[F8]
6.5
7.4
(99mT
cR
BC
)20
.3(20
1 Tl)
1.8
�8.
94.
40.
52.
18.
8
Swed
en[M
87]
3.5
10(99
mT
cM
IBI)
20(20
1 Tl)
1.1
0.2
(99mT
c)2.
4(99
mT
c)72
d(
3M
Bq
131 I)
6d
(0.
5M
Bq
131 I)
0.7
(MA
G3)
0.00
8(51
Cr
ED
TA
)�
8.4
(HM
PAO
)
Uni
ted
Kin
gdom
[A20
]3
(5e )
8(99
mT
c)18
(201 T
l)1
(2e )
0.2
(81mK
r)0.
4(99
mT
c)0.
4(13
3 Xe)
1(99
mT
c)6
(131 I)
0.4
(123 I)
0.5
(99mT
c)
2(D
TPA
)0.
7(D
MSA
)0.
7(M
AG
3)0.
2(12
3 I)
0.8
(2e )
(col
loid
)5
Uni
ted
Stat
es[I
23]
4.4
10.4
(201 T
l)�
�2
(99mT
c)59
(131 I)
0.2
(123 I)
�4.
8(D
TPA
)0.
5(13
1 I)�
�
Hea
lth
-car
ele
velI
I
Iran
(Isl
am.R
ep.o
f)[M
10]
6.5
2.9
(99mT
c)6.
9(20
1 Tl)
2.5
�1.
4(99
mT
c)25
(131 I)
f14
.6(13
1 I)3.
3(D
TPA
)10
(DM
SA)
1.9
(Sco
lloid
)0.
6(11
3mIn
)12
.4(T
cO4)
5.9
(DT
PA)
Hea
lth
-car
ele
velI
II
Gha
na[A
16]
2.85
��
�1
(99mT
c)�
0.4
0.62
5.4
ANNEX D: MEDICAL RADIATION EXPOSURES420
ANNEX D: MEDICAL RADIATION EXPOSURES 421
a Figures in brackets are scaling factors for activity based on body weights shown. Doses calculated using age-specific coefficients from [I19].
Table 43Typical effective doses to patients from diagnostic PET imaging[A20]
Radionuclide Chemical form InvestigationAdministeredactivity (MBq)
Effective dose(mSv)
Dose to uterus(mGy)
11C11C13N15O15O18F18F18F
L-methyl-methionineL-methyl-methionineAmmoniaWater (bolus)Water (bolus)FDGFDGFluoride
Brain tumour imagingParathyroid imagingMyocardial blood flow imagingCerebral blood flow imagingMyocardial blood flow imagingTumour imagingMyocardial imagingBone imaging
400400550
2 0002 000400400250
22222
10107
11111775
Table 44Typical effective doses to paediatric patients from diagnostic nuclear medicine procedures[G47]
Radiopharmaceutical
Activity foradult
patient(MBq)
Effective dose per procedure by patient age a (mSv)
Adult70 kg[1.0]
15 years-old55 kg[0.9]
10 years-old33 kg[0.69]
5 years-old18 kg[0.44]
1 year-old10 kg[0.27]
99mTc-MAG3 (normal renal function)99mTc-MAG3 (abnormal renal function)99mTc-DTPA (normal renal function)99mTc-DTPA (abnormal renal function)99mTc-DMSA (normal renal function)99mTc-pertechnetate (no thryoid block)99mTc-IDA (normal biliary function)99mTc-HMPAO99mTc-leukocytes99mTc-erythrocytes99mTc-phosphates99mTc-MIBI (resting)201Tl-chloride123I-iodide (55% thyroid uptake)123I-iodide (total thyroid block)123I-MIBG (no impurity)67Ga-citrate
1001003003008080150500200800600400802020400150
0.70.61.61.40.71.02.34.72.25.33.63.3207.20.25.615
0.80.71.81.60.71.22.45.02.76.03.74.030
10.20.36.518.9
0.70.72.11.90.81.32.95.93.06.64.14.412912.10.39.122.8
0.60.51.81.80.81.43.05.72.96.74.24.895
16.30.38.823.1
0.60.52.22.00.81.43.76.53.47.64.95.486
18.80.310.127.9
Tab
le57
Pre
scri
bed
do
ses
top
atie
nts
un
der
go
ing
rad
iati
on
tele
ther
apy
by
dis
ease
cate
go
ry(1
991-
1996
)D
ata
from
UN
SC
EA
RS
urve
yof
Med
ical
Rad
iatio
nU
sage
and
Exp
osur
esun
less
othe
rwis
ein
dica
ted
Cou
ntry
/are
a
Typi
cald
ose
ato
targ
etvo
lum
e(G
y)
Leuk
aem
iaLy
mph
oma
Bre
ast
tum
our
Lung
/thor
axtu
mou
rG
ynae
colo
-gi
calt
umou
rH
ead/
neck
tum
our
Bra
intu
mou
rSk
intu
mou
rB
ladd
ertu
mou
rP
rost
ate
tum
our
Tum
our
ofre
ctum
Ben
ign
dise
ase
Hea
lth
-car
ele
velI
Arg
entin
aA
ustr
alia
Bel
arus
Bul
gari
aC
anad
aC
roat
iaC
ypru
sC
zech
Rep
ublic
Den
mar
kE
cuad
orH
unga
ryIr
elan
dK
uwai
tN
ethe
rlan
dsN
ewZ
eala
ndPa
nam
aR
oman
iaR
ussi
anFe
dera
tion
Slov
akia
Slov
enia
Swed
enU
nite
dA
rab
Em
irat
esU
nite
dSt
ates
[I23
]
14(1
0 �20
)15
(11 �
22)
30(2
0 �40
)24
(24 �
30)
25(1
2 �30
)30 18
12(1
2 �24
)12
25(±
25%
)�
30(2
5�30
)18
(18 �
24)
�
15(6�
28)
12(1
2 �24
)(1
0 �40
)�
18(1
8�24
)5
(5�
12)
�
12(1
2�24
)�
36(2
5�45
)34
(17 �
46)
40(3
0 �46
)36
(36 �
44)
40(2
0 �50
)48
(40 �
55)
40(3
5 �45
)30
(30 �
40)
40(3
5 �40
)40
(±10
%)
�
(30�
60)
36(3
0 �40
)40
(40 �
48)
40(8�
50)
40(4
0 �45
)(6�
45)
(25 �
60)
36(3
5 �40
)30
(20 �
40)
37(2
6b )
40(3
5 �44
)�
60(5
5�65
)53
(26 �
64)
50(3
0 �70
)50
(40 �
60)
50(4
0 �60
)52
(50 �
60)
5050
(50 �
60)
48(4
8 �58
)60
(±16
%)
�
45(4
0�50
)50
(50 �
65)
66(6
4 �68
)50
(8�
65)
50(5
0 �60
)�
(40�
70)
50(4
6 �50
)50
(50 �
60)
49(3
5b )
50(4
5 �65
)(4
5 �50
)
66(4
5�70
)44
(22 �
63)
60(4
0 �70
)56
(40 �
60)
40(1
7 �60
)60
(52 �
68)
(20 �
60)
55(5
0 �60
)(3
0 �50
)50
(±10
%)
�
(40�
55)
60(5
5 �60
)64
(60 �
68)
50(8�
60)
50(5
0 �60
)(2�
74)
(40 �
70)
6050
(30 �
60)
51(3
4b )
60(5
0 �60
)�
50(4
5�60
)49
(32 �
57)
40(4
0 �60
)56
(50 �
60)
45(2
5 �70
)60
(52 �
65)
45(4
5 �50
)60
(45 �
65)
46c
50(
(±30
%)
� 4046
(40 �
46)
46(4
2 �48
)45
(27 �
65)
50(5
0 �70
)(1
8 �70
)(4
0 �60
)60
(60 �
80)
50(5
0 �60
)55
(35
b )45
(40 �
60)
�
70(4
5�75
)56
(28 �
67)
60(4
0 �70
)60
(60 �
70)
60(5
0 �70
)60
(60 �
70)
60(2
0 �70
)60
(45 �
65)
64(6
2 �68
)50
(±20
%)
�
60(4
0�66
)60
(60 �
66)
66(6
4 �70
)60
(40 �
70)
60(6
0 �70
)(2�
87)
(40 �
70)
60(6
0 �80
)60
(50 �
70)
59(3
7b )
66(6
0 �66
)�
65(4
0�65
)50
(29 �
58)
60(4
0 �70
)55
(50 �
60)
50(2
0 �60
)60
(50 �
66)
6060
(45 �
65)
5440
(±30
%)
� 4060
(55 �
60)
60(6
0 �64
)50
(20 �
66)
50(4
0 �60
)(1
6 �60
)�
56(5
6�60
)40
(30 �
50)
52(3
7b )
54(5
0 �60
)�
75(6
0�78
)45
(25 �
62)
65(6
0 �70
)60
(50 �
70)
35(2
0 �50
)60
(60 �
70)
5055
(50 �
60)
4850
(12 �
72)
�
35(3
5�50
)40
(30 �
40)
60(6
0 �64
)40
(18 �
64)
50 �
(40�
70)
60(6
0 �70
)60
(50 �
70)
46(3
1b )
50(5
0 �64
)�
58(5
0�64
)49
(27 �
62)
60(4
0 �60
)60
(50 �
70)
50(2
0 �70
)60
(54 �
66)
66(2
0 �66
)60
(55 �
60)
6050
(±20
%)
�
60(6
0�70
)60
(60 �
64)
60(6
0 �64
)60
(30 �
64)
50(1
6 �74
)(4
0 �60
)60
50(4
0 �60
)48
(31
b )64
(60 �
64)
�
70(5
0�76
)52
(33 �
62)
60(4
0 �60
)60
(50 �
70)
60(5
0 �66
)60
(60 �
65)
6465
(60 �
70)
�
50(±
10%
)�
66(6
6�70
)60
(60 �
66)
�
65(6
0�68
)60
(60 �
70)
(12 �
70)
(40 �
60)
60(6
0 �66
)50
(20 �
60)
64(3
5b )
64(6
0 �66
)(6
0 �72
)
55(4
5�60
)49
(26 �
54)
75(4
0 �80
)60
(50 �
70)
50(4
0 �60
)55
(55 �
65)
5450
(45 �
60)
46d
50(
(±20
%)
�
50(4
5�50
)50
(50 �
54)
(45 �
60)
45(1
8 �60
)50
(50 �
60)
(20 �
70)
(40 �
60)
50(5
0 �60
)50
(20 �
60)
38(3
6b )
45(4
0 �60
)�
(15�
75)
15(6�
26)
�
5(1�
50)
(6�
20)
15(8�
40)
12(6�
18)
6(4�
8)� 30
4(1�
5)� � �
30(8�
50)
15(1
5 �20
)�
(0.5�
5)4
(4�
20)
20(2
0 �50
)�
30(3
0�45
)�
Ave
rage
1739
5449
5060
5348
5759
496
Hea
lth�
care
leve
lII
Jord
anL
ibya
nA
rab
Jam
ahir
iya
Mex
ico
Peru
Tun
isia
Tur
key
20(6�
24)
18(1
8 �24
)24
(18 �
24)
18(1
8 �30
)35
22(1
0 �30
)
35(2
5 �40
)45
(45 �
50)
40(3
5 �45
)44
(30 �
50)
(45 �
55)
34(2
0 �58
)
50(4
2 �50
)50
(50 �
60)
50(5
0 �65
)60
(45 �
60)
50(5
0 �75
)50
(45 �
70)
30(2
0 �60
)30
(30 �
60)
55(5
0 �65
)50
(30 �
60)
(45 �
65)
59(4
5 �66
)
44(3
0 �50
)50
(50 �
60)
80(5
0 �80
)50
(45 �
55)
(20 �
60)
51(4
5 �62
)
60(4
0 �66
)66
(60 �
66)
75(5
0 �75
)60
(50 �
75)
75(5
5 �75
)63
(50 �
70)
50(3
0 �60
)55
(50 �
60)
65(5
5 �65
)60
(30 �
70)
5555
(45 �
60)
50(4
0 �55
)45
(45 �
50)
65(5
5 �65
)50
(45 �
55)
(65 �
75)
58(4
0 �70
)
66(3
0 �66
)60
(60 �
65)
65(6
5 �70
)60
(55 �
65)
65(5
5 �65
)61
(50 �
66)
60(3
0 �60
)65
(60 �
65)
65(6
5 �70
)70
(60 �
72)
65(5
5 �65
)61
(50 �
60)
50(3
0 �50
)60
(50 �
60)
65(6
5 �70
)50
(45 �
55)
(35 �
65)
50(4
0 �60
)
10(1
0 �40
)�
24(2
4�32
)� 20
14(9�
25)
Ave
rage
2236
5057
6367
5760
6264
5318
ANNEX D: MEDICAL RADIATION EXPOSURES444
Tab
le57
(con
tinue
d)
aPr
escr
ibed
dose
for
com
plet
eco
urse
oftr
eatm
ent.
Ran
geor
stan
dard
devi
atio
nin
pare
nthe
ses.
Mea
ndo
ses
for
each
heal
th-c
are
leve
lare
freq
uenc
y-w
eigh
ted
aver
ages
ofna
tiona
lval
ues.
The
sedo
ses
shou
ldno
tbe
used
toin
fer
dete
rmin
istic
orst
ocha
stic
risk
ssi
nce
thes
ede
pend
inte
ral
iast
rong
lyon
irra
diat
ion
tech
niqu
e(d
ose
dist
ribu
tion)
and
frac
tiona
tion.
bPa
lliat
ive
trea
tmen
t.c
Plus
brac
hyth
erap
y.d
Plus
boos
t.
Cou
ntry
Typi
cald
ose
tota
rget
volu
me
(Gy)
Leuk
aem
iaLy
mph
oma
Bre
ast
tum
our
Lung
/thor
axtu
mou
rG
ynae
colo�
gica
ltum
our
Hea
d/ne
cktu
mou
rB
rain
tum
our
Skin
tum
our
Bla
dder
tum
our
Pro
stat
etu
mou
rTu
mou
rof
rect
umB
enig
ndi
seas
e
Hea
lth�
care
leve
lIII
Mad
agas
car
Mor
occo
Suda
n
2424
(18 �
24)
30(2
0 �30
)
4036
(36�
40)
50(4
0 �50
)
45 50 45
45(3
0�70
)45
(40 �
50)
45 4655
(50�
60)
45 7055
(50�
60)
45 60 �
50 7055
(50 �
60)
50 7055
(50�
60)
45 7025
(20�
30)
45(5
0�70
)45
(40 �
50)
� �
25(2
0�30
)
Ave
rage
2945
4545
4948
4553
5445
4525
Hea
lth�
care
leve
lIV
Uni
ted
Rep
.ofT
anza
nia
30(2
0 �30
)30
(20�
30)
50(3
0�50
)30
(30�
45)
64(3
0�64
)60
(30�
60)
45(3
0�45
)60
(30�
60)
60(3
0�60
)60
(30�
60)
60(3
0�60
)6
The
entr
ies
inth
isT
able
are
qual
ifie
das
follo
ws:
Arg
entin
a:O
nth
eba
sis
ofda
tafr
omon
ela
rge
natio
nalc
entr
e.A
ustr
alia
:Su
rvey
data
from
only
8of
31ra
diot
hera
pytr
eatm
entc
entr
es(r
epre
sent
ing
abou
t42%
ofna
tiona
lpra
ctic
e).
Can
ada:
On
the
basi
sof
data
from
the
Nov
aSc
otia
Can
cer
Tre
atm
enta
ndR
esea
rch
Foun
datio
nan
dth
epr
ovin
ceof
Man
itoba
(col
lect
ivel
yre
pres
entin
gab
out8
%of
the
popu
latio
n).
Cro
atia
:D
ata
from
one
larg
ece
ntre
serv
ing
abou
tone
-fif
thof
popu
latio
n.C
ypru
s:T
arge
tdos
eof
50G
yfo
rbr
east
tum
our
refe
rsto
trea
tmen
twith
60C
oun
it;th
isis
supp
lem
ente
dby
trea
tmen
twith
xra
ys(t
arge
tdos
eof
14G
y);t
arge
tdos
eof
45G
yfo
rgy
naec
olog
ical
tum
our
refe
rsto
trea
tmen
twith
60C
oun
it;th
isis
supp
lem
ente
dby
trea
tmen
twith
xra
ys(t
arge
tdos
eof
15G
y).
Jord
an:
Surv
eyda
tafr
omon
eho
spita
l.M
adag
asca
r:T
reat
men
tssh
own
for
Bre
ast,
Lun
g/th
orax
,Gyn
aeco
logi
cal,
Hea
d/ne
ck,B
rain
,Ski
n,B
ladd
er,P
rost
ate
and
Rec
tum
tum
ours
supp
lem
ente
dby
addi
tiona
lirr
adia
tion
with
xra
ys.
New
Zeal
and:
Dat
afr
om50
%of
radi
othe
rapy
cent
res
(ser
ving
abou
ttw
oth
irds
ofpo
pula
tion)
.P
eru:
Surv
eyda
tafr
omIN
EN
(Can
cer
Inst
itute
,Lim
a,se
rvin
gpo
pula
tion
ofab
out7
mill
ion)
.U
nite
dR
epub
licof
Tanz
ania
:D
ata
for
‘Lun
g/th
orax
tum
our’
incl
ude
trea
tmen
tsof
the
oeso
phag
us.
Turk
ey:
Surv
eyda
tafr
omH
acet
tepe
Uni
vers
ityH
ospi
tal,
Çuk
urov
aU
nive
rsity
Hos
pita
l,Is
tanb
ulU
nive
rsity
Hos
pita
l,C
erra
hpa ş
aH
ospi
tal,
and
Gül
hane
Mili
tary
Hos
pita
l.U
nite
dA
rab
Em
irat
es:
Dos
esfo
rra
dica
ltre
atm
ents
only
.U
nite
dSt
ates
:B
reas
ttum
ours
rece
ive
anad
ditio
nal1
0 �20
Gy
“boo
st”
with
eith
erel
ectr
ons
orbr
achy
ther
apy.
ANNEX D: MEDICAL RADIATION EXPOSURES 445
ANNEX D: MEDICAL RADIATION EXPOSURES446
a Prescribed dose for complete treatment. Range or standard deviation in parentheses. Mean doses for each health-care level are frequency-weightedaverages of national values. These doses should not be used to infer deterministic or stochastic risks since these depend inter alia strongly onirradiation technique (dose distribution) and fractionation.
Table 58Prescribed doses to patients undergoing radiation brachytherapy by disease category (1991-1996)Data from UNSCEAR Survey of Medical Radiation Usage and Exposures unless otherwise indicated
Country / areaTypical dose a to target volume (Gy)
Head/neck tumour Breast tumour Gynaecological tumour Prostate tumour
Health-care level I
ArgentinaAustraliaBelarusBulgariaCanadaCyprusCzech RepublicDenmarkEcuadorIrelandKuwaitNetherlandsNew ZealandPanamaRussiaSlovakiaSloveniaUnited Arab Emirates
75 (68�78)30 (22�45)40 (30�50)60 (60�70)
60�
65 (60�70)�
�
30 (30�60)�
60 (20�30 boost)45 (25�65)20 (20�30)
(30�50)20 (20�30)
�
10 (5�10)
�
10 (10�25)40 (30�40)40 (30�40)
�
�
12 (10�12)�
�
30�
(20�24)15�
(20�40)15�
�
60 (50�65)32 (15�42)45 (30�50)70 (30�70)45 (11�50)
3060 (60�70)
35 (plus teletherapy)35 (±15%)15 (10�20)36 (30�36)
(30�60)70 (15�70)20 (20�30)
(20�40)30 (10�60)
�
20 (15�20)
70�
40 (30�60)�
30 (25�40)�
65 (60�70)�
�
�
�
60�
�
�
�
�
�
Average 44 16 45 35
Health�care level II
MexicoPeruTunisiaTurkey
30 (20�40)�
(55�75)21 (18�40)
15 (10�20)�
�
20 (20�25)
30 (20�30)40 (30�80)
(20�60)24 (16�24)
�
�
�
�
Average 22 19 29 �
Health�care level III
MoroccoSudan
24�
�
�
2435 (30�40)
�
�
Average 24 � 24 �
The entries in this Table are qualified as follows:
Argentina: On the basis of data from one large national centre.Australia: Survey data from only 8 of 31 radiotherapy treatment centres (representing about 42% of national practice).Canada: On the basis of data from the Nova Scotia Cancer Treatment and Research Foundation and the province of Manitoba (collectively
representing about 8% of the population).New Zealand: Data from 50% of radiotherapy centres (serving about two-thirds of population).Peru: Survey data from INEN (Cancer Institute, Lima, serving population of about 7 million).Turkey: Survey data from Hacettepe University Hospital, Çukurova University Hospital, Istanbul University Hospital, Cerrahpaşa Hospital, and
Gülhane Military Hospital.United Arab Emirates: Doses for radical treatments only.
Tab
le70
Ave
rag
ea
acti
viti
esad
min
iste
red
(MB
q)
inth
erap
euti
ctr
eatm
ents
wit
hra
dio
ph
arm
aceu
tica
ls(1
991-
1996
)D
ata
from
UN
SC
EA
RS
urve
yof
Med
ical
Rad
iatio
nU
sage
and
Exp
osur
esun
less
othe
rwis
ein
dica
ted
Cou
ntry
/are
aTh
yroi
dm
alig
nanc
y
131 I
iodi
de
Hyp
erth
yroi
dism
131 I
iodi
de
Pol
ycyt
haem
iave
ra32
Pph
osph
ate
Bon
em
etas
tase
sSy
novi
tis
89Sr
chlo
ride
32P
phos
phat
eO
ther
90Y
Oth
er
Hea
lth
-car
ele
velI
Arg
entin
aB
ulga
ria
Can
ada
Cro
atia
Den
mar
kE
cuad
orFi
nlan
d[K
59]
Ger
man
yIr
elan
dIt
aly
Japa
nK
uwai
tN
ethe
rlan
dsN
ewZ
eala
nd[L
28]
Pana
ma
Slov
akia
Slov
enia
Swed
enU
nite
dA
rab
Em
irat
esU
nite
dK
ingd
om[C
27]
447
7(±
1258
)3
300
(300
0 �5
500)
(550
0 �7
400)
470
6(3
452 �
596
0)�
370
0(±
50%
)4
334
(350
0 �5
550)
(100
0 �8
000)
370
0(1
110 �
740
0)55
50(2
500 �
1110
0)3
330
740
05
500
(800
0m
ax.)
330
3(1
000 �
700
0)5
550
(293
4 �8
166)
370
0(2
600 �
555
0)�
680
0(4
000�
740
0)3
700
(227
5 �5
550)
�
433
(±12
2)18
5(3
00�
150
0)72
6(±
510)
420
370
(±50
%)
321
(148�
425)
(200�
200
0)40
0(1
85�
500)
555
(185�
111
0)16
010
650
0(1
800
max
.)38
1(1
50�
100
0)46
3(±
131)
260
(185�
370)
350
(185�
550)
525
(240�
150
0)42
2(2
00�
462)
�
�
(74�
370)
185� � �
154
(110�
222)
(150�
200)
148
(111�
185)
185� �
(250�
400)
174
(120�
259)
� � 3720
0(1
60�
400)
� 166
� � � � � 150
148
150
150� � 14
815
015
0� � 15
015
0(1
25�
150)
� 136
� � � � �
5� � � � � � � � � � � � � �
� � � � � �
130
0d ,2
564
(129
5�3
000)
f
130
0d
� � � �
130
0d
� � � � � � �
� � 300� � �
168
(148�
185)
168� � � � 18
518
5� � 18
517
0(1
10�
220)
� 200
� � � � � �
555
b
(15�
30)
c ,(35�
185)
d
� � � � � � � � � � � �
Ave
rage
476
041
517
014
0�
�25
0�
Hea
lth
-car
ele
velI
I
Jord
anM
exic
oPe
ruT
urke
y
370
0(±
20%
)3
700
(184
0 �5
560)
555
0(5
000 �
600
0)3
238
550
(±20
%)
370
(185�
555)
260
(200�
300)
185
�
148
e(1
11�
185)
� 148
� � 148
111
� 185
444�
�
46f(3
7�55
5)3
885
(350
0 �4
000)
f
�
� � � �
� � � �
Ave
rage
351
034
014
811
1�
��
�
ANNEX D: MEDICAL RADIATION EXPOSURES458
Tab
le70
(con
tinue
d)
Cou
ntry
/are
aTh
yroi
dm
alig
nanc
y
131 I
iodi
de
Hyp
erth
yroi
dism
131 I
iodi
de
Pol
ycyt
haem
iave
ra32
Pph
osph
ate
Bon
em
etas
tase
sSy
novi
tis
89Sr
chlo
ride
32P
phos
phat
eO
ther
90Y
Oth
er
aR
ange
orst
anda
rdde
viat
ion
inpa
rent
hese
s.b
Dat
are
late
tous
eof
166 H
o.c
Dat
are
late
tous
eof
169 E
r.d
Dat
are
late
tous
eof
186 R
e.e
Dat
are
late
tous
eof
90Y
.f
Dat
are
late
tous
eof
153 Sm
.
Hea
lth
-car
ele
velI
II
Mor
occo
Suda
n3
700
(333
0 �4
440)
371
029
6(2
22�
444)
300
� �
� �
� 291
� �
� �
� �
Ave
rage
370
030
0�
��
��
�
Hea
lth
-car
ele
velI
V
Eth
iopi
aU
nite
dR
ep.
ofT
anza
nia
�
350
018
5(1
11�
370)
350
(±2%
)� �
� �
� �
� �
� �
� �
Ave
rage
350
022
0�
��
��
�
The
entr
ies
inth
isT
able
are
qual
ifie
das
follo
ws:
Arg
entin
a:O
nth
eba
sis
ofda
tafr
oma
sam
ple
of25
%of
nucl
ear
med
icin
ece
ntre
s.C
anad
a:D
ata
from
Lon
don
Hea
lthSc
ienc
esC
entr
e,SW
Ont
ario
(rep
rese
ntin
g50
%of
the
serv
ices
prov
ided
topo
pula
tion
ofab
out1
mill
ion)
.Tu
rkey
:Su
rvey
data
from
Gül
hane
Mili
tary
Hos
pita
l,H
acet
tepe
Uni
vers
ityH
ospi
tal,
and
Sam
sun
Ond
okuz
May
isU
nive
rsity
Hos
pita
l.
ANNEX D: MEDICAL RADIATION EXPOSURES 459